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Abstract 
The current thesis work consists of two projects presenting the pharmacometric analyses 
in drug exposure and response data. The first project applied population pharmacokinetic 
modeling approach to estimate the in vivo inhibition constant (Ki) across different 
CYP2C9 genotypes. In the second project, a model-based meta-analysis was performed 
to describe the time-course of virologic response in hepatitis C clinical trials across 
current approved treatments.   
The inhibition constant (Ki) of an inhibitor is usually estimated from in vitro experiments. 
Given the differences between in vivo and in vitro experiments, the in vitro Ki may not 
truly reflect the inhibitor-enzyme interaction in vivo. A previous study demonstrated that 
the in vitro Ki of fluconazole varied across different CYP2C9 genotypes, suggesting the 
inhibitor potency of interacting with CYP2C9 in vivo also depends on enzyme genotypes.  
The current study presented a population model-based approach to determine the in vivo 
Ki of fluconazole across three CYP2C9 genotype groups (*1*1, *1*3 and *3*3) with the 
CYP2C9 substrate, flurbiprofen. An integrated model was developed describing the 
pharmacokinetic profile of the flurbiprofen and competitive inhibition of fluconazole on 
flurbiprofen metabolism through CYP2C9.  The estimates of in vivo Ki was 14.7 µM for 
CYP2C9 *1*1, 18.7 µM for CYP2C9*1*3 and 32.9 µM for CYP2C9*3*3. The estimates 
of in vivo Ki of fluconazole are comparable to those estimates from in vitro studies. The 
result suggests the presence of CYP2C9*3 is associated with diminished interaction 
between fluconazole and enzyme. In addition, the contribution of CYP2C9 mediated 
metabolic clearance to the total flurbiprofen clearance is less significant in CYP2C9*3 
group than CYP2C9*1*1 group. The magnitude of overall in vivo drug interaction was 
also quantitatively evaluated. Patients with CYP2C9*3 is less susceptible to fluconazole 
inhibition. The present findings showed the potential of metabolism-based drug 
interaction could be different across individuals featured with various metabolic enzyme 
polymorphisms. The recommendation on dosing adjustment due to the overall effect of 
  v 
drug interaction on metabolism, accordingly, should take into consideration genotypes of 
metabolizing enzyme, elimination pathways of the substrate and inhibitor potency.  
In the second project, a model-based meta-analysis was performed to quantitatively 
assess the time course of longitudinal virologic response across currently approved 
hepatitis C treatments including peginterferon plus ribavirin (PR), telaprevir plus PR 
therapy and boceprevir plus PR therapy.  A total of 18 studies with 47 treatment arms 
were enrolled in the current analysis. The information collected in the analytic dataset 
included numbers of responders whose hepatitis C viral RNA level is undetectable at a 
given time, treatment strategy and patient population characteristics.  The analysis was 
firstly conducted in NONMEM 7 to obtain maximum likelihood estimates. However, the 
initial model had several limitations and ran into computational difficulties when trying 
to incorporate random effects at multiple levels. One of major limitations is that the 
model did not account for the potential decrease in the response rate which was observed 
during later phase of treatment in some treatment arms. To overcome these limitations, 
the meta-analysis was implemented in a Bayesian framework using Markov Chain Monte 
Carlo algorithm. The response rate model was developed incorporating the component of 
possibility of response reverse.  The analysis found the telaprevir had the fastest response 
onset, followed by boceprevir and PR therapy alone. The maximum response rates were 
lower in treatment arms with greater proportion of genotype 1 patients, black patients and 
prior null-responders. In the model, the SVR rate was compared to the response rate at 
the end of treatment. Their ratio was associated with the therapy and duration of the 
treatment. The probability of having a response reverse event increased quite slightly 
over time in triple therapy with telaprevir or boceprevir, compared to PR therapy alone.  
The study demonstrates, for the first time, the model-based meta-analysis of longitudinal 
hepatitis C virologic response. It allows the indirect comparison between telaprevir and 
boceprevir on the time-course of response rate.  
 
  vi 
Table of Contents 
 
Acknowledgements .............................................................................................................. i 
Dedication .......................................................................................................................... iii 
Abstract .............................................................................................................................. iv 
Table of Contents ............................................................................................................... vi 
List of Tables ...................................................................................................................... x 
List of Figures .................................................................................................................... xi 
CHAPTER 1 Drug and Drug Interaction .......................................................................... 1 
1.1 Introduction .......................................................................................................... 1 
1.2 DDI involving metabolism inhibition .................................................................. 1 
1.3 Prediction of in vivo drug interaction .................................................................. 2 
1.4 Inhibition constant Ki ........................................................................................... 6 
1.5  Scope of current project ...................................................................................... 8 
1.5.1 Rationale ....................................................................................................... 8 
1.5.2 Objective ....................................................................................................... 8 
1.5.3 Approach ....................................................................................................... 9 
1.6 Reference ............................................................................................................ 10 
CHAPTER 2 Population Model-Based Estimates of Furbiprofen Oral Clearance and In 
Vivo Inhibition Constant (Ki) of Fluconazole across CYP2C9 Polymorphism ............... 15 
2.1 Introduction ........................................................................................................ 15 
2.2 Methods .............................................................................................................. 16 
  vii 
2.2.1 Study Subjects ............................................................................................. 16 
2.2.2 Assessment of CYP2C9 Genotype ............................................................. 17 
2.2.3 Study Design ............................................................................................... 17 
2.2.4 Sample Collection and Concentration Analysis ......................................... 17 
2.2.5 Population Pharmacokinetic Analysis ........................................................ 18 
2.3 Results ................................................................................................................ 22 
2.3.1 Dataset......................................................................................................... 22 
2.3.2 Population Pharmacokinetic Model ............................................................ 22 
2.3.2 Model Evaluation ........................................................................................ 23 
2.4 Discussion .......................................................................................................... 24 
2.5 References .......................................................................................................... 45 
CHAPTER 3 Hepatitis C and Current Treatments .......................................................... 50 
3.1 Introduction ........................................................................................................ 50 
3.1.1 Hepatitis C .................................................................................................. 50 
3.1.2  Hepatitis C Virus......................................................................................... 50 
3.1.3 Current HCV Antiviral Treatments ............................................................ 51 
3.1.4 Scope of Current Research.......................................................................... 52 
3.2 HCV viroglogic response in clinical trials ......................................................... 53 
3.3 Predictors for SVR ............................................................................................. 55 
3.3.1 Viral Factors................................................................................................ 56 
3.3.2 Baseline Patient Characteristics .................................................................. 58 
3.4  Clinical trials of telaprevir................................................................................. 61 
3.4.1 Therapeutic Efficacy ................................................................................... 62 
  viii 
3.4.2 Tolerability .................................................................................................. 64 
3.5  Clinical trials of boceprevir ............................................................................... 65 
3.5.1 Therapeutic Efficacy ................................................................................... 66 
3.5.2 Tolerability .................................................................................................. 68 
3.6 References .......................................................................................................... 75 
CHAPTER 4 Systematic Review of Hepatitis C Clinical Trials ..................................... 83 
4.1 Literature search ................................................................................................. 83 
4.2 Dataset construction ........................................................................................... 84 
4.3 Dataset for meta-analysis ................................................................................... 85 
4.4 References .......................................................................................................... 93 
CHAPTER 5 Initial Model-Based Meta-Analysis of Virologic Response in Hepatitis c 
Clinical Trials Using NONMEM ...................................................................................... 96 
5.1 Introduction ........................................................................................................ 96 
5.2 Methods .............................................................................................................. 98 
5.2.1 Literature Review and Dataset Construction .............................................. 98 
5.2.2 Model Development.................................................................................... 98 
5.2.3 SAEM Estimation ..................................................................................... 101 
5.3 Results .............................................................................................................. 102 
5.3.1 Systematic review result and Analytic dataset .......................................... 102 
5.3.2 Longitudinal HCV Response Meta-Analysis............................................ 103 
5.4 Discussion ........................................................................................................ 105 
5.5 References ........................................................................................................ 112 
  ix 
CHAPTER 6 Model-Based Meta-Analysis of Hepatitis C Virologic Response Using a 
Bayesian Approach ......................................................................................................... 118 
6.1 Introduction ...................................................................................................... 118 
6.2 Methods ............................................................................................................ 120 
6.2.1 Systematic Review and Dataset Construction .......................................... 120 
6.2.2 Bayesian Analysis ..................................................................................... 120 
6.2.3 Model Development.................................................................................. 121 
6.2.4 Model Evaluation ...................................................................................... 125 
   6.3       Results ............................................................................................................... 126 
6.3.1 Systematic Review Result and Analytic Dataset ...................................... 126 
6.3.2 Longitudinal Model-Based Meta-Analysis ............................................... 126 
6.4 Discussion ........................................................................................................ 130 
6.5 References ........................................................................................................ 148 
CHAPTER 7 Conclusions ............................................................................................. 151 
7.1 In vivo inhibition constant................................................................................ 151 
7.2 Model-based meta-analysis of hepatitis C response rate ................................. 153 
7.3 References ........................................................................................................ 157 
BIBLIOGRAPHY ........................................................................................................... 161 
APPENDIX ..................................................................................................................... 173 
 
 
  x 
List of Tables 
Table 2.1 Final parameter estimates from population analysis in NONOMEM and 
Bootstrap analysis ............................................................................................................. 30 
Table 2.2 Predicted degree of drug interaction according to Equation 2.8 ...................... 31 
Table 3.1 Findings from Phase 2 and Phase 3 studies of telaprevir and boceprevir in 
treatment-naïve patients with chronic hepatitis C genotype 1 infection ........................... 69 
Table 3.2 Findings from Phase 2 and Phase 3 studies of telaprevir and boceprevir in 
previously treated patients with chronic HCV genotype 1 infection ................................ 71 
Table 3.3 Definition of virologic response....................................................................... 73 
Table 4.1 Summary information of baseline characteristics in arms included in the 
analysis .............................................................................................................................. 89 
Table 4.2 Summary of studies in dataset for meta-analysis ............................................. 90 
Table 5.1 Population estimates of model parameters ..................................................... 108 
Table 6.1 Prior distribution ............................................................................................ 136 
Table 6.2 Summary of Bayes estimate and 95% credible interval of model parameters 
and convergence statistics ............................................................................................... 137 
Table 6.3 Posterior estimation of maximum response rate (Pmax) in arms with certain 
population characteristics................................................................................................ 139 
Table 6.4 Model-based prediction of response rate in arms with certain population 
characteristics (95% prediction interval) ........................................................................ 140 
 
 
  xi 
List of Figures 
Figure 2.1 Population pharmacokinetic model of flurbiprofen and its metabolite, 4’-
hydroxy flurbiprofen ......................................................................................................... 32 
Figure 2.2 Observations versus Predictions of flurbiprofen (FLB) plasma concentration 
across CYP2C9 genotypes. ............................................................................................... 33 
Figure 2.3 Observations vs. Predictions of flurbiprofen (FLB) urine concentration across 
CYP2C9 genotypes ........................................................................................................... 34 
Figure 2.4 Observations vs. Predictions of 4’-hydroxyflurbiprofen (4’-OH-FLB) urine 
concentrations across CYP2C9 genotypes........................................................................ 35 
Figure 2.5 CWRES vs. Population Predictions (PRED) of FLB plasma concentrations 
across CYP2C9 genotypes ................................................................................................ 36 
Figure 2.6 CWRES vs. Population Predictions (PRED) of flurbiprofen urine 
concentrations across CYP2C9 genotypes........................................................................ 37 
Figure 2.7 CWRES vs. Population Predictions (PRED) of 4’-hydroxyflrubirpofen (4’-
OH-FLB) urine concentrations across CYP2C9 genotypes.............................................. 38 
Figure 2.8 CWRES vs.Time of flurbiprofen (FLB) plasma concentration across CYP2C9 
genotypes .......................................................................................................................... 39 
Figure 2.9 CWRES vs.Time of flurbiprofen (FLB) urine concentration across CYP2C9 
genotypes .......................................................................................................................... 40 
Figure 2.10 CWRES vs.Time of4’-hydroxyflurbiprofen (4’-OH-FLB) urine 
concentration across CYP2C9 genotypes ......................................................................... 41 
Figure 2.11 Visual predictive check (VPC) of flurbiprofen (FLB) plasma concentration 
in CYP2C9*1*1 ................................................................................................................ 42 
  xii 
Figure 2.12 Visual predictive check (VPC) of flurbiprofen (FLB) plasma concentration 
in CYP2C9*1*3 ................................................................................................................ 43 
Figure 2.13 Visual predictive check (VPC) of flurbiprofen (FLB) plasma concentration 
in CYP2C9*3*3 ................................................................................................................ 44 
Figure 3.1 Virologic response based on the course of treatment ..................................... 74 
Figure 4.1 Flow chart of systematic review ..................................................................... 88 
Figure 5.1 Observed response rate over time in a treatment arm during treatment ....... 109 
Figure 5.2 Individual prediction versus observation in each arm .................................. 110 
Figure 5.3 Model-based prediction and observation versus time .................................. 111 
Figure 6.1 Observed response rate over time during  treatment period according to 
therapies .......................................................................................................................... 141 
Figure 6.2 Mathematical structure of model .................................................................. 142 
Figure 6.3 Comparison of observations and individual prediction in each treatment arm.
......................................................................................................................................... 144 
Figure 6.4 Model-based prediction for 48-week PR therapy in arms with certain 
population characteristics................................................................................................ 145 
Figure 6.5 Model-based prediction for 48-week telaprevir therapy in arms with certain 
population characteristics................................................................................................ 146 
Figure 6.6 Model-based prediction for 48-week boceprevir therapy (with 4-week lead-in 
period) in treatment arms with certain population characteristics. ................................. 147 
  
 
  
1 
 
CHAPTER 1  
Drug-Drug Interactions  
1.1 INTRODUCTION 
Anticipating a drug-drug interaction (DDI) is an important issue during drug 
development and clinical practice, due to its potential to alter drug efficacy and safety. 
The United States Food and Drug Administration (USFDA) and Pharmaceutical Research 
and Manufacturers of America (PhRMA) have published guidance documents to address 
the procedure of evaluating DDIs during the development of a new molecular entity 
(NME) that assess whether the NME would be subject to certain DDIs or would have 
potential inhibitory or inducing effect on other drug pharmacokinetics.
1,2
 These 
guidelines emphasize the importance of DDI assessment for drug safety and effectiveness 
and illustrate the integrated approach by means of in vitro and in vivo studies. The drug 
interaction studies commonly start in vitro. Results from the in vitro studies are 
subsequently used to predict the potential of drug interactions in vivo and serve as a 
guide for further in vivo studies. Extrapolating in vitro results to predict the in vivo DDI 
could offer time and cost savings that minimize the human risk in clinical studies. 
However, the predictive utility of in vitro approaches can be confounded by uncertainty 
and variability during in vitro experiments and complexities in clinical practice.
3–5
  
1.2 DDI INVOLVING METABOLISM INHIBITION 
Drug-drug interactions impact drug pharmacokinetics primarily through metabolism. 
DDIs involving metabolic inhibition can lead to higher systematic exposure of the 
inhibited drug and may result in serious adverse events and toxicity, especially in drugs 
with a narrow therapeutic index.
6–8
 Modification of dosage regimen might be suggested 
in response to the change in drug efficacy or toxicity.
1
 Numerous drugs have been 
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identified as substrates, inhibitors and inducers of cytochrome P450 enzymes (CYP450) 
that are responsible for drug metabolism. Inhibition in drug metabolism mediated by 
CYP450 enzymes has been identified with three types of mechanisms (1) reversible 
inhibition (2) irreversible inhibition and (3) quasi-irreversible inhibition. Among these, 
reversible inhibition is the most common mechanism for the reported inhibitory DDIs.
3,9
 
There are four types of reversible inhibition including competitive, noncompetitive, 
uncompetitive and linear mixed. Competitive inhibition is the most common and simplest 
type. The inhibitor competes with the substrate for the same binding site at the active site 
of the enzyme. The metabolic rate (v) with competitive inhibition can be described by 
Equation 1.1. 
  
        
   (  
   
  
)    
 (1.1) 
where [S] and [I] represent the concentration of  substrate and inhibitor at the active site 
of the enzyme, respectively; Vmax is the maximum metabolic rate; Km is the Michaelis-
Menten constant of substrate and Ki is the inhibition constant of inhibitor. Competitive 
inhibition results in an increase in apparent Km but no change in Vmax. The inhibitory 
effect depends on both Ki and [I]. A wide range of substrate and inhibitor concentration 
levels are required for defining the interaction model that best fits the in vitro data. The in 
vitro Ki is subsequently determined based on the interaction model.  
1.3 PREDICTION OF IN VIVO DRUG INTERACTIONS 
According to the USFDA guideline, the potential of in vivo DDI for an NME, that is a 
reversible inhibitor for a CYP450 enzyme, can be predicted by comparing the in vitro Ki 
to the estimated in vivo inhibitor concentration.
1,10
 The in vivo DDI  is assessed to be 
quite likely if the ratio of in vitro Ki to [I] is greater than 1, possible if the ratio between 
0.1 and 1 and is not likely if the ratio is smaller than 0.1.
10–12
 Theoretically, [I] should be 
the inhibitor concentration at the active site of the enzyme. Since that concentration is 
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quite difficult to measure, the guideline suggests using the estimated mean maximum 
total (bound and unbound) plasma concentration at steady state of the highest clinical 
dose of the inhibitor.
1
 The ratio has been used to determine the need for further in vivo 
drug interaction studies. If the ratio is greater than 0.1, a clinical drug interaction study 
should be conducted in the NME due to its potential risk of a significant pharmacokinetic 
DDI.
1
 This approach also helps to prevent unnecessary in vivo studies in the NME when 
there is a low risk of in vivo inhibition (e.g., ratio <0.1).  
However, there are some limitations and uncertainties when using this method to predict 
the in vivo DDI.
3,5,13–15
 One of the key challenges is which inhibitor concentration should 
be used to represent [I] in the ratio. Numerous studies have been done for evaluating 
various estimates of inhibitor concentrations including unbound versus total 
concentration and systematic plasma versus hepatic inlet concentrations.
12,16–20
 The 
selection of inhibitor concentration affects the predictability of the ratio, but, to date, no 
common agreement exists on the choice of surrogate inhibitor concentration. A recent 
study which evaluated the utility of in vitro CYP450 enzyme inhibition data in prediction 
of in vivo DDI illustrated the unbound hepatic inlet concentration of inhibitors obtained 
more accurate prediction of in vivo DDI.
20
 Using the Ki derived from in vitro studies also 
causes some inconsistencies, primarily attributed to variation in the in vitro experiments 
and the biochemical/biophysical differences between the in vivo and in vitro 
environments.
3,5
 More details regarding Ki estimation will be discussed in Section 1.4. In 
addition, a ratio only based on inhibition potency in vitro and an anticipated inhibitor 
concentration does not provide sufficient information to definitively evaluate the in vivo 
DDIs which are also dependent on pharmacokinetics of substrate and inhibitor, and other 
in vivo factors. Despite these limitations, extrapolation from in vitro data to predict in 
vivo DDI is plausible in terms of a qualitative assessment. However, the quantitative 
prediction of in vivo DDI is more complex and challenging.  
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The inhibitory effect of a DDI on metabolism is directly related to an increase in the 
systematic exposure of the substrate which can be reflected by the area under the plasma 
concentration-time curve (AUC). Thus, the magnitude of the inhibitory drug interaction 
on metabolism can be estimated in clinical studies by comparing AUCs with and without 
the presence of inhibitor as shown in Equation 1.2. The equation also offers the 
theoretical basis for the ratio criteria ([I]/Ki) used in prediction of the in vivo DDI of 
inhibitor (DDIinh). 
                 
      
      
 
         
         
   
   
  
 (1.2) 
The ratio of AUCs is associated with the ratio of intrinsic metabolic clearance in the 
absence (CLint, con) and presence (CLint, inh) of inhibitor.  It should be apparent that this 
equation only describes the simplest in vivo phenomenon of DDI which requires multiple 
assumptions.  For instance, the substrate is orally administered and exclusively cleared by 
liver through a single metabolic pathway mediated by a specific CYP450 enzyme which 
is subject to the inhibition. However, this is usually not true. Drugs may involve parallel 
elimination pathways including both renal and metabolic clearance involving multiple 
CYP450 enzymes. The contribution of the metabolic pathway subject to the inhibition to 
the total drug clearance is an important factor that may influence the overall degree of 
DDI on drug pharmacokinetics. The USFDA guidelines suggest that an in vivo DDI  
study is needed for an NME if a metabolizing enzyme contributes greater than 25% of the 
total clearance of the drug.
1
 An analysis of  DDI studies involving CYP2D6 showed that  
quantitative predictions were substantially improved after considering the enzyme 
contribution as shown in Equation 1.3 where fm represents the fraction of metabolic 
pathway of CYP enzyme subject to the inhibition to the total clearance of substrate.
21–23
 
A significant variation was observed in predicted degree of DDI even with a small 
change in CYP2D6 contribution when the enzyme was predominately responsible for the 
substrate elimination (e.g., fm  greater than 0.9).
21
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 (1.3) 
Besides substrate disposition in vivo, inhibitor concentration [I] and inhibition constant 
Ki are still important determinants for predicting the degree of inhibitory metabolism-
based drug interaction. The extent and rate of oral absorption of the inhibitor which is 
associated with inhibitor concentration in vivo could affect the prediction of DDI.
22
 The 
Ki determined from in vitro studies is commonly used for in vivo DDI prediction.  
Predicting in vivo DDIs is complicated by large inter-individual variability, which may 
arise from multiple sources including substrate pharmacokinetics, concentration and 
potency of inhibitor, and genetic polymorphism of metabolizing enzyme.
9
 Uncertainty in 
selection of inhibitor concentration and variation in inhibitor concentrations resulting 
from inter-individual variability in inhibitor pharmacokinetics (e.g., oral absorption) 
could increase the variability in in vivo DDI prediction. As mentioned before, variability 
in the in vitro experiment (e.g., different microsomal system or assay method) could 
result in different values of in vitro Ki.
3,5,14
 In addition, the affinity of in vitro inhibitor 
binding to enzyme may not be the same as that in vivo. Although the Ki in vitro is 
commonly estimated, in vivo Ki should be used to obtain more accurate prediction for in 
vivo drug interactions involving the enzyme inhibition.
24
 Genetic polymorphism of 
metabolizing enzyme (e.g., CYP2C9, 2C19 and 2D6) is also associated with differential 
individual response to drug interaction. Varied activity presented by polymorphic variant 
alleles affect their roles in substrate metabolism and their interaction with the inhibitor. 
The individual susceptibility to enzyme inhibition is subsequently altered. CYP2C9*3 is 
one of the mutant alleles that was found to have reduced catalytic activity from both in 
vitro and in vivo studies.
25,26
 Lower oral clearance of flurbiprofen has been observed in 
individuals with CYP2C9*3 compared to individuals with CYP2C9*1*1(wild type).
27,28
 
An in vitro study using five probe CYP2C9 substrates showed potential enzyme 
inhibition was dependent on the CYP2C9 genotype (CYP2C9*1 and CYP2C9*3) and Ki 
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estimation  varied across genotype groups.
29
 Individual genotypes for the polymorphic 
enzyme should be accounted when evaluating the significance of clinical drug 
interaction. 
1.4 INHIBITION CONSTANT KI 
The inhibition constant Ki of the inhibitor is the dissociation constant for the inhibitor-
enzyme complex and represents the inhibitor potency/affinity of interacting with the 
enzyme. Ki is usually determined from in vitro experiments using human liver 
microsomes, hepatocyte, or recombinant enzyme systems. An accurate and reliable 
estimation of Ki requires an appropriate in vitro experiment that needs multiple levels of 
substrate and inhibitor concentrations with a proper range. The in vitro Ki has been used 
to predict the potential of in vivo DDI. However, such extrapolation from in vitro data 
can bring bias and error to a quantitative prediction.
5,13,14
 The estimation of an in vitro Ki 
can vary from one experiment to another. Multiple factors may contribute to inter-
experiment variability, including different in vitro system (e.g., human liver microsomes 
versus recombinant enzyme system), and different incubation conditions (e.g., pH, 
temperature, buffer type) and experimental procedures.
3,5,13–15
 Another factor that may 
influence the estimation of in vitro Ki is nonspecific binding of substrate to the 
microsomes in vitro. Studies have stressed the importance of correction for such 
binding.
30,31
 Furthermore, clinical relevance of the in vitro Ki can be confounded by the 
discrepancies between in vivo and in vitro systems.
3,5
 For example, the inhibitor 
concentration available at the active site of the enzyme may not be the same in two 
systems.
24
 The nature of two environments is quite different.  
Due to these limitations, some studies have proposed to determine the in vivo Ki which is 
considered a more rational and practical indictor of the inhibitor-enzyme interaction in 
vivo.
24,32–34
 Given competitive or noncompetitive inhibition,  the in vivo Ki (Ki, iv) can be 
directly estimated from formation clearances of metabolite in the presence (       ) and 
  
7 
 
absence (       ) of the inhibitor along with inhibitor concentration in vivo as described 
in Equation 1.4. The equation assumes that the substrate exhibits linear kinetics and that 
its concentration is much lower than Km. It also assumes the metabolite formation is only 
associated with one single CYP enzyme. In studies, plasma concentrations of inhibitor at 
steady state are used as the value of     in Equation 1.4.24,33 
      
   
       
       
  
 (1.4) 
Comparing the estimates of Ki from in vivo and in vitro studies allows evaluation of the 
in vitro-in vivo correlation of inhibition potency of the inhibitor. The disparity between in 
vitro and in vivo estimates of Ki reflects the difference in inhibitor-enzyme interactions 
between in vitro and in vivo systems. Further studies are needed to investigate the 
potential factors that contribute to this difference. Even though the in vitro Ki is 
correlated with in vivo Ki, the in vivo Ki is the parameter which directly represents the 
inhibitor potency given the in vivo environment and provides more accurate information 
for predicting the magnitude of in vivo drug interactions.  
In the view of this approach, the information required before estimating an in vivo Ki are 
the formation clearances of the metabolite in the presence and absence of the inhibitor 
and the inhibitor plasma concentration. An appropriate approach in determining this 
information is necessary to obtain the accurate estimation of the in vivo Ki. Generally, 
formation clearance of the metabolite is determined based on the amount of the 
metabolite excreted in the urine and AUCs of the substrate calculated by the trapezoid 
rule. In these studies, two formation clearances of the metabolite and the inhibitor plasma 
concentration were estimated first for each individual and then the corresponding in vivo 
Ki was calculated based on Equation 1.4.  The mean of in vivo Kis from all subjects is 
usually reported as the final estimate of the in vivo Ki. Such sequential approaches 
involve multiple calculation steps. If one considers inaccuracies in these calculations, 
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variability in estimation of in vivo Ki could arise from the inter-individual variability in 
the formation clearance of the metabolite and the inhibitor plasma concentration. 
1.5  SCOPE OF CURRENT PROJECT 
1.5.1 Rationale 
Previous studies have showed that the in vitro Ki was associated with genetic 
polymorphisms of CYP2C9.
28,29
 This suggests the in vivo Ki may also depend on 
CYP2C9 genotypes. Given the difference between the in vivo and in vitro environment 
and potential variability in experimental conditions, an in vitro Ki may not accurately 
describe the inhibitor potency of interacting with the enzyme in vivo. Some studies have 
proposed a sequential approach to determine the in vivo Ki, where individual in vivo Ki 
values are calculated from the formation clearance of the metabolite and the inhibitor 
concentration, followed by taking the average of the individual in vivo Kis. 
24,32–34
 
However, the inter-individual variability in formation clearance of the metabolite and 
inhibitor plasma concentration affects the estimation of in vivo Ki.  
According to USFDA guidance, the potential for an in vivo DDI is evaluated based on in 
vitro Ki and estimated inhibitor concentration in vivo. This approach serves a good 
qualitative assessment of in vivo DDI that suggests whether a further clinical study is 
necessary. In contrast, a quantitative evaluation of in vivo DDI needs a more rigorous and 
efficient method that enables acknowledgement of multiple clinical factors, such as 
disposition of the substrate and the inhibitor, inhibitor potency in vivo and genetic 
polymorphism of enzyme.  
1.5.2 Objective 
The current project was undertaken to implement a population modeling-based approach 
to directly determine the in vivo Ki of the inhibitor (fluconazole) with the substrate 
flurbiprofen across three CYP2C9 genotypes and compare them to in vitro estimates. 
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Subsequently, the magnitude of DDI was to be evaluated based on the in vivo Ki and 
flurbiprofen pharmacokinetics.  
1.5.3 Approach 
A population pharmacokinetic modeling approach was adopted in the current work. An 
integrated model was developed incorporating the plasma and urine data of CYP2C9 
substrate flurbiprofen and its major metabolite 4’-hydroxy flurbiprofen in the presence 
and absence of the inhibitor fluconazole. This approach allows us to identify and estimate 
the in vivo Ki of the inhibitor simultaneously with pharmacokinetics of the substrate 
across three CYP2C9 genotypes. The inter-individual variability arising from substrate 
pharmacokinetics and unexplained residual variability were also quantitatively described. 
The population estimates of the in vivo Ki were compared to in vitro estimates previously 
determined. The degree of drug interaction was further assessed based on estimates of in 
vivo Ki and the substrate pharmacokinetic parameters. The methods, results and 
conclusion are presented in Chapter 2. 
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CHAPTER 2  
Population Model-Based Estimates of Furbiprofen Oral Clearance and 
In Vivo Inhibition Constant (Ki) of Fluconazole across CYP2C9 
Polymorphism 
2.1 INTRODUCTION 
Given the complexity of certain diseases, patients may receive multiple concomitant 
medications where a drug-drug interaction needs to be considered in terms of its impact 
on efficacy and safety. The potential for a drug-drug interaction is usually evaluated with 
respect to the disposition profile of the target drug (substrate) and mechanism of drug 
interaction. Genetic polymorphism, especially in metabolizing enzymes (e.g., CYP2C9, 
CYP2D6 and CYP2C19), has recently emerged as an important factor attributable to the 
drug interactions.
1–6
 The presence of genotype polymorphisms could lead to varied 
activity of the enzyme.  
CYP2C9 is one of the essential P450 enzymes responsible for metabolic oxidation 
reactions. Among allelic variants coded in CYP2C9, the presence of a *3 allele is 
associated with significantly lower oral clearance for several CYP2C9 substrates
7–12
 and 
also leads to more frequent adverse events in some substrates with a narrow therapeutic 
index, such as, warfarin and phenytoin.
13–15
 Furthermore, both in vitro and in vivo studies 
showed the different interacting effect of CYP2C9 inhibitors on the disposition of 
substrates among different CYP2C9 genotypes. Not only is substrate metabolism affected 
by CYP2C9 genotypes, the potency (Ki) of the inhibitor is also related to varied activities 
expressed by CYP2C9 polymorphism.
16
 An in vitro study demonstrated that the 
magnitude of in vitro Ki of fluconazole inhibition on flurbiprofen hydroxylation was 
larger with the presence of the CYP2C9*3 than in wild type CYP2C9*1*1,
1
  suggesting 
that inhibitor potency is dependent on CYP2C9 genotypes.  
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The Ki is typically estimated from in vitro rather than in vivo studies. Such in vitro 
estimates of Ki are usually applied to predicting the in vivo drug interaction. According 
to United States Food and Drug Administration guidance,
 17
 the ratio of the estimated 
maximum plasma concentration of inhibitor to the in vitro Ki is used to predict the 
potential of competitive inhibition in vivo which determines whether a further in vivo 
study is needed for a new drug. Such in vitro extrapolation provides a qualitative 
prediction of the likelihood of an in vivo drug interaction and helps to avoid unnecessary 
clinical drug interaction studies, such as, a ratio smaller than 0.1 suggests a drug 
interaction is unlikely.
17,18
  There can be issues when the in vitro data are used as a 
quantitative assessment of an in vivo drug interaction, primarily due to the difference 
between the in vitro and in vivo environments.
19–24
 Similarly, the Ki estimated from in 
vitro studies may not truly reflect the capability of the inhibitor interacting with the 
enzyme in vivo.
25
 In addition, potential variability could arise when estimating an in vitro 
Ki, due to differences in experimental design, the in vitro system and data analysis 
methods.
19,23–25
 
In our study, we proposed a population pharmacokinetic modeling approach to identify 
and determine the in vivo Ki. An integrated pharmacokinetic model of the CYP2C9 
substrate flurbiprofen and its metabolite was established along with the interacting effect 
of the CYP2C9 inhibitor fluconazole. The in vivo Ki of fluconazole was to be assessed 
for individuals with CYP2C9*1*1, CYP2C9*1*3 and CYP2C9*3*3. Subsequently, the 
estimated in vivo Ki combined with the pharmacokinetics of flurbiprofen was used to 
quantitatively evaluate the magnitude of the in vivo drug interaction.  
2.2 METHODS 
2.2.1 Study Subjects 
The institutional review board at the University of Minnesota reviewed and approved the 
study protocol. One hundred and eighty-nine healthy subjects underwent genotype 
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screening. From these subjects, twenty-one subjects (11 with CYP2C9*1*1, 8 with *1*3 
and 2 with *3*3) were further enrolled in the current drug-drug interaction study. All 
subjects were non-smokers and were not taking any medicine at the time of enrollment. 
Their health conditions were determined based on medical history, physical examination, 
vital signs, and routine biochemical and urinalysis tests.
1
 
2.2.2 Assessment of CYP2C9 Genotype 
DNA isolation was conducted according to the method previously described. CYP2C9 
genotype was subsequently determined by using the isolated DNA samples. The detailed 
method has been described in Kumar, et al.
1
 
2.2.3 Study Design 
The study was conducted as a three-way, open-label, randomized, crossover design with 
a one-week washout period. Subjects were randomly assigned to take one single oral 
tablet of flurbiprofen at a dose of 50 mg (Mylan Pharmaceutical Inc., Morgantown, WV) 
alone or following 7 daily tablets of fluconazole at 200 mg or 400 mg (Ivax 
Pharmaceutical Inc., Miami, FL). Thus, fluconazole was administered at three dosing 
levels of 0, 200 or 400 mg in the current study.  
2.2.4 Sample Collection and Concentration Analysis 
Blood samples for measuring flurbiprofen plasma concentration were collected at 0.25, 
0.5, 1, 2, 4, 6, 8 and 24 h after the administration of flurbiprofen. Total voided urine was 
collected following flurbiprofen administration at intervals of 0 to 12 h and 12 to 24 h. 
Blood samples of fluconazole were collected before and at 2, 8, 12 and 24 h after the last 
steady-state dose on the 7
th
 day. Flurbiprofen concentration was quantified in plasma and 
urine samples. Its primary metabolite, 4’-hydroxyflurbiprofen was analyzed for its 
concentration in the urine only; its plasma concentration is too low to measure. For the 
inhibitor fluconazole, the plasma concentration was measured at 0, 2, 8, 12 and 24 h after 
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the dose on the 7
th
 day. The quantitation method for urine and plasma concentrations 
have been described previously.
1,26,27
 
2.2.5 Population Pharmacokinetic Analysis 
The population pharmacokinetic analysis was performed using a nonlinear mixed-effect 
modeling approach implemented in the NONMEM software (version 7, ICON 
Development Solutions, Ellicot City, MD, USA). The subroutine ADVAN 6 was used for 
developing the model. The first-order conditional estimation algorithm with interaction 
(FOCE-I) was used for parameter estimation in all model runs. The package “Xpose4”28 
was installed through the statistical software R (version 2.14.2)
29
 and was used to process 
NONMEM output and to construct diagnostic plots for evaluating the goodness of model 
fit. The commands in R were executed through the interface software Rstudio (version 
0.97.449, Rstudio Inc., MA, US). A nonparametric bootstrap was performed through 
Perl-speaks-NONMEM (PsN)
30
 and visual predictive checks were performed through the 
software PDxPop 4.1 (ICON Development Solutions, Ellicott City, MD, USA). 
Model Development  
Model development was guided based on research objectives, plausible mechanism, prior 
knowledge, changes in NONMEM maximum likelihood objective function and 
improvement in various diagnostic plots.  
Previous studies showed that a one-compartment model adequately described the 
pharmacokinetics of flurbiprofen.
1
 In the current study, two urine compartments were 
added to account for the urine data of flurbiprofen and its primary metabolite 4’-
hydroxyflurbiprofen as presented in Figure 2.1. Although the metabolite’s plasma 
concentration was too low to quantitate, its urine data still allowed estimation of the 
formation clearance of the CYP2C9 metabolite. However, the renal clearance of the 
metabolite itself cannot be estimated. Given the available data, the proposed model 
permits the analysis of multiple elimination pathways of flurbiprofen, including its renal 
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clearance, CYP2C9-mediated 4’-hydroxyflubiprofen formation clearance and residual 
clearance through unknown elimination pathways. Prior studies have established 
competitive inhibition as the mechanism for fluconazole interacting with flurbiprofen 
CYP2C9-mediated metabolism.
1,16
 The Rowland-Matin equation
31
 assuming competitive 
inhibition was adapted to evaluate the inhibitory effect of fluconazole as a function of 
inhibition constant (Ki) and fluconazole plasma concentration ([I]) as shown in Equation 
2.1. 
          
         
  
   
  
 (2.1) 
where           indicates the inhibited CYP2C9-mediated metabolic clearance,  
          indicates control CY2C9-mediated metabolic clearance in the absence of 
inhibitor. It should be noted that           and    were estimated separately for each 
CYP2C9 genetic polymorphism. Since fluconazole concentrations fluctuated little over 
the dosing interval, the average plasma concentration at steady-state was calculated from 
the trapezoidal area under concentration-time curve (AUC) of fluconazole plasma data 
and the dosing interval as shown in Equation 2.2. This single number for each individual 
was considered as the value of fluconazole concentration     in Equation 2.1. 
     ̅̅ ̅̅ ̅̅  
      
 
                  (2.2) 
The total oral clearance of flurbiprofen can be expressed as the sum of renal clearance 
(       ), CYP2C9-mediated metabolic clearance and residual clearance through 
unknown elimination pathways (           ) as in Equation 2.3. 
        
         
  
   
  
                    (2.3) 
where         and            were assumed common across CYP2C9 genotypes. 
Pharmacokinetic parameters in the model were assumed to follow a log-normal 
distribution as Equation 2.4. 
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   (2.4) 
          
   (2.5) 
where    is the pharmacokinetic parameter in i
th
 individual,      is the typical population 
mean of the pharmacokinetic parameter and    is the inter-individual variability (IIV) 
which is normally distributed with a mean of zero and variance of   
  to be estimated as 
expressed in Equation 2.5. 
In the current study, the population means of fluconazole    and uninhibited flurbiprofen 
          were estimated for each of CYP2C9 genotypes. In contrast, the population 
means of          and             were assumed to be the same across CYP2C9 
genotypes and fluconazole concentrations; they were shared among these three CYP2C9 
genotype groups. All parameters were assumed to be constant across the three 
fluconazole dosing arms (0, 200 or 400 mg). The inter-individual variability was assessed 
for flurbiprofen volume of distribution, first-order absorption rate constant, absorption lag 
time, metabolic clearance, renal clearance, and residual clearance through unknown 
elimination pathways. 
Residual unexplained variability (RUV) was explored in an additive, proportional and 
combination error models. Since the concentration data of flurbiprofen and its metabolite 
were analyzed simultaneously in the pharmacokinetic model, two indicator variables 
(TYPE1 and TYPE2) were defined to differentiate RUVs which were separately 
estimated for plasma flurbiprofen, urine flurbiprofen and urine 4’-hydroxyflurbiprofen as 
shown in Equation 2.6. 
         ̂                                                              (2.6) 
             
               (2.7) 
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where         and   ̂        are observed and model-predicted concentration j
th
 subject at 
time point i,       equals 1 for plasma concentration of flurbiprofen and 0 for others,  
      equals 1 for urine concentration of flurbiprofen and 0 for others;       ,       ,       
represents residual errors for flurbiprofen concentration in plasma and urine and 4’-
hydroxyflrubiprofen concentration in urine, respectively.  Each of these RUVs is 
assumed independently, normally distributed with a mean of zero and a variance (  
  ) to 
be estimated as expressed in Equation 2.7. 
Model Evaluation 
A nonparametric bootstrap was employed to evaluate the reliability and stability of the 
proposed population model.
32
 Bootstrapping is one of the resampling techniques which 
randomly generate samples with replacement from the original dataset. The simulated 
dataset has the same number of subjects as the original dataset. Bootstrap is also used to 
examine the precision of model parameter estimates, especially when the sample size is 
small. In our study, the numbers of individuals were not balanced among three CYP2C9 
genotypes; there were only 2 subjects with the CYP2C9*3*3. It was possible that fewer 
or no subjects with CYP2C9*3*3 might be drawn during the resampling process.  To 
retain the proportion of subjects in each CYP2C9 genotype as in the original dataset, a 
stratified bootstrap was used and resampling was stratified based on CYP2C9 
genotypes.
30
 In this stratified bootstrap, the simulated dataset had approximately the same 
number of the individuals in each of CYP2C9 genotype as that in the original dataset. 
Five hundred bootstrap samples were generated and the proposed PK model was fitted in 
each of these samples to get parameter estimates. The results from successful 
minimization runs were extracted to compute the summary statistics (e.g., median, 95% 
confidence internals) for each of the model parameters. The bootstrap results were 
compared with the original NONMEM results.  
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Additionally, a visual predictive check (VPC) was carried out to evaluate the 
performance of the established population pharmacokinetic model. Two hundred datasets 
were simulated using the pharmacokinetic model and parameter estimates from 
NONMEM results. The simulated datasets also adopt the same study design as in the 
original dataset. The median, 5th and 95th percentile of simulated concentration data 
were calculated at each nominal observation time point after dosing and plotted over 
these time points.  The same percentiles were also constructed in the observed data and 
the plot was overlaid with those of the simulated data for a visual comparison. VPC plots 
were evaluated for flurbiprofen plasma concentration with respect to CYP2C9 genotypes. 
VPC would not be helpful for the evaluation of urine data which were measured only at 
two time points in the study. An appropriate model is expected to have distributions of 
predictions generally consistent with observations over time. 
2.3 RESULTS 
2.3.1 Dataset  
The dataset consisted of 630 observed plasma and 126 urine concentrations of 
flurbiprofen, and 126 observed urine concentration of 4’-hydroxyflurbiprofen from 21 
healthy study participants. Among these subjects, 11 persons had CYP2C9*1*1, 8 
persons had CYP2C9*1*3 and 2 had CYP2C9*3*3.  
2.3.2 Population Pharmacokinetic Model 
The pharmacokinetics of flurbiprofen were described in a model consisting of one 
compartment for flurbiprofen plasma observation and two compartments for flurbiprofen 
and its metabolite in urine connected to the plasma compartment as shown in Figure 2.1. 
The parameter estimate and relative standard error from the NONMEM output were 
summarized along with the bootstrap results in Table 2.1.  
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The population mean of in vivo Ki was estimated to be 14.7 µM for CYP2C9 *1/*1, 18.7 
µM for CYP2C9*1/*3 and 32.9 µM for CYP2C9*3/*3. The CYP2C9-mediated 
metabolic clearance was 1.09 L/hr for CYP2C9*1/*1, 0.449 L/hr for CYP2C9*1*3 and 
0.0481 L/hr for CYP2C9 *3*3. The flurbiprofen renal clearance and residual clearance 
were estimated at 0.191 L/hr and 0.219 L/hr, respectively.  
The inter-individual variability (shrinkage %) was estimated to be 21.1% (12.4), 31.3% 
(6.09) and 63.2% (7.2) for flurbiprofen metabolic clearance, renal clearance and residual 
clearance through an unknown elimination pathway, respectively. High inter-individual 
variability (shrinkage %) was found in the oral absorption rate constant at 94.2% (5.3). 
The proportional RUV was estimated to be 48.4% for flurbiprofen plasma concentration, 
29.6% for flurbiprofen urine concentration and 36.9% for 4’-hydroxyflurbiprofen urine 
concentration. 
2.3.2 Model Evaluation 
Diagnostic plots were presented according to the types of concentration data and 
CYP2C9 genotypes. Observations were plotted versus population predictions and versus 
individual predictions separately for flurbiprofen plasma concentration, urine 
concentration and 4’-hydroxy-flurbiprofen urine concentration as shown in Figure 2.2, 
2.3, 2.4, respectively. Most of predictions from the model were consistent with the 
observations. The model had a tendency to under predict at high flurbiprofen plasma 
concentrations and over predict at high metabolite 4’-hydroxyflubiprofen urine 
concentrations in subjects with the CYP2C9*1*1genotype.  
Conditional weighted residual (CWRES) were plotted against population predicted 
concentrations in Figure 2.5, 2.6 and 2.7. CWRES of plasma flurbiprofen concentration 
were generally scattered well and did not show a specific pattern. A large CWRES, 
approximately 5.8, was seen in one urine flurbiprofen sample in an individual with 
CYP2C9*1*3, meaning the current model underpredicted this observation by a large 
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amount.  The CWRES of urine flurbiprofen were not evenly scattered across the zero-
ordinate in the CYP2C9*3*3 group. It might be due to a small sample size in this 
subgroup (N=2), sparse sampling in urine flurbiprofen and analytical error in urine assay. 
For 4’-hydroxy-flurbiprofen urine concentrations, a pattern of negative CWRES trended 
to become prominent at population predictions that were higher than 10 μg/mL for both 
CYP2C9*1*1 and CYP2C9*1*3. Different error models were tried, but did not improve 
the plot. It could be related to model misspecification. CWRES was also evaluated 
against time in Figure 2.8, 2.9 and 2.10 for each type of concentration. The CWRES plot 
for plasma flurbiprofen concentrations did not show systemic bias. Urine samples were 
only collected at 12 hours and 24 hours after dosing. Due to a lack of sampling at other 
time points, it’s difficult to interpret and assess CWRES-time plots and assess model fit 
in urine data as a function of time. Nevertheless, there appears to be model 
misspecification of the 4-hydroxyflurbiprofen metabolite data, which may affect the 
estimation of formation clearance of the metabolite and the Ki.  In spite of a slight model 
misspecification indicated by some of the diagnostic plots, the current model was still 
capable of adequately describing most of the data and to meet our research objectives.   
In addition to diagnostic plots, the model was qualified by visual predictive check (VPC). 
The VPC plot of flurbiprofen plasma concentrations were inspected for each of CYP2C9 
genotypes in Figure 2.11, 2.12, 2.13. Approximately 10.3% of the observed data fell 
outside 90% of simulated data. The 5
th
, 50
th
 and 95
th
 percentiles of predictions were 
comparable to the corresponding percentile of observations. The model generally 
indicated the overall trend of observed data over time and revealed a good predictive 
behavior.   
2.4 DISCUSSION 
The genetic polymorphism of CYP2C9 has been found to be a crucial factor for 
disposition of multiple CYP2C9 substrates.
11
 It is necessary to account for the impact of 
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genetic polymorphisms when evaluating metabolism-based drug interactions. Not only is 
the substrate’s metabolism affected, but the inhibitor potency in interacting with CYP2C9 
is also associated with varied enzyme activity of CYP2C9 genotypes.
16
 The inhibition 
constant (Ki) is usually determined from an in vitro system, e.g., human liver microsomes. 
A wide range of concentrations of substrate and inhibitor are needed to identify the 
inhibition model and obtain a reliable estimate of Ki. The in vitro studies can be laborious. 
Limitations are known due to differences between in vitro and in vivo systems including 
the distribution of the enzyme, concentrations of inhibitor and substrate at the active site 
of the enzyme and patient characteristics. It is also recognized that the in vitro study does 
not account for the pharmacokinetics of substrate and inhibitor that may be important for 
evaluating the in vivo drug interaction. Inconsistencies and even bias could be introduced 
when extrapolating the in vitro result to predict the in vivo response.  In our study, a 
population pharmacokinetic modeling approach was employed to estimate the in vivo Ki 
and evaluate the drug interaction across three CYP2C9 genotypes. 
A population pharmacokinetic model was proposed that incorporated the CYP2C9 
prototype substrate flurbiprofen. The model described the flurbiprofen concentrations in 
plasma and urine as well as its primary metabolite, 4’hydroxy-flurbiporfen urine 
concentration in the presence and absence of fluconazole. The model allowed evaluation 
of multiple elimination pathways of flurbiprofen. The flurbiprofen total oral clearance 
consisted of renal clearance, CYP2C9-mediated metabolic clearance and residual 
clearance through unknown pathways. The inhibitory effect of fluconazole on 
flurbiprofen CYP2C9-mediated metabolic clearance was described in a competitive 
inhibition model. The population means of in vivo Ki values for fluconazole interacting 
with CYP2C9 were estimated separately for each of CYP2C9 polymorphisms. The in 
vivo Ki values were estimated to be greater in subjects with the presence of *3 allele than 
in subjects with wild type *1*1. The CYP2C9*3*3 group had the highest value of in vivo 
Ki, meaning the affinity of fluconazole binding to this genotype was quite weak. In 
  
26 
 
contrast, fluconazole had a very strong interaction with CYP2C9*1*1 where the 
estimated in vivo Ki was small. Such differences are attributed to the reduced activity of 
CYP2C9*3 allele. Of note is that the estimates of in vivo Ki by using the population 
approach were comparable with those results from in vitro studies, suggesting a good in 
vitro-in vivo correlation of Ki for fluconazole for these three CYP2C9 genotypes.  
In a previous population model, the flurbiprofen clearance was only evaluated based on 
two elimination pathways which were metabolic clearance through CYP2C9 and non-
CYP2C9 clearance.
1
 Given the urine data available in this analysis, the current model 
enabled the differentiation of flurbiprofen renal clearance from CYP2C9 metabolic 
clearance and the remaining non-CYP2C9 elimination pathways. Renal clearance and 
residual clearance were assumed to be common among the three groups of CYP2C9 
polymorphisms. In contrast, the formation clearance of 4’-hydroxyflurbiprofen was 
associated with CYP2C9 genotypes and was estimated for each of the groups. As 
expected, the CYP2C9-mediated metabolic clearance in the absence of inhibitor deceased 
in the presence of *3 alleles in CYP2C9 genotype. The *1*1 (wild type) group had a 
much greater formation clearance of 4’-hydroxyflurbiprofen than did *1*3 and *3*3. The 
estimate of uninhibited CYP2C9 was the smallest in the CYP2C9 *3*3 group compared 
to *1*1 and *1*3 groups, presumably due to reduced protein function present in 
CYP2C9*3 allele. This pattern of CL2C9 across CYP2C9 genotypes agreed with the 
findings from the previous study.
1
 The population estimates of uninhibited formation 
clearance of 4’-hydroxyflurbiprofen and the derived total flurbiprofen clearance from the 
current model were consistent with results from previous noncompartmental analyses,
1
 
but were smaller than the estimates from earlier population models which only accounted 
for two elimination pathways for flurbiprofen. 
1
 It was also notable that the contribution 
of CYP2C9-mediated metabolism to the total flurbiprofen elimination varied across 
individuals with different CYP2C9mutations. According to results from the current 
population analysis, the proportion of CYP2C9 metabolic clearance in total clearance was 
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quite low in individuals having the CYP2C9*3 allele. Formation clearance of 4’-
hydroxyflurbiprofen accounts for approximately 10 % and 52% of the total flurbiprofen 
clearance in individuals with CYP2C9*3*3 and CYP2C9*1* 3, respectively, which were 
significantly lower than 73% in those with CYP2C9*1*1.  This suggests that the impact 
of CYP2C9 inhibition was diminished in subjects with CYP2C9*3 due to the small 
contribution of CYP2C9 metabolism to their flurbiprofen elimination.  
The overall influence of the drug interaction between flurbiprofen and fluconazole was 
therefore evaluated based on substrate disposition and inhibitor interaction, both of which 
were associated with CYP2C9 polymorphisms. Given the parallel elimination pathways 
of flurbiprofen, the magnitude of the drug interaction can be evaluated using Equation 
2.8.
22,31,33
 
              
      
      
 
 
        
  
   
  
             
  (2.8) 
The degree of drug-drug interaction and the ratio of substrate AUC in the presence 
(       ) and absence of inhibitor (       ) were predicted based on fraction of 
CYP2C9 mediated metabolism (         ) to the total clearance, inhibitor concentration 
    at the active site of enzyme and inhibitor constant  . There has been considerable 
controversy in what inhibitor plasma concentration should be used as a surrogate for the 
concentration available at the active site of the enzyme in the hepatocyte which is 
difficult to measure.
25,34
 In our study, the CYP2C9 inhibitor fluconazole had achieved 
steady-state. The average concentration of fluconazole at steady state in each individual 
was derived from Equation 2.2 and was used as the value of     in Equation 2.3. To 
predict the overall in vivo drug interaction, the mean of all individual average steady state 
concentration was calculated at each dose level and used as     in Equation 2.8. 
According to the population estimates from the proposed model, the magnitude of the 
drug-interaction was derived from Equation 2.8 and the values of relevant parameters 
were summarized in Table 2.2. The effect of the drug interaction varied across the 
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CYP2C9 genotype and also changed with inhibitor dosing level. Given the same dose of 
inhibitor, the inhibitory effect was greater in the CYP2C9*1*1 group than those in the 
CYP2C9*1*3 and CYP2C9*3*3 groups. Especially in CYP2C9*3*3, the inhibitory 
effect was quite slight. Within a given genotype group, the effect of fluconazole 
inhibition on the overall disposition of flurbiprofen was not doubled when the dose of 
fluconazole was doubled, since not all the elimination pathways of flurbiprofen was 
subject to the fluconazole inhibition. From the clinical perspective, the present findings 
showed that the potential of metabolism-based drug interactions could be different across 
individuals with different metabolic enzyme polymorphisms. The recommendation on 
dosing adjustment due to the overall effect of a drug interaction involving metabolism by 
CYP2C9, should take into consideration the presence of particular CYP2C9 
polymorphisms and elimination pathways of the substrate and inhibitor potency.  
In conclusion, the current study presents a population pharmacokinetic modeling 
approach to estimate the in vivo Ki and to evaluate the in vivo drug interaction exhibited 
across three CYP2C9 polymorphisms. The estimates of in vivo Ki were different among 
genotypes and were comparable to the results from in vitro studies. Such a modeling 
approach can be used to determine the in vivo Ki for inhibitors interacting with CYP 
enzymes and to examine the in vitro-in vivo correlation. Incorporation of potential 
elimination pathways of the substrate refined the evaluation of the net influence of drug 
interaction. The population pharmacokinetic analysis provides more information 
regarding the substrate pharmacokinetics and inhibitor potency to characterize the in vivo 
drug interaction and could help further determination of the dosage modifications needed 
for the substrate drug. Based on the current findings, the potential drug interaction highly 
depends on the individual CYP2C9 genotypes. This suggests that CYP2C9 genotypes 
need to be checked when making decisions on dosage modifications with drugs that 
interact. One major limitation of the model include a degree of model misspecification, 
which is probably due to small sample size and could cause the bias in the estimation of 
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the fm and Ki. In the present work, we only had 2 subjects with CYP2C9*3*3. Future 
studies are needed with more subjects with each genotype. By using a population 
pharmacokinetic approach, it is possible to determine the in vivo Ki and the magnitude of 
the drug interaction in larger numbers of subjects with fewer samples of substrate and 
fewer levels of inhibitor. The relevant simulation is needed to optimize the study design 
with an improved sampling technique without introducing bias and decreasing precision 
of the parameter estimates.  
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Table 2.1 Final parameter estimates from population analysis in NONOMEM and Bootstrap analysis 
 
 
 
 
 
 
Estimate (% RSE) 95% CI Median (2.5
th
, 97.5
th
) percentile
Ki (μMol)
CYP2C9*1*1 14.7 (13.7) (10.8, 18.6) 14.8 (11.3, 19.0)
CYP2C9*1*3 18.7 (16.3) (12.7, 24.7) 18.8 (14.6, 28.5)
CYP2C9*3*3 32.9 (14.6) (23.5, 42.3) 32.8 (27.5, 45.8)
CL2C9/F, uninhibited (L/hr)
CYP2C9*1*1 1.09 (5.39) (0.975, 1.21) 1.08 (0.987, 1.21)
CYP2C9*1*3 0.449 (20.5) (0.269, 0.629) 0.456 (0.282, 0.637)
CYP2C9*3*3 0.0481 (9.21) (0.0394, 0.0568) 0.0483 (0.0404, 0.0562)
CLrenal/F  (L/hr) 0.191 (8.9) (0.158, 0.224) 0.191 (0.163, 0.223)
CLresidual/F  (L/hr) 0.219 (14.4) (0.157, 0.281) 0.219 (0.165, 0.280)
V/F  (L/hr) 8.22 (6.25) (7.21, 9.23) 8.21 (7.35, 9.18)
Ka (hr
-1
) 2.05 (22.4) (1.15, 2.95) 2.05 (1.37, 3.44)
Tlag (hr) 0.2 (4.9) (0.181, 0.219) 0.2 (0.179, 0.217)
Variance of Interindividual Variability (IIV)
ω2CL2C9 0.0447 (75.8) CV%=21.2 (0, 0.111) 0.0328 (0.0026, 0.0991)
ω2CLrenal 0.0981(41.9), CV%=31.1 (0.0175, 0.179) 0.0912 (0.0373, 0.191)
ω2CLresidual 0.399 (51.4), CV%=63.2 (0, 0.801) 0.365 (0.112, 0.793)
ω2 V 0.0443 (44.2), CV%=21.0 (0.00588, 0.0827) 0.0411 (0.0125, 0.0875)
ω2Ka 0.887 (28.5), CV%=94.2 (0.391, 1.38) 0.86 (0.452, 1.41)
ω2Tlag 0.0197 (50.8), CV%=14.0 (0.0001, 0.0393) 0.0181 (0.00602, 0.0474)
Variance of Residual Unexplained Variability (RUV)
σ2plasma flurbiprofen 0.234 (9.15), CV%=48.4 (0.192, 0.276) 0.235 (0.197, 0.278)
σ2urine flurbiprofen 0.0875 (27.2), CV%=29.6 (0.0409, 0.134) 0.085 (0.0483, 0.134)
σ2urine 4'-hydroxyflurbiprofen 0.136 (16.6), CV%=36.9 (0.0917, 0.180) 0.131 (0.0954, 0.173)
Population Analysis (NONMEM) Bootstrap Analysis
Parameter
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Table 2.2 Predicted degree of drug interaction according to Equation 2.8 
 
Note: DDI: drug-drug interaction; Ki, inhibition constant; [I] inhibitor (Fluconazole) plasma concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CYP2C9*1*1 CYP2C9*1*3 CYP2C9*3*3
14.7 18.7 32.9
0.73 0.52 0.11
2.02 1.5 1.06
2.51 1.69 1.08
Fluconazole (Dose=200mg) 
[I]=33 μMol
Fluconazole (Dose=400mg) 
[I]=69 μMol
Degree of 
DDI
Ki (μMol)
fm, CYP2C9
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Figure 2.1 Population pharmacokinetic model of flurbiprofen and its metabolite, 4’-hydroxy 
flurbiprofen 
 
Note: FLB, flurbiprofen; ka: first-order absorption rate constant; 4’-OH-FLB, 4’-hydroxy 
flurbiprofen;CL2C9, CYP2C9 mediated formation clearance of 4’-hydroxy flurbiprofen; CLrenal, flurbiprofen 
renal clearance; CLresidual, flurbiprofen clearance through residual elimination pathway; CLmeta,renal, 
metabolite renal clearance. 4’-hydroxy flurbiprofen plasma data was not available in the study (dash box) 
and its renal clearance was not estimated (dash arrow). 
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Figure 2.2 Observations versus Predictions of flurbiprofen (FLB) plasma concentration across 
CYP2C9 genotypes. 
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Figure 2.3 Observations vs. Predictions of flurbiprofen (FLB) urine concentration across CYP2C9 
genotypes 
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Figure 2.4 Observations vs. Predictions of 4’-hydroxyflurbiprofen (4’-OH-FLB) urine concentrations 
across CYP2C9 genotypes 
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Figure 2.5 CWRES vs. Population Predictions (PRED) of FLB plasma concentrations across 
CYP2C9 genotypes 
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Figure 2.6 CWRES vs. Population Predictions (PRED) of flurbiprofen urine concentrations across 
CYP2C9 genotypes 
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Figure 2.7 CWRES vs. Population Predictions (PRED) of 4’-hydroxyflurbirpofen (4’-OH-FLB) urine 
concentrations across CYP2C9 genotypes 
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Figure 2.8 CWRES vs.Time of flurbiprofen (FLB) plasma concentration across CYP2C9 genotypes 
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Figure 2.9 CWRES vs.Time of flurbiprofen (FLB) urine concentration across CYP2C9 genotypes 
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Figure 2.10 CWRES vs.Time of4’-hydroxyflurbiprofen (4’-OH-FLB) urine concentration across 
CYP2C9 genotypes 
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Figure 2.11 Visual predictive check (VPC) of flurbiprofen (FLB) plasma concentration in 
CYP2C9*1*1 
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Figure 2.12 Visual predictive check (VPC) of flurbiprofen (FLB) plasma concentration in 
CYP2C9*1*3 
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Figure 2.13 Visual predictive check (VPC) of flurbiprofen (FLB) plasma concentration in 
CYP2C9*3*3 
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CHAPTER 3  
Hepatitis C and Current Treatments 
3.1 INTRODUCTION 
3.1.1 Hepatitis C 
Hepatitis C is a contagious liver disease caused by infection with the hepatitis C virus 
(HCV). Currently, it has been estimated that nearly 130-170 million people worldwide, 
approximately 3% of population, are chronically infected with HCV.
1–3
 HCV is mainly 
transmitted through exposure to contaminated blood or needles. About 3 to 4 million 
people are newly infected by HCV every year.
1
 Although not everyone carrying HCV 
develops chronic hepatitis, there is approximately a 60%-70% chance that a HCV 
infection will become chronic, leading to a high risk of progression to severe liver disease 
including cirrhosis, hepatic dysfunction and hepatocellular carcinoma.
1,4–6
 In the United 
States, hepatitis C is the most common cause of liver transplantation and a major cause of 
death from liver disease.
7
 
3.1.2  Hepatitis C Virus 
HCV is a virus primarily infecting the hepatocytes and causing inflammation in the liver. 
It is a single positive strained RNA virus. HCV is reproduced through RNA-dependent-
RNA replication. With better understanding of the viral life cycle, more efforts have been 
focused on developing novel agents which directly interfere with certain steps during the 
viral replication process.
8
 
HCV is characterized by a broad variety of genotypes and subtypes. This heterogeneity 
makes HCV treatment and management challenging due to their different responsiveness 
to therapy.
9,10
 At least six major genotypes have been identified and their distribution 
varies geographically. Genotype 1, genotype 2 and genotype 3 are commonly observed 
worldwide. Subtype 1a is predominating in North America and Northern Europe, and 
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subtype 1b is prevalent in Southern and Eastern Europe and Japan. 
9,10
  Genotype 3 is 
more common in Southeast Asia. Genotype 4 predominates in the Middle East, especially 
in the Egypt, and is also found in Central Africa.
9,10
 Genotype 5 is primarily found in 
South Africa and genotype 6 distributes differently across countries in Asia. 
9,10
 
3.1.3 Current HCV Antiviral Treatments 
Unlike hepatitis A or B virus, there is no vaccine available for preventing HCV infection. 
However, HCV is curable through the use of antiviral treatment. The primary goal of the 
treatment is to eradicate the HCV in the long term. The success of HCV therapy is 
established by achieving sustained virologic response (SVR, more details in Section 3.2). 
Monotherapy with interferon was initially used for treating HCV by its inhibitory effect 
on viral replication. Pegylated interferon was then formed by adding the polyethylene 
glycol to interferon to prolong the elimination half-life and reduce the clearance. 
Meanwhile, ribavirin was found to have a synergistic effect with interferon-based therapy 
by enhancing the viral elimination and decreasing virologic breakthrough and relapse 
with multiple mechanisms of action.
11,12
 Until recently, the combination of peginterferon 
alpha (pegINF) and ribavirin (RBV) has been used as standard of care for chronic 
hepatitis among genotype 1 to 6.
13
 The dual therapy of pegINF and RBV (PR) is 
generally administered for 48 weeks in patients with HCV genotype 1, 4, 5 or 6 infection 
and given for 24 weeks in patients with HCV genotype 2 or 3 infection.
13
 Studies have 
shown SVR rates were 40-50% in patients with HCV genotype 1 infection and 70-80% in 
patients with genotype 2 or 3 infection.
14–18
 
With the increasing knowledge on molecular pathways of the viral life cycle, more efforts 
have been focused on developing agents that directly act on certain targets during viral 
replication.
8
 These direct acting agents (DAAs) are classified based on their action. One 
target is a nonstructural 3/4A (NS3/4A) serine protease essential for processing viral 
polyprotein to be mature and ready for further viral replication. Two protease inhibitors 
(PIs), telaprevir (Inciveck
TM
, Vertex Pharmaceutical) and boceprevir (Victrelis
TM
, Merck), 
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were approved by the US Food and Drug Administration (USFDA) and European 
Medicines Agency (EMA) in 2011 as a treatment for chronic HCV genotype 1 infection 
in adult patients. Both of them should be administered along with pegIFN and RBV, 
which enhance the suppression of HCV and reduce the development of viral resistance-
associated mutation. With the addition of the PI, SVR rate is improved up to 68%-75% in 
treatment naïve patients and to 41%-52% in patients who failed to achieve SVR in 
previous PR treatment.
19–22
 Furthermore, the duration of PI-based therapy could be 
adapted based on the viral response measured during the early stage of treatment by using 
a response-guided approach.
19–22
 However, current PI-based therapy is accompanied by 
viral resistant mutation and more side effects. Findings from major Phase 2 and Phase 3 
clinical trials of telaprevir and boceprevir are summarized in Table 3.1 and Table 3.2, and 
will be discussed in Section 3.4 and Section 3.5.  
3.1.4 Scope of Current Research  
Rationale 
To better understand the therapeutic effect of antiviral treatment and minimize the 
potential risk, it has been recommended that patient HCV RNA levels be monitored 
during treatment. More data have emerged regarding the virologic response evaluated at 
various time points, typically at treatment weeks 4, 12, 24 and at the end of treatment as 
well as 24 weeks after treatment completion. Virologic responses assessed early in the 
treatment have been demonstrated to have a strong predictive value for attaining SVR 
during the follow-up period.  Most clinical trials reported virologic response as the 
number of responders whose HCV RNA is undetectable at a given time. However, the 
evaluation of clinical efficacy of HCV antiviral treatment is generally based on the 
primary endpoint, SVR. Several published meta-analyses or systematic reviews 
compared the treatment effectiveness only according to the SVR data, while virologic 
responses at other time points were not included.
23–28
 Such one-endpoint analysis might 
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be affected by the variability in treatment duration. In addition, it did not account for the 
information of virologic responses developed during treatment.  
Objectives 
The objectives of the current work were:  
(1) to develop a statistical model describing the time course of longitudinal virologic 
response during treatment and follow-up periods across three HCV antiviral 
treatments: PR, telaprevir plus PR, and boceprevir plus PR. 
(2) to investigate the potential influence of patient population characteristics (e.g., race 
and advanced fibrosis)  and viral factors (e.g., HCV genotype and baseline viral 
level) on the response-time profile 
(3) to compare response parameters across different antiviral therapeutic regimens 
Approach 
A longitudinal model-based meta-analysis was applied to provide a framework for the 
quantitative assessment of response data across different HCV antiviral treatments. The 
initial analysis was conducted in NONMEM 7 by using a maximum likelihood algorithm. 
However, the initial model had some limitations and ran into computational difficulties 
when trying to incorporate variability at multiple levels. Later, a Bayesian analysis was 
used with a Markov Chain Monte Carlo algorithm. A hierarchical nonlinear mixed-effect 
model was developed characterizing the longitudinal HCV response data with 
acknowledgement of variability at both arm and study levels. 
3.2 HCV VIROGLOGIC RESPONSE IN CLINICAL TRIALS   
Sustained virologic response (SVR) is the primary clinical endpoint indicating the 
success of HCV therapy. The endpoint has a strong correlation with enduring clearance 
of virus and a reduced risk of progression to severe liver disease with improved outcomes 
in patients.
29–31
 SVR is defined as undetectable HCV RNA level 24 weeks after 
completion of therapy. Detectability of HCV RNA for defining SVR should be 
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determined through a sensitive assay with lower limit of detection of 50 IU/mL or less. 
Patient HCV RNA level has been recommended to be monitored at multiple time points 
along the course of therapy.
32,33
 Recently, more data have emerged regarding assessments 
of treatment effectiveness during treatment and at the end of treatment shown in Figure 
3.1 and Table 3.3. These endpoints provide more information about how patients 
typically respond to treatment and may also aid clinicians in modifying and optimizing 
the treatment strategy based on patient viral kinetics.
34
 Generally, a more sensitive assay, 
with a lower limit of detection in the range of 10-15 IU/mL, is used to determine if HCV 
RNA is detectable when evaluating the virologic response during treatment and making 
decisions on response-guided therapy and treatment discontinuation. Furthermore, 
clinical studies have found the undetectable HCV RNA levels during treatment, e.g., at 
week 4 and 12, were significantly associated with the SVR during the follow-up period. 
Thus, SVR can be predicted given the knowledge of early response. In our study, we 
aimed to understand the evolvement of virologic response during treatment and to further 
relate it to the primary clinical outcome, SVR. 
Virologic breakthrough occurs with reappearance of detectable HCV RNA while on 
treatment. The incidence of breakthrough could rise with reduced doses of ribavirin or 
peginterferon alpha in PI-based therapy, or patient non-adherence to the treatment. The 
emergence of HCV mutations with resistance or a reduced sensitivity to PIs are major 
contributing factors of virologic breakthrough in PI-based therapy. 
Null response and partial response are usually used to describe the treatment-experienced 
patients who failed the previous PR therapy. Retreatment with the addition of telaprevir 
or boceprevir substantially improves the SVR rates in these patients.
20,22
 In addition, the 
improvement is more significant in partial responders than null responders.
20,22
 
Virologic relapse occurs when the HCV RNA level reappears as detectable during the 
follow-up period even with an undetectable level at the end of treatment. Among those 
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who failed to achieve SVR in previous PR therapy, patients with virologic relapse 
benefited the most from addition of a protease inhibitor (telaprevir or boceprevir) to 
retreatment, compared to prior null and partial responders.
20,22
   
3.3 PREDICTORS FOR SVR 
Although chronic hepatitis C can be cured by antiviral therapy, high medication cost, 
complicated treatment regimen and frequent adverse events make the treatment burden 
heavy in patients. The emergence of resistant mutations to DAA is another issue for 
newly approved triple therapy of protease inhibitors (telaprevir or boceprevir) plus PR.
35
 
It is important to recognize factors which are predictive of the treatment outcomes. These 
factors may guide the choice of initial treatment for a patient; they also provide 
information concerning adjustment of the treatment regimen for patients to maximize the 
therapeutic benefit and minimize the cost and risk. 
The predictors for SVR can be categorized into several classes based on their sources: 
baseline patient (host) characteristics, baseline viral features, antiviral intervention and 
on-treatment virologic response. The first three classes of factors are usually determined 
before initiation of the treatment. These factors can help to select a more appropriate 
regimen for patients and identify patients who are more likely to respond to treatment. 
The virologic benchmarks assessed during the course of treatment can help to adapt the 
regimen with respect to the actual patient viral kinetics, which avoids unnecessary 
prolonged treatment and minimizes the potential risk while improving the clinical 
outcome.  
In this section, several factors are presented that are potentially associated with SVR in 
HCV antiviral treatment. Some predictors for PR therapy could remain important for new 
PI triple therapy, whereas some might not be significant. 
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3.3.1 Viral Factors 
Genotype 
HCV genotype is one of the most important baseline predictors of the response to HCV 
antiviral treatment, especially in PR therapy. Genotype 1 has less responsiveness to PR 
therapy than does genotype 2 or 3. It usually requires a higher dose of ribavirin during a 
longer term of treatment than genotype 2 or 3.
13
 Patients with chronic HCV genotype 2 or 
3 infection usually receive a lower dose of ribavirin at 800 mg per day in PR therapy for 
24 weeks, while patients with chronic HCV genotype 1are usually given a weight-based 
ribavirin dose of 1000 to 1400 mg per day in PR therapy for 48 weeks. PR therapy leads 
to a higher SVR rate (up to 80%) in patients with HCV genotype 2 or 3 infection than in 
those with genotype 1 (40%-50%).
13,14,36
 Protease inhibitors, telaprevir and boceprevir, 
are approved by the FDA only for treatment of chronic HCV genotype 1 infection. One 
telaprevir study enrolled a small number of treatment-naïve patients with HCV genotype 
2 and 3 infections. The telaprevir showed antiviral activity in patients with genotype 2 
HCV but limited effect against genotype 3.
37
 However, it appears less effective in these 
two genotypes compared to that in genotype 1. 
Baseline Viral Load 
Baseline viral load is another factor predicting the response in PR therapy. Patients with 
higher viral RNA levels (greater than 800,000 IU per ml or 200,000 copies per ml) are 
less likely to achieve SVR, possibly due to rapid viral replication and reproduction.
14,16,36
  
The predictive value of baseline viral load for SVR rate is also observed in PI triple 
therapy among patients with chronic HCV genotype 1 infection. In the SPRINT-2 study, 
boceprevir-based therapy led to SVR rates of 61% and 63% in patients with baseline viral 
levels more than 800,000 IU per ml, while SVR rates were 76% and 85% in those with 
viral loads less than 800,000 IU per ml.
21
 The ADVANCE trial showed SVR rate of 
telaprevir arms were 78% in patients with baseline viral loads less than 800,000 IU per 
ml and 74% in baseline viral higher than 800,000 IU per ml.
19
 Both phase 3 trials showed 
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that lower baseline viral load was associated with slightly higher SVR rate. However, the 
predictive effect of baseline viral load was not as significant as in PR therapy.  
Virologic Responses During Treatment 
The patient HCV RNA level is recommended to be monitored during treatment. A 
virologic response is defined as an undetectable HCV RNA level is achieved. Achieving 
a rapid virologic response at week 4 of treatment (RVR) is strongly associated with the 
success of SVR in PR therapy, even in patients with unfavorable baseline factors. It has 
been demonstrated as the most important predictor of SVR.
38–40
 Although the predictive 
value of an early virologic response at week 12 (EVR) is less significant than RVR, 
failure to obtain the EVR strongly suggests little chance of having the SVR in PR 
therapy.
13,41,42
 Accordingly, a negative EVR sometimes is used as one of the study futility 
rules to discontinue  treatment in patients who are unlikely to achieve the SVR due to 
inadequate response to the treatment.
13
 
Early on-treatment viral kinetics remains important in the context of PI triple therapy. 
Phase 3 studies of telaprevir confirmed the predictability of virologic response at week 4 
and week 12 for SVR among treatment-naïve and previously treated patients
19,20
, and 
suggested a therapy strategy guided by response.
19,43
 Virologic response at treatment 
week 8 of boceprevir treatment was found to be significantly associated with SVR 
rate.
21,22
 A response-guided strategy is also applied to guide the further boceprevir 
therapy among both treatment-naïve and treatment-experienced patients.
21,22,44
 In addition, 
virologic response during lead-in PR therapy was also demonstrated as a strong predictor 
of SVR for the subsequent boceprevir therapy. 
21,22
 In the SPRINT 2 study, 81% and 79% 
of treatment naïve patients who had a lead-in response achieved the SVR in response 
guided boceprevir therapy and 48-week boceprevir-base therapy, respectively. The strong 
predictive effect of lead-in PR response on SVR even overcame the negative impact of 
undesirable baseline host (e.g., IL28B TT or CT genotype) or viral factors (e.g., high 
baseline viral level).
21
 In the RESPONSE 2 trial among previously treated patients, the 
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odds ratio of the SVR rate in patients with lead-in response to those without the lead-in 
response was 5.2 (p<0.001). 
22
 
Monitoring viral kinetics during treatment also helps to determine treatment 
discontinuation in patients who are unlikely to achieve the SVR. It is important to 
recognize PI treatment futility to avoid unnecessary prolonged therapy and to reduce the 
potential risk of adverse events and further development of viral resistibility which may 
comprise future therapy. It is recommended that telaprevir treatment should be 
discontinued in patients whose HCV RNA levels are greater than 1000 IU/ml at week 4 
or in patients who fail to have a 2 log drop in HCV RNA level by week 12 or in those 
who have detectable HCV RNA at week 24 of therapy.
45
 Boceprevir treatment should be 
discontinued in patients with HCV RNA levels greater than 100 IU/ml at week 12 or in 
those who have detectable HCV RNA at week 24.
44
 
3.3.2 Baseline Patient Characteristics 
Race/Ethnicity 
Clinical trials conducted in western countries reported that dual therapy of PR led to the 
SVR rates of 40%-50% and70%- 80% in patients with HCV genotype1 infection and in 
patients with genotype 2 or 3 infection respectively.
14–18
  Remarkably higher SVR rates 
were reported from PR therapy trials in Asia as approximately 70% in genotype 1 and 90% 
in genotype 2 or 3 infection.
46
 Furthermore, African Americans are less likely to achieve 
SVR during the PR therapy than non-African Americans. The SVR rates in African 
Americans were 19% -28% compared to 39%–52% in non-African-Americans.47–51 
Hispanic patients also have less chance of achieving SVR in PR therapy than non-
Hispanic white patients.
52
 
The addition of a PI (telaprevir or boceprevir) to PR therapy significantly improves the 
SVR rate in black patients; however, the SVR rate is still lower than that in nonblack 
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patients.
19,21
 Telaprevir-based therapy led to 62% of SVR rate among black patients and 
75% in nonblack patients, compared to 25% and 46%  in PR alone. In the black cohort, 
SVR rates were 53% in 48-week boceprevir-based therapy, 42% in response-guided 
boceprevir therapy and 23% in PR therapy; whereas in nonblack cohort, SVR rates were 
68%, 67% and 40% respectivelly.
21
 It is still unclear how race/ethnicity affects the 
clinical outcome of HCV treatment. Race has been found to be correlated with the 
frequency of IL28B genotypes, suggesting that a lack of the favorable IL28B CC 
genotype in African Americans might be responsible for poor response in this 
subgroup.
53
  
Liver Fibrosis 
The progression to advanced fibrosis, e.g., bridging fibrosis or cirrhosis, is linked to 
failure in response to HCV treatment. Given the small number of patients with cirrhosis 
in most studies, the effect of advanced fibrosis on clinical outcome is not always found to 
be significant in the analysis. Among patients with HCV genotype 1 or 4 treated by PR 
therapy, the SVR rate was gradually diminished as 60% in patients without advanced 
fibrosis to 51% in patients with bridging fibrosis followed by 33% in those with 
cirrhosis.
54
 
The combination of a PI (telaprevir or boceprevir) with PR therapy improved the SVR 
rate in patients with mild or advanced fibrosis. However, patients with advanced fibrosis, 
especially with cirrhosis, are still at a great risk of failure in response to PI triple therapy. 
Boceprevir-based treatment led to a SVR rate of 67% in patients with mild fibrosis 
(metavir score 0-2) while a SVR rate of 52% in patients with advanced fibrosis (metavir 
score 3 or 4), compared with PR therapy which led to a 38% SVR rates in both 
subgroups.
21
 Sixty-two percent of patients with bridging fibrosis achieved SVR in 
telaprevir-based therapy, compared to 33% in PR therapy.
19
 The likelihood of SVR in 
patients with minimal or portal fibrosis was dramatically increased by telaprevir and was 
higher than that in patients with advanced cirrhosis.
19
 Still, the effect of advanced fibrosis 
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should be interpreted with caution in these studies due to the enrolment of a limited 
number of patients with severe fibrosis enrolled.   
Polymorphism of IL28B 
A genetic polymorphism identified near the human gene interleukin 28B (IL28B) 
encoding interferon lambda 3 gene is associated with the elimination of HCV and is a 
strong predictor of SVR in PR therapy. 
53,55,56
 The genome wide association study 
(GWAS) showed patients with the CC genotype achieved a higher SVR rate than those 
with TT genotype in PR therapy.
56
  IL28B polymorphism was also associated with early 
on-treatment virologic response in PR therapy.
57
 Varied distribution of genetic 
polymorphism of IL28B among races/ethnicity could partially explain the difference in 
treatment outcome in these groups of patients. 
53
 The C allele leading to greater HCV 
clearance has the highest prevalence in Asia, followed by Europe. Low frequency of the 
C allele and high frequency of the T allele in African American patients could contribute 
to the poor response to PR therapy.
53
 
However, the predictive effect of IL28B polymorphism in PI triple therapy is not found 
to be as strong as that in PR therapy, but is still associated with response to the therapy. 
Knowing the patient IL28B genotype could help to predict the likelihood of achieving 
SVR and the possibility of shortening the PI-based treatment. From retrospective analysis 
of Phase 3 studies of boceprevir and telaprevir, the improvement in SVR rate by adding a 
PI to PR therapy was more substantial in treatment-naïve patients with the unfavorable T 
allele (e.g., CT or TT genotype) than was that in patients with CC genotype.
58,59
 But the 
CC genotype was still associated with a higher SVR rate in PI-based therapy and early 
virologic response which might lead to a shorter term treatment. 
58–60
 Furthermore, IL28B 
genotype appeared to be associated with the responsiveness to lead-in PR therapy at week 
4 of boceprevir treatment. However, the predictive effect of IL28B for SVR was 
diminished when considering the response at the end of lead-in PR therapy in boceprevir. 
The REALIZE trial of telaprevir among the treatment-experienced patients showed that 
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the SVR rates were comparable among groups of CC, CT and TT genotypes given one 
type of prior response to PR therapy. The predictive effect of IL28B genotype for SVR 
rate was not as strong as prior PR response in telaprevir retreatment.
61
  
Response to Prior Interferon-based Therapy 
Previous response to interferon therapy is a crucial determinant for predicting patient 
response to retreatment. It has been demonstrated that prior patient response to PR 
therapy is strongly associated with SVR rate of retreatment by adding a PI to PR therapy. 
PI-based treatment is given to retreat three major types of patients who failed previous 
PR therapy, which are null responders, partial responders and relapsers (definitions seen 
in Section 3.2.1). The addition of PI to PR therapy significantly improved the likelihood 
of SVR by 41%-52% in patients who did not response well to previous PR therapy.
20,22
 
However, the incremental benefit in SVR rate varies with respect to patient prior 
interferon response. Prior relapsers are most likely to achieve the SVR in retreatment of 
PI triple therapy, followed by prior partial responders. Null responders have the lowest 
SVR rate as compared to prior relapsers and partial responders.  In the REALIZE trial, 
the SVR rate in two telaprevir arms were 83% and 88% in prior relapsers, 59% and 54% 
in partial responders and 29% and 33% in null responders .
20
 For boceprevir, SVR rates 
were higher in prior relapsers (75% and 69% in two boceprevir arms) than in prior partial 
responders (52 % and 40% in boceprevir arms).
22
  
3.4  CLINICAL TRIALS OF TELAPREVIR 
Telaprevir is an inhibitor with specific binding to HCV nonstructural (NS) 3/4A serine 
protease which an essential factor catalyzing the HCV polyprotein cleavage during the 
polyprotein processing.  The viral replication is thus inhibited by telaprevir. The drug is 
produced by Vertex Pharmaceuticals (Cambridge, Massachusetts, United States).
45
 It was 
approved by the USFDA for treating chronic hepatitis C genotype 1 infection in adult 
patients who are treatment-naïve or have failed to respond to previous therapy of 
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interferon and ribavirin, including null responders, partial responders and relapsers. The 
labeled dose is 750 mg orally taken three times a day (every 7 to 9 hours) with food.
45
 
Telaprevir must be administered in combination with peginterferon alpha and ribavirin.
45
  
The clinical efficacy and tolerability of telaprevir-based triple therapy has been 
established in several clinical trials including three Phase 2 studies (PROVE 1
62
, PROVE 
2
63
, and PROVE 3
64
) and three Phase 3 studies (ADVANCE
19
, ILLUMINATE
43
 and 
REALIZE
20
). Among these studies, four (PROVE 1, PROVE2, ADVANCE and 
ILLUMINATE) were conducted in treatment-naïve patients and two (PROVE 3 and 
REALIZE) in patients previously treated but failing interferon-based therapy. In all 
studies, telaprevir was administered with peginterferon alpha-2a and ribavirin. 
Peginterferon alpha-2a was given at 180 μg per week by subcutaneous injection and 
ribavirin was orally taken at weight-based doses of 1000 mg per day in patients with 
body weight less than 75 kg or at 1200 mg per day in those with body weight greater than 
or equal to 75 kg. The assays used for quantifying the plasma HCV RNA levels during 
the trials had lower limit of quantification of 25 IU/mL and a lower limit of detection of 
10 IU/mL. 
3.4.1 Therapeutic Efficacy 
In the Phase 2 studies, telaprevir was given in combination with PegINF and RBV for 12 
weeks, followed by PR therapy alone for addition 12 weeks or 36 weeks, which made the 
whole treatment for 24 weeks (T12PR24) or 48 weeks (T12PR48). Studies showed the 
addition of telaprevir significantly improved the SVR rate up to 69% among treatment 
naïve patients, compared to less than 50% in the 48-week PR therapy alone.
62,63
 
Telaprevir-based therapy also yielded a substantial increase in SVR rate in treatment-
experienced patients who failed to achieve the SVR in previous interferon-based therapy. 
The SVR rate was improved up to 53% among previously treated patients compared to 14% 
in 48-week PR therapy (PR48) alone.
64
 Virologic relapse occurred less frequently in 
telaprevir-based therapy given for at least 24 weeks in total than that in 48-week PR 
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therapy. The treatment with only 12-week triple therapy of telaprevir plus PR led to a 
high virologic relapse rate. It suggests the extended PR therapy after telaprevir period 
helped to enhance the viral elimination and prevent future viral relapse when the whole 
treatment was completed.
62,63
 Virologic breakthrough was seen more commonly in 
patients treated with telaprevir-based therapy. It was attributed to the variants with 
resistance to telaprevir.  Telaprevir treatment without RBV was also evaluated and 
resulted in the diminished SVR rates and increased viral breakthrough. 
63,64
 
The Phase 3 studies further evaluated and confirmed the efficacy and safety of telaprevir 
in combination with PegINF and RBV. A response-guided therapy (RGT) was introduced 
to guide the telaprevir-based therapy. In the ADVANCE trial
19
, telaprevir was 
administered in conjunction with PegINF and RBV for 8 weeks (T8PR) or 12 weeks 
(T12PR), and the subsequent PR alone therapy was determined based on patient HCV 
RNA levels measured at week 4 and week12. If patients achieved the eRVR 
(undetectable HCV RNA at both weeks 4 and 12), the PR therapy after the telaprevir 
period was given up to week 24. Otherwise, patients received a longer PR therapy until 
week 48. The study showed the superiority of telaprevir-based treatment with higher 
SVR rate over PR therapy alone. The SVR rates were 75% in the T12PR and 69% in the 
T8PR, significantly higher than 44% in the 48-week PR therapy (PR48). 
19
 Based on 
response-guided therapy, 57% and 58% of patients in the T8PR and T12PR groups 
achieved the eRVR, respectively, and 83% and 89% obtained the SVR, respectively. 
19
 It 
suggested the eRVR was a strong predictor for the SVR. The ILLUMINATE study 
further presented the robustness of eRVR-guided telaprevir treatment. After receiving 12-
week telaprevir triple therapy, patients who had the eRVR were randomly assigned to 
receive the PR therapy for either 12 weeks or 36 weeks, leading to the whole treatment 
for 24 weeks (T12PR24) or 48 weeks (T12PR48). 
43
 A total of 65% of patients achieved 
the eRVR and received the RGT which led to SVR rates of 92% in the T12PR24 and 88% 
in the T12PR48. 
43
 In contrast, The SVR rate was only 64% in patients who did not 
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achieve the eRVR during the telaprevir period and received the PR therapy up to week 48. 
43
The study suggested the telaprevir-based therapy could be shortened by using the RGT 
treatment without diminishing the therapeutic effect in treatment-naïve patients. 
43
  
The REALIZE study evaluated the telaprevir-based retreatment among patients who 
previously failed to achieve the SVR during the PR therapy. The study consisted of three 
treatment arms, one received telparevir triple therapy for first 12 weeks and PR therapy 
alone for additional 36 weeks (T12PR48), one received a 4-week lead in period of PR 
therapy followed by 12-week telaprevir triple therapy and 36-week PR therapy alone 
(Lead-in T12PR48), and the control arm received 48-week PR therapy (PR48). 
20
 The 
addition of telaprevir to PR therapy significantly improved the SVR rate in all these 
previous treated patients (64% in T12PR48 and 66% in Lead-in T12PR48 versus 17% in 
PR48). 
20
 Similar to the PROVE 3 study, the prior response to interferon-based therapy 
was strongly associated with the outcome of the telaprevir-based retreatment. The SVR 
rates for relapsers were 83% in the T12PR48 and 88% in the Lead-in T12PR48, were 59% 
and 54% for partial responders, respectively, and were 29% and 33% for null 
responders.
20
 Relapsers retreated with telaprevir achieved the SVR rate as high as 
treatment naïve patients. Although there is no study directly evaluating the RGT 
telaprevir therapy in relapsers, the current label approved by FDA recommends the RGT 
guided by eRVR could be used in relapsers.
45
 As in the Phase 2 studies, virologic relapse 
was less common in telaprevir combination therapy than in PR therapy, irrespective of 
treatment-naïve or treatment-experience patients.
19,20
 Variants with resistance to 
telaprevir were observed in the telaprevir treatment.
19,20
  
3.4.2 Tolerability 
Since telaprevir is used in combination with pegINF and RBV, interferon-related adverse 
events are consistently observed in such combination therapy, such as fatigue and 
influenza-like symptoms. However, more adverse events were noted and attributed to 
telaprevir administration than PR therapy alone, including rash (56% in telaprevir versus 
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34% in PR), pruritus (47% versus 28%), nausea (39% versus 28%), anemia (36% versus 
17%) and diarrhea (26% versus 17%).
65
Among these, rash, anemia and pruritus were the 
most common serious adverse events occurring during the telaprevir combination therapy 
with pegINF and RBV. In the Phase 2 and 3 clinical trials, treatment discontinuation due 
to adverse events occurred more frequently in telaprevir –based therapy versus that in PR 
therapy , 21% versus 11% in the PROVE 1 study
62
, 12% versus 7% in the PROVE 2 
study
63
, 15% versus 4% in the PROVE 3 study
64
, 10% versus 7% in the ADVANCE 
study
19
, and 13% versus 3% in the REALIZE study. 
20
  
3.5  CLINICAL TRIALS OF BOCEPREVIR  
Boceprevir is another DAA which directly targets the hepatitis C viral life cycle. Like 
telaprevir, it inhibits HCV polyprotein processing by specifically binding to the 
nonstructural protein NS3/4A serine protease. The drug is produced by Merck (New 
Jersey, United States). It is approved by the USFDA as a treatment for chronic hepatitis C 
genotype 1 infection in adult patients who are previously untreated before or who have 
failed previous treatment of interferon and ribavirin, including prior null responders, 
partial responders and relapsers. Boceprevir must be used in combination with 
peginterferon alpha and ribavirin. It is recommended to orally take 800 mg (four 200 mg 
capsules) three times a day (every 7 to 9 hours) with food.
44
  
The clinical efficacy and tolerability of boceprevir-based therapy have been established 
in several clinical trials among treatment-naïve patients in a Phase 2 study (SPRINT-1)
66
 
and a Phase 3 study (SPRINT-2)
21
 and among previously treated patients in a Phase 3 
study (RESPOND-2).
22
 In all clinical trials, boceprevir was administered with 
peginterferon alpha-2b and ribavirin. Peginterferon alfa-2b was subcutaneously injected 
at a dose of 1.5 μg/kg, and ribavirin was orally taken with a total dose of 600 mg to 1400 
mg per day. The assays used for quantifying the plasma HCV RNA levels during the 
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trials had lower limit of quantification of 25 IU/mL and a lower limit of detection of 9.3 
IU/mL. 
3.5.1 Therapeutic Efficacy 
The Phase 2 study SPRINT-1 consisted of two parts to evaluate the efficacy and safety of 
boceprevir-based therapy. The first part of the study included the boceprevir therapy with 
and without a 4-week lead-in PR therapy for 28 weeks (PR4/PRB24, PRB28) or 48 
weeks (PR4/PRB44, PRB48). The second part of the study compared the efficacy of 48-
week boceprevir-therapy with a standard dose (800-1400 mg per day) of ribavirin and a 
lower dose (400-1000 mg per day) of ribavirin. 
66
 All treatments containing boceprevir 
significantly improved the likelihood of achieving the SVR, compared to the 48-week PR 
therapy (PR48) alone. The SVR rates were 54% in PRB28, 56% in PR4/PRB24, 67% in 
PRB48, and 75% in PR4/PRB48, versus 38% in PR48. 
66
 Interestingly, the regimen 
including a lead-in PR period before the addition of boceprevir appeared to have the 
higher SVR rate and the lower rates of relapse and virologic breakthrough. The 
responsiveness to the lead-in PR therapy was introduced as having a drop in HCV RNA 
by at least 1.5-log10 at week 4, which was shown as a strong predictive factor for the SVR. 
Patients responding to the lead-in PR were more likely to achieve the SVR. 
66
 The second 
part of the study showed the reduced dose of RBV in boceprevir combination therapy 
was associated with a lower rate of SVR and higher rate of relapse compared to the 
therapy with standard dose of ribavirin, suggesting the crucial role of RBV in the 
boceprevir therapy. 
In the Phase 3 studies, the boceprevir-based therapy with lead-in PR period was further 
investigated given with response-guided therapy (RGT) strategy and fixed term. In the 
SRPINT-2 study, treatment-naïve patients were randomized to one of three regimens. 
The control group received PR therapy alone for 48 weeks (PR48). Following the 4-week 
PR therapy period, one of boceprevir arms was given with boceprevir combined with PR 
therapy up to week 48 (PR4/PRB48). 
21
 The other boceprevir arm was adopted with RGT 
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strategy that patients who had the undetectable HCV RNA at week 8 through week 24 
(i.e., early responders) received boceprevir plus PR therapy up to week 28; and patients 
whose HCV RNA level was detectable at week 8 or any subsequent visit but was still 
undetectable at week 24 (i.e., slow responders) continued with PR therapy until week 48 
after boceprevir triple therapy stopped at week 28 (RGT-PRB). 
21
 Overall, 57% of the 
patients in both boceprevir arms and 17% in PR48 arm had the undetectable HCV RNA 
at week 8 during treatment.  Among these patients, the SVR rates were 88% in the RGT-
PRB, 90% in PR4/PRB48 and 85% in PR48. In contrast, among patients who did not 
show the early response at week 8, the SVR rates were 36%, 40%, and 30%, respectively. 
21
 This result suggests undetectable HCV RNA at week 8 is a strong predictive factor for 
a high SVR rate. Response to the lead-in PR therapy (defined as having at least 1-log10 
drop in HCV RNA level at week 4) was also associated with higher SVR rate in both 
boceprevir treatment arms. 
21
 Theoretically, the lead-in PR therapy aid to decrease the 
HCV RNA level before the patient is exposed to boceprevir and to lower the risk of viral 
resistance. In addition, a lead-in regimen allows the assessment of the patient 
responsiveness, compliance and tolerability to PR which is the backbone of boceprevir 
triple therapy before the boceprevir is initiated. 
21
  
The boceprevir treatment was also evaluated in previously treated patients who failed to 
respond to PR therapy in the RESPOND-2 trial. In this study, the boceprevir treatment 
was guided by the viral responses at week 8 and week 12. After 4-week lead-in period, 
patients with undetectable HCV RNA levels at both weeks 8 and 12 completed the 
boceprevir triple therapy at week 36, and patients with detectable HCV RNA levels at 
week 8 but undetectable HCV at week 12 continued to receive PR therapy for additional 
12 weeks up to week 48 after boceprevir triple therapy stopped at week 36. 
22
 The 
RESPOND-2 trial showed boceprevir combined with PR therapy significantly improved 
the SVR rate in prior partial responders and relapsers. The SVR rates were 75%, 69% and 
29% in prior relapsers with PR4/BPR48, response-guided boceprevir treatment and PR48, 
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respectively, and 52%, 40% and 7% in partial responders in the corresponding treatment 
groups. 
22
 Like treatment-naïve patients, the study also showed the association of 
undetectable HCV RNA at week 8 with the success of SVR, suggesting the boceprevir 
therapy could be shortened based on virologic response at week 8 without jeopardizing 
the clinical outcome for treatment-experienced patients. It is noted that null responders 
were not included in the RESPOND-2 trial. An ongoing, open-label, single-arm trial 
recently evaluated the boceprevir therapy in prior null responders to interferon and 
ribavirin therapy (PROVIDE). 
67
 In this study, null responders received 4-week PR lead-
in treatment followed by the triple therapy of boceprevir plus PR up to week 48. The 
SVR rate was significantly higher in boceprevir-based therapy than that in the PR48 arm 
as 38% versus 14%. 
67
 
3.5.2 Tolerability 
Boceprevir-based therapy is associated with a higher rate of serious adverse events and 
more treatment discontinuation due to adverse events, although there were no new side 
effects reported from boceprevir. The most notable side effects in boceprevir treatment 
include anemia and dysgeusia compared to PR therapy.  In the SPRINT-1 study, rates of 
dysgeusia and anemia were higher in groups receiving boceprevir treatment than that in 
PR group (27% vs. 9% for dysgeusia and 55% vs. 34% for anemia).
66
 In the SPRINT-2 
study, dysgeusia occurred more than twice frequently in boceprevir arms than in PR arm. 
Rates of anemia (hemoglobin<10 g/dL) were 49% for both fixed-duration and response-
guided boceprevir treatment, compared to 29% in PR48.
21
 In the RESPOND-2 trial 
among treatment-experienced patients, 45% of patients with boceprevir treatment and 20% 
patients with PR therapy reported anemia as adverse events and 20% of patients. 
22
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Trial Intervention Regimen group (N) SVR (%) P value Relapse (%)
T12PR12 (N=17) 35 _ 33
T12PR24 (N=79) 61 0.02 2
T12PR48 (N=79) 67 0.002 6
PR48 (control, N=75) 41 _ 23
T12PR12 (N=82) 60 0.12 30
T12PR24 (N=81) 69 0.004 14
T12P12 (N=78) 36 0.2 48
PR48 (control, N=82) 46 _ 22
T8PR (N=363) 69 <0.001 9
T12PR (N=364) 75 <0.002 9
PR48(control, N=361) 44 _ 28
With eRVR, T12PR24 (N=162) 92 _ 6
With eRVR, T12PR48 (N=160) 88 _ 3
Without eRVR,  T12PR48 (N=118) 64 _ 11
PRB28 (N=107) 54 0.013 30
PRB48 (N=103) 67 <0.0001 7
PR4/PRB24 (N=103) 56 0.005 24
PR4/PRB44 (N=103) 75 <0.0001 3
PR48 (control, N=104)) 38 _ 24
LD-PRB48 (N=59) 36 _ 22
SD-PRB48 (N=16) 50 _ 11
PR4/PRB44 (N=366) 76 <0.001 9
PR4/PRB (N=368) 71 <0.001 9
PR48 (control, N=363) 53 _ 22
PROVE-2
60
PROVE-1
59
 ILLUMINATE
45
ADVANCE
19
SPRINT-1
64
SPRINT-2
21
Boceprevir (PO): 800 mg three times per day;                                             
Peginterferon alfa-2b (SC): 1.5 μg/kg once per week;                                                 
Ribavirin (PO): 800-1400 mg per day based on body weight as standard dose (SD) 
or 400-1000 mg per day base on body weight as low dose (LD) 
Boceprevir (PO): 800 mg three times per day;                                                     
Peginterferon alfa-2b (SC): 1.5  μg/kg onceper week;                                                
Ribavirin (PO): 600-1400 mg per day based on body weight
Telaprevir (PO): 1250 mg loading dose on 1st day, followed by 750mg every 8 hours;  
Peginterferon alfa-2a (SC): 180 μg once per week;                                      
Ribavirin (PO): 1000 mg (BW<75kg) or 1200 mg (BW≥75kg) per day                                                                       
Telaprevir (PO): 1250 mg loading dose on 1st day, followed by 750mg every 8 hours;  
Peginterferon alfa-2a (SC): 180  μg once per week;                                      
Ribavirin (PO): 1000 mg (BW<75kg) or 1200 mg (BW≥75kg) per day                                                                       
Telaprevir (PO):750 mg every 8 hours;                                                            
Peginterferon alfa-2a (SC): 180  μg once per week;                                       
Ribavirin (PO): 1000 mg (BW<75kg) or 1200 mg (BW≥75kg) per day                                                                      
Telaprevir (PO):750 mg every 8 hours;                                                           
Peginterferon alfa-2a (SC): 180  μg once per week;                                      
Ribavirin (PO): 1000 mg (BW<75kg) or 1200 mg (BW≥75kg) per day                                                                    
Table 3.1 Findings from Phase 2 and Phase 3 studies of telaprevir and boceprevir in treatment-naïve patients with chronic hepatitis C genotype 1 
infection 
Note: PO, orally; SC, subcutaneously; BW, body weight; eRVR: extended rapid virologic response; PR: peginterferon alpha and ribavirin; PR48: peginterferon 
alpha and ribavirin were given for 48 weeks; T12PR12, triple therapy of telaprevir combined with PR was given for 12 weeks; T12PR24, triple therapy of 
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telaprevir and PR was given for 12 weeks, followed by PR therapy alone for another 12 weeks; T12PR48, triple therapy of telaprevir and PR was given for 12 
weeks, followed by PR therapy alone for another 36 weeks; T12P12, telaprevir was administered with only peginterferon alpha for 12 weeks; T8PR, telaprevir 
combined with PR was given for 8 weeks and the following term of PR-alone therapy was determined by patient viral response (eRVR); T12PR, telaprevir 
combined with PR was given for 12 weeks and the following PR-alone therapy the term of which was determined by patient viral responses at treatment weeks 4 
and 12 (eRVR); PRB28, triple therapy of boceprevir and PR was given for 28 weeks; PRB48, triple therapy of boceprevir and PR was given for 48 weeks; 
PR4/PRB24, triple therapy of boceprevir and PR was given for 24 weeks after 4-week lead-in PR therapy; PR4/PRB44, triple therapy of boceprevir and PR was 
given for 44 weeks after 4-week lead-in PR therapy;  LD-PRB48, boceprevir was administered together with peginterferon alpha and low-dose ribavirin for 48 
weeks; SD-PRB48, boceprevir was administered together with peginterferon alpha and standard-dose ribavirin for 48 weeks. PR4/PRB, 4-week lead-in PR 
therapy was given, followed by triple therapy of boceprevir plus PR the duration of which was guided by patient viral response at treatment weeks 8 and 12. 
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Table 3.2 Findings from Phase 2 and Phase 3 studies of telaprevir and boceprevir in previously treated patients with chronic HCV genotype 1 infection 
Trial Intervention 
Previous virologic 
response 
Regimen group (N) 
SVR 
(%) 
P value 
Relapse 
(%) 
REALIZE
20
 
Telaprevir(PO): 750 mg every 8 hours;                                                                      
Peginterferon alfa-2a (SC): 180 μg once per week;                      
  Ribavirin (PO): 1000 mg (BW<75kg) or 1200 mg 
(BW≥75kg) per day 
total  
T12PR48 (N=266) 64 <0.001 12 
Lead-in T12PR48 (N=264) 66 <0.001 12 
PR48 (control, N=132) 22 _ 65 
null response  
T12PR48 (N=72) 29 <0.001 27 
Lead-in T12PR48 (N=75) 33 <0.001 25 
PR48 (control, N=37) 5 _ 60 
partial response 
T12PR48 (N=49) 59 <0.001 21 
Lead-in T12PR48 (N=48) 54 <0.001 25 
PR48 (control, N=27) 15 _ 0 
relapse  
T12PR48 (N=145) 83 <0.001 7 
Lead-in T12PR48 (N=141) 88 <0.001 7 
PR48 (control, N=68) 24 _ 65 
RESPOND-2
22
 
Boceprevir(PO): 800 mg three times per day; 
Peginterferon alfa-2b (SC): 1.5 μg/kg once per week; 
Ribavirin (PO): 600-1400 mg per day based on body 
weight 
total  
PR4/PRB44(N=161) 66 <0.001 12 
PR4/PRB (N=162) 59 <0.001 15 
PR48(control, N=80) 21 _ 32 
partial responder 
PR4/PRB44 (N=58) 52 _ _ 
PR4/PRB (N=57) 40 _ _ 
PR48 (control, N=29) 7 _ _ 
relapse  
PR4/PRB44 (N=103) 75 _ _ 
PR4/PRB (N=105) 69 _ _ 
PR48 (control, N=51) 29 _ _ 
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Table 3.2 Continued  
Note: PO, orally; SC, subcutaneously; BW, body weight; eRVR: extended rapid virologic response; PR: peginterferon alpha and ribavirin; PR48: peginterferon 
alpha and ribavirin were given for 48 weeks; T12PR24, triple therapy of telaprevir and PR was given for 12 weeks, followed by PR therapy alone for another 12 
weeks; T12PR48, triple therapy of telaprevir and PR was given for 12 weeks, followed by PR therapy alone for another 36 weeks; T12P24, telaprevir was 
administered with only peginterferon alpha for 24 weeks; Lead-in T12PR48, a 4-week lead-in PR therapy was given, followed by 12-week telaprevir triple 
therapy and then PR therapy through treatment week 48; PR4/PRB44, triple therapy of boceprevir and PR was given for 44 weeks after 4-week lead-in PR 
therapy; PR4/PRB, 4-week lead-in PR therapy was given, followed by triple therapy of boceprevir plus PR the duration of which was guided by patient viral 
response at treatment weeks 8 and 24. 
Trial Intervention 
Previous virologic 
response 
Regimen group (N) 
SVR 
(%) 
P value 
Relapse 
(%) 
PROVE-3
61
 
Telaprevir(PO): 1125 mg loading dose on 1st day, 
followed by 750 mg every 8 hours;                                                                                          
Peginterferon alfa-2a (SC): 180 μg once per week;                                                       
Ribavirin (PO): 1000 mg (BW<75kg) or 1200 mg 
(BW≥75kg) per day 
total  
T12PR24(N=115) 51 <0.001 30 
T24PR48(N=113) 53 <0.001 13 
T12P24(N=111) 24 0.02 53 
PR48(control,N=114) 14 _ 53 
null response  
T12PR24(N=66) 39 _ 37 
T24PR48(N=64) 38 _ 4 
T12P24(N=62) 11 _ 68 
PR48(control,N=68) 9 _ 40 
breakthrough  
T12PR24(N=7) 57 _ 0 
T24PR48(N=8) 62 _ 20 
T12P24(N=11) 36 _ 20 
PR48(control,N=5) 40 _ 0 
relapse  
T12PR24(N=42) 69 _ 18 
T24PR48(N=41) 76 _ 0 
T12P24(N=38) 42 _ 46 
PR48(control,N=41) 20 _ 62 
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Table 3.3 Definition of virologic response  
Virologic response Definition 
RVR (rapid virologic response) Undetectable  HCV RNA at TW 4 
EVR (early virologic response) Complete (cEVR): Undetectable HCV RNA at TW12; 
Partial(pEVR): At least 2-log10 drop in HCV RNA from 
baseline at TW12 
eRVR(extended rapid virologic 
response) 
Undetectable HCV RNA at both TW 4 and TW12 
(telaprevir) 
ETR(end-of-treatment response) Undetectable HCV RNA at the end of treatment 
SVR (sustained virologic response) Undetectable HCV RNA 24 weeks after treatment 
completion 
Null response Less than 2-log10 drop in HCV RNA from baseline at TW12 
Partial response Detectable HCV RNA although with 2-log10 drop in HCV 
RNA from baseline at TW12 
Virologic breakthrough Reappearance of detectable HCV RNA while on therapy 
Virologic relapse Reappearance of detectable HCV RNA after treatment 
completion 
Note: TW, treatment week; HCV RNA viral load should be assessed by using a sensitive assay with at least 
50 IU/mL in lower limit of detection. Generally, telaprevir and boceprevir-based therapies use a lower limit 
of detection of 10-15 IU/mL to determine the “undetectable” HCV RNA during treatment when 
considering the response-guided therapy and treatment discontinuation.
  
74 
 
Figure 3.1 Virologic response based on the course of treatment 
 
Note: RVR, rapid virologic response; EVR, early virologic response; ETR, end-of-treatment response; 
SVR, sustained virologic response. Modified the figure from 
http://www.hepatitis.va.gov/provider/guidelines/2012HCV-definitions-of-response.asp
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CHAPTER 4  
Systematic Review of Hepatitis C Clinical Trials  
4.1 LITERATURE SEARCH  
A broad systematic literature search was carried out in January 2012 in public databases 
including PubMed and clinicaltrials.gov. We also reviewed the Summary Basis of 
Approval available from the website of United States Food and Drug Administration and 
the equivalent approval documents from the European Medicines Agency for approved 
agents. The literature search was focused on telaprevir, boceprevir, and peginterferon 
plus ribavirin (PR). The key search terms included, but were not limited to: “chronic 
hepatitis C”, “sustained virologic response”, “hepatitis C virus”, “peginterferon 
alfa”,”telaprevir” and ”boceprevir”. Various combinations of search terms were applied 
according to disease and intervention of interest, such as “telaprevir + chronic hepatitis 
C”. We restricted the search to English-language reports of human clinical trials. 
A flow diagram of systematic review was constructed according to the template from 
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)
19
 in 
Figure 4.1. The initial search resulted in 101 records. Further inspection was given to the 
title and abstract of the literature, followed by a full-paper examination. Information of 
HCV clinical studies was reviewed, including study design, patient population, 
intervention, clinical outcomes, analysis and results. Treatments of interest included dual 
therapy of PR, and telaprevir and boceprevir combined with PR therapy. The virologic 
response/ treatment outcomes of interest for evaluating the HCV response included the 
number and percent of patients with undetectable HCV RNA measured at protocol-
determined time points and SVR rate (24 weeks after the end of treatment).  
Studies that met the following criteria were included for meta-analysis. (1) Studies should 
be human trials enrolling adult patients aged at least 18 years; (2) Patients were 
 84 
 
diagnosed with chronic hepatitis C virus infection; (3) Study design can be randomized or 
non-randomized, open-label or blinded; (4) Studies should report at least one clinical 
outcome of HCV response; (5) Studies should evaluate and report clinical outcomes at 
protocol-determined time points; (6) Treatments should be administered for a standard or 
fixed term which have been specified in the protocol; (7) Patients should be given a 
standard dose of ribavrin and peginterferon alpha in PR or PI-based therapy; (8) The 
sample size of a treatment arm or study should be greater than 15.  
Studies were excluded if trials were conducted in animal or in vitro or in patients who 
had undergone liver transplantation, or had other severe disease besides HCV, such as 
HIV and HBV, or had decompensated liver disease. Trials or treatment arms were 
excluded if the course of treatment was determined based on patients’ early on-treatment 
virologic responses by using response-guided therapy. Treatment regimens without 
standard dose of medication (e.g., ribavirin or peginterferon alpha) were not considered 
in this meta-analysis. Other reasons for literature exclusion included pharmacokinetic 
studies, reviews, case studies, editorials, letters and meta-analyses.  
4.2 DATASET CONSTRUCTION 
Data pertaining to baseline characteristics of patient population, clinical outcomes and 
treatment strategy were extracted from published manuscripts.  The information was 
usually summarized and reported for each of the treatment arms that were administered 
with different therapeutic regimens. Where possible, data were extracted for the intent-to-
treat patients, generally defined as patients who underwent the randomization and 
received at least one dose of study medication. The numbers of patients were extracted 
according to patient demographics, such as race/ethnicity, and clinical characteristics, 
including prior treatment experience and advanced fibrosis. Data were also extracted on 
patient viral information, for example, baseline viral load and HCV genotype. Clinical 
outcomes were recorded as number of responders with undetectable HCV RNA level. 
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The sample size in each arm of the trial was retained in the dataset. Due to high 
variability in treatment strategies, information was abstracted on medication, start and 
end times of drug administration and the duration of the whole therapy. Data extraction 
was conducted by one researcher and independently reviewed by another researcher. All 
the data were synthesized to a dataset ready for the model-based meta-analysis.  
4.3 DATASET FOR META-ANALYSIS 
After screening the literature identified from the database, a total of 24 studies were 
eligible for further assessment. Of these 24 studies, six studies were excluded due to 
small sample size and use of response-guided therapy (RGT) without fixed course of 
treatment. Studies that were included in the analysis may have specific arms excluded if 
they met the exclusion criteria. The final dataset available for model-based meta-analysis 
consisted of 18 HCV clinical trials with 47 treatment arms in total. The median (range) 
number of patients in each study is 407 (32-2054), and the median (range) number of 
patients per treatment arm is 114 (16-1035).  Sustained virologic response at 24 weeks 
after completion of treatment was reported in all trials while virologic response assessed 
at other time points were available to different extents across studies.  
Among arms enrolled in the dataset, 27 arms received the dual therapy of peginterferon 
alpha and ribavirin, and 20 arms received the triple therapy of a protease inhibitor 
combined with PR (12 with telaprevir and 8 with boceprevir). In one PR therapy, 
peginterferon alfa-2a was subcutaneously injected at a dose of 180 μg once per week and 
ribavirin was orally taken at a weight-based dose of 1000 mg for patients with body 
weight less than 75 kg or 1200 mg for patients with body weight greater than or equal to 
75 kg. For HCV genotype 2 or 3 infection, ribavirin was administered with a lower dose 
level at 800 mg. In another PR therapy, peginterferon alfa-2b was subcutaneously 
injected at a dose of 1.5 μg per kg per week and ribavirin is orally taken at weight-based 
dose of 800 to 1400 mg per day.  Telaprevir was administered with an oral dose of 750 
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mg three times a day (every 7-9 hours) or a loading dose the first day followed by 750 mg 
every eight hours. 
3-5 
Telaprevir was used in combination with peginterferon alfa-2a and 
ribavirin. Boceprevir was administered at an oral dose of 800 mg three times a day (every 
7-9 hours) together with peginterferon alfa-2b and ribavirin. Arms receiving a PI-based 
treatment but in the absence of ribavirin or with a low-dose ribavirin were not included in 
current analysis. PR therapy was generally given for 48 weeks in patients with genotype 
1 and for 24 weeks in patients with genotype 2 or 3.The duration of the whole PI-based 
therapy varied from 12 weeks to 48 weeks. Any study or arm receiving response-guided 
therapy had been excluded. The current meta-analysis is only focused on treatments with 
fixed course which was previously determined by the protocol.  
Twelve studies were conducted in treatment naïve patients who had not received any 
HCV treatment before, and six studies were in patients who had been previously treated 
by interferon-based therapy but failed to achieve the SVR. Most studies (n=12) only 
enrolled patients with chronic HCV genotype 1 infection. Two studies were focused on 
HCV genotype 2 or 3 infection and four studies enrolled patients infected with various 
HCV genotypes. Telaprevir and boceprevir are approved only for HCV genotype 1 
infection, while, PR therapy is used for treating both genotype 1 and other genotypes of 
HCV infection. To investigate the effect of treatment term, a covariate called “short term” 
was created as a binary data item with only two values of 1 and 0. For patients with 
genotype 1 HCV infection, treatments given for less than 48 weeks (standard term) were 
considered as a short-term therapy with 1as the value of this covariate; otherwise, 
treatments with 48 weeks were assigned with 0. For non-genotype 1 patients (genotype 2 
or 3), 24-week PR therapy is the standard course for the treatment, while any treatment 
shorter than 24 were assigned with 1 as the value of the covariate “short term”. Baseline 
characteristics that potentially influence the treatment outcome were incorporated in the 
current dataset with respect to HCV genotype, race/ethnicity, prior HCV treatment 
experience (e.g., null responders, relapsers), fibrosis stage (bridging fibrosis or cirrhosis), 
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and baseline HCV RNA level. The effect of IL28B genotype was investigated separately 
in retrospective analyses of Phase 3 studies of telaprevir and boceprevir.
20-23
 However, 
the information regarding IL28B genotype was not available in most enrolled studies. 
The current dataset did not incorporate the information of the patient IL28B genotypes, 
although IL28B may have significant effect on SVR and the time course of response. The 
covariates incorporated in the data set were summarized based on treatment arms in 
Table 4.2. The median (mean) proportion of black patients across all arms was 7.79% 
(11.3%), of patients with HCV genotype 1 infection was 100% (81.1%), of patients with 
bridging fibrosis or cirrhosis was 20.2% (20.8%), and patients with high baseline HCV 
RNA level was 82.9% (77.6%). Several studies were lacking of information regarding 
some of baseline population characteristics, such as black race 
13,17,18
 and advanced 
fibrosis
15
. During the analysis, these missing values were replaced with the corresponding 
median value. The study and relevant information in the analytic dataset were 
summarized in Table 4.2. 
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Figure 4.1 Flow chart of systematic review 
Note: Among 6 full-text articles excluded with reasons, five studies were excluded because of using only 
response-guided therapy and one study was excluded due to sample size smaller than 15. 
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Table 4.1 Summary information of baseline characteristics in arms included in the analysis 
Baseline Characteristics  Mean  Median Range  
Number of subjects 208 114 (16, 1035) 
Patients with HCV genotype 1 infection (%) 81.1 100 (0, 100) 
Prior null responder (%) 10.1 0 (0, 100) 
Prior relapsers (%) 11.3 0 (0, 84.4) 
Black patients (%) 11.3 7.79 (0, 100) 
Patients with bridging fibrosis or cirrhosis (%) 20.8 20.2 (0, 49.6) 
Patients with high baseline HCV RNA level (%) 77.6 82.9 (20.6, 100) 
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Table 4.2 Summary of studies in dataset for meta-analysis 
 
 
Study
Treatment 
Regimen
Treatment 
duration 
(weeks)
Short term       
(1: yes,0: no)
Patients 
(number)
Treatment-
naïve patients 
(1: yes, 0: no)
HCV genotype 
1 infection (%)
Prior null 
responders 
(%)
Prior 
relapsers 
(%)
Bridging 
fibrosis or 
cirrhosis (%)
Black 
(%)
High baseline 
HCV RNA (%)
Comments
Jacobson et al
1 PR48 48 0 361 1 100 0 0 20.2 7.76 77.3
Two telaprevir arms using RGT 
were excluded 
T12PR48 48 0 266 0 100 27.1 54.5 49.6 4.14 89.5
Lead-in T12PR48 48 0 264 0 100 28.4 53.4 47.3 3.03 88.6
PR48 48 0 132 0 100 28 51.5 44.7 8.33 86.4
T12PR24 24 1 115 0 100 57.4 36.5 39.1 7.83 92.2
T24PR48 48 0 113 0 100 56.6 36.3 46.9 9.73 92
PR48 48 0 114 0 100 59.6 36 38.6 8.77 91.2
T12PR24 24 0 79 1 100 0 0 17.7 8.86 83.5
T12PR48 48 0 79 1 100 0 0 17.7 10.1 86.1
T12PR12 12 1 17 1 100 0 0 23.5 17.6 88.2
PR48 48 0 75 1 100 0 0 25.3 12 92
T12PR24 24 0 81 1 100 0 0 11.1 1.23 90.1
T12PR12 12 1 82 1 100 0 0 7.32 2.44 81.7
PR48 48 0 82 1 100 0 0 9.76 2.44 82.9
T12PR24 24 1 24 0 100 100 0 45.8 8.33 95.8
T12PR48 48 0 27 0 100 100 0 40.7 11.1 100
PR48 48 0 311 1 100 0 0 7.4 0 83
PR4/PRB44 48 0 311 1 100 0 0 11.6 0 84.2
PR48 48 0 52 1 100 0 0 1.92 100 96.2
PR4/PRB44 48 0 55 1 100 0 0 10.9 100 92.7
PR48 48 0 80 0 100 0 63.8 18.8 15 81.3
PR4/PRB44 48 0 161 0 100 0 64 19.3 11.8 87.6
PR48 48 0 104 1 100 0 0 7.69 15.4 90.4
PR4/PRB24 28 1 103 1 100 0 0 6.8 14.5 87.4
PR4/PRB44 48 0 103 1 100 0 0 5.83 14.6 90.3
PRB28 28 1 107 1 100 0 0 6.54 16.8 91.6
PRB48 48 0 103 1 100 0 0 8.73 13.6 91.3
PRB48 48 0 16 1 100 0 0 0 25 81.3
Zeuzem et al
2
McHutchison et al
3
McHutchison et al
4
Hezode et al
5
Muir et al
6
Poordad et al
7
Bacon et al
8
Kwo et al
9 Boceprevir arm with low-dose 
ribavirin was excluded
T12P24 arm without ribavirin 
was excluded 
T12P12 arm without ribavirin 
was excluded
 Arms receiving RGT were 
excluded.
Arms receiving RGT were 
excluded
RGT arm was excluded
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Table 4.2 Continued  
 
Note: RGT, response-guided therapy; PR: peginterferon alpha and ribavirin; PR48: peginterferon alpha and ribavirin were given for 48 weeks; T12PR12, triple 
therapy of telaprevir combined with PR was given for 12 weeks; T12PR24, triple therapy of telaprevir and PR was given for 12 weeks, followed by PR therapy 
alone for another 12 weeks; T12PR48, triple therapy of telaprevir and PR was given for 12 weeks, followed by PR therapy alone for another 36 weeks; T12P12, 
telaprevir was administered with only peginterferon alpha for 12 weeks; T12P24, telaprevir was administered with peginterferon alpha for 12 weeks, followed by 
12-week peginterferon alone; PRB28, triple therapy of boceprevir and PR was given for 28 weeks; PRB48, triple therapy of boceprevir and PR was given for 48 
weeks; PR4/PRB24, triple therapy of boceprevir and PR was given for 24 weeks after 4-week lead-in PR therapy; PR4/PRB44, triple therapy of boceprevir and 
PR was given for 44 weeks after 4-week lead-in PR therapy;  Short term: For patients with genotype-1 infection, PR therapy, telaprevir and boceprevir therapy 
Study
Treatment 
Regimen
Treatment 
duration 
(weeks)
Short term       
(1: yes,0: no)
Patients 
(number)
Treatment-
naïve patients 
(1: yes, 0: no)
HCV genotype 
1 infection (%)
Prior null 
responders 
(%)
Prior 
relapsers 
(%)
Bridging 
fibrosis or 
cirrhosis (%)
Black 
(%)
High baseline 
HCV RNA (%)
Comments
PR16 16 1 372 1 0 0 0 27.7 3.2 78
PR16 16 1 358 1 0 0 0 22.6 2.8 60.3
PR24 24 0 369 1 0 0 0 20.3 0.813 62.9
PR24 24 0 356 1 0 0 0 25.3 5.05 75
Fried et al
11 PR48 48 0 453 1 65.8 0 0 12.4 6 64.7
Arm with interferon or low-
dose peginterferon was 
excluded 
Rodriguez-Torres et al
12 PR48 48 0 569 1 100 0 0 11.4 0 75.6
Manns et al
13 PR48 48 0 511 1 68.1 0 0 26.6 NA 68.7
Arm with interferon or low-
dose peginterferon was 
excluded 
PR24 24 0 96 1 0 0 0 20.8 0 64.6
PR24 24 0 118 1 100 0 0 22.9 0 39.8
PR24 24 0 144 1 0 0 0 27.1 0 67.4
PR48 48 0 99 1 0 0 0 20.2 0 66.7
PR48 48 0 271 1 100 0 0 28.8 0 68.6
PR48 48 0 153 1 0 0 0 21.6 0 68.6
T12PR24 24 0 126 1 100 0 0 NA 0 20.6
PR48 48 0 63 1 100 0 0 NA 0 28.6
PR48 48 0 1019 1 100 0 0 10.9 18 82
PR48 48 0 1035 1 100 0 0 10.6 19.3 82.3
Husa et al
17 PR48 48 0 203 0 100 43.3 51.7 9.85 NA 39.4
Herrine et al
18 PR48 48 0 32 0 78.1 0 84.4 28.1 NA 56.3
McHutchison et al
16
Shiffman et al
10
Hadziyanniset al
14
Kumada et al
15
Arm with low dose 
peginterferon was excluded
Arms with interferon or low-
dose ribavrin were excluded
 92 
 
were considered as a short-term therapy if treatment was given less than 48 weeks, while, for patients with genotype 2 or 3 infection, PR therapy was considered 
to be short if less than 24 weeks.
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CHAPTER 5  
Initial Model-Based Meta-Analysis of Virologic Response in Hepatitis C 
Clinical Trials Using NONMEM 
5.1 INTRODUCTION 
Hepatitis C is an infectious liver disease which is associated with a high risk of cirrhosis, 
hepatic dysfunction and hepatocellular carcinoma.
1–4
 Recently, it has been estimated that 
approximately 170 million people worldwide  and 3 to 4 million people in the United 
States are chronically infected with hepatitis C.
1,5–7
 Although there is no vaccine 
available to prevent the hepatitis C disease, it can be cured by antiviral treatments. The 
success of treatment is presented by achievement of sustained virologic response (SVR) 
at week 24 after completion of treatment. The combination therapy of pegylated 
interferon and ribavirin (PR) has been used for decades as a standard of care for chronic 
hepatitis C. It lead to a 70%-80% SVR rate in patients with chronic HCV genotype 2 or 3 
infection, but only 40%-50% in those with genotype 1.
8–13
 With the increasing knowledge 
in viral replication, more research interest and efforts have been focused on developing 
drugs which can target directly certain steps of viral life cycle.
14
 In 2011, United States 
Food and Drug Administration (USFDA) approved the first two direct-acting antiviral 
agents, telaprevir and boceprevir. 
15,16
 These two drugs are the inhibitors specifically for 
NS3/4A protease which is needed for translating and processing the viral polyproteins.  
Both of these two protease inhibitors (PI) are required to be administered in combination 
with peginterferon and ribavirin for treating chronic hepatitis C genotype 1 infection in 
adult patients. These new “triple therapies” dramatically improved the SVR rate to 68-
75% in patients chronically infected with HCV genotype 1.
17–20
 
To better understand the therapeutic effect of antiviral treatment and prevent the potential 
risk, it has been recommended that patient HCV RNA level be monitored along the 
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therapy at various time points, such as, treatment week 4, 12, 24 and at the end of 
treatment. Virologic response is defined and reported in clinical trials as the number or 
percentage of patients with undetectable HCV RNA at a given time point. The efficacy of 
HCV antiviral treatment is frequently evaluated based on the primary efficacy endpoint, 
the SVR rate evaluated at 24 weeks after completion of treatment. Recently, meta-
analyses and systematic review have been performed to provide an indirect comparison in 
therapeutic effectiveness across current antiviral treatments.
21–26
 However, these analyses 
only included primary efficacy endpoint, the SVR rate. Virologic response evaluated at 
other time points was not taken into consideration. A one-endpoint analysis could be 
affected by inconsistence in treatment duration. The response from 24-week treatment 
could be different from that 48-week treatment. In addition, the risk of bias may arise 
from potential heterogeneity among studies, including differences in study design and 
study population. Moreover, the development of virologic response during the treatment 
period could be different among different treatments.  
In the current study, a model-based meta-analysis (MBMA) was employed to integrate 
the longitudinal information of virologic response from multiple clinical trials. It permits 
us to quantitatively describe the time course of virologic response and to investigate the 
comparative effect of current HCV antiviral treatments on response-time profiles. Given 
the nature of meta-analysis, potential variability arises when pooling the data from 
different sources. Both inter-study variability and inter-arm variability should be 
considered. A previous study by Ahn and French presented how multiple random effects 
in meta-analysis were handled using NONMEM software for nonlinear mixed effects 
modeling.
27
 In this chapter, we explored the MBMA of longitudinal HCV virologic 
response in NONMEM using a maximum likelihood estimation algorithm.  
The objectives of the current study were to develop a mathematical model describing the 
time-course of longitudinal virologic response and compare the response-time profile 
between PI-based therapy and PR therapy. The study also explored multiple ways to 
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incorporate and estimate the inter-study variability and inter-arm variability. Potential 
covariates (e.g., HCV genotype) were evaluated for their effects on parameters of time-
course of response. 
5.2 METHODS 
5.2.1 Literature Review and Dataset Construction 
The literature search and systematic review of published HCV clinical trials were 
described in Chapter 4. Information has been abstracted from literature including 
longitudinal virologic response rates, baseline patient characteristics and treatment 
regimen. The dataset developed for model-based meta-analysis was summarized in 
Chapter 4. Additional details regarding the study selection and dataset construction were 
provided in Chapter 4. 
5.2.2 Model Development  
The longitudinal model-based meta-analysis was implemented by means of a nonlinear 
mixed-effects approach using NONMEM version 7 (ICON Development Solutions, 
Ellicott City, MD, USA). NONMEM was initiated to run through an R package 
“metrumrg” (Metrum Research Group, Tariffville, CT, USA) installed in the statistical 
software R (version 3.0). 
28
 Data management, graphic exploration, post-processing of 
NONMEM output and simulations were performed using R with the interface software 
RStudio (version 0.97.449, RStudio.Inc, Boston, MA, USA).   Model development and 
selection were guided by research interest, exploratory data analysis, change in objective 
function value (OFV) from importance sampling, and improvement in the diagnostic 
plots. A visual predictive check was conducted based on treatments to assess whether 
predictions from final model were consistent with observations.  
The response data collected in the meta-dataset was the number of patients who 
responded to the treatment with HCV RNA level below detection limit at a given time. 
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The number of responder (    )  at time s in arm j in study i is considered to follow a 
binomial distribution that depends on the sample size in arm j in study i and the response 
rate at time s in the arm j in study i (         ) as described in Equation 5.1. 
                              (5.1)                              
The observed response rate was calculated using number of responders divided by sample 
size in the corresponding arm. Data visualization was achieved by graphic exploration. 
Figure 5.1 shows how the observed response rate changed over time according to dual 
therapy of PR and triple therapy of a PI (telaprevir or boceprevir) plus PR. According to 
the graph, the observed response rate increased dramatically in the beginning of the 
treatment. Most of arms seemed to reach an asymptote later during the treatment period. 
An asymptotic structural model was chosen to describe the time course of response rates 
as expressed in Equation 5.2.   
                  [   
(     (           ))] (5.2) 
where         ,     and         denote the maximal response rate, response onset speed 
and delayed time of response onset in the j
th
 treatment arm of the i
th
 study, respectively. 
The model assumed response start to onset until tlag that the probability of response was 
0 when time < tlag. 
After the treatment was completed, the only virologic response examined was the SVR 
rate measured at week 24 of the follow-up period. It was evaluated relative to the 
predicted response rate at the end of treatment (       ) as in Equation 5.3. 
                              (   
(     (             )) )       (5.3) 
Where       and      denote the end of treatment time and response ratio of SVR rate to 
ETR rate in the j
th
 treatment arm of the i
th
 study, respectively. An effective HCV antiviral 
treatment is expected to have virus suppressed for a long term that the response rate after 
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completion of treatment does not decrease much. The RR is expected to be close to 1. 
The information regarding when the treatment was completed was collected from studies 
and retained in the dataset as a covariate called “EOT” (end of treatment). 
Random effects were accommodated by incorporating the inter-study variability and 
inter-arm variability for each of parameters. The inter-arm variability was weighted by 
the sample size (     in the j
th
 treatment arm of the i
th
 study. 
                  
           
      (5.4) 
  
          (          
 )        
        (  
     
 
   
) (5.5) 
where the log-scaled     is described in Equation 5.4 incorporating the population mean 
       and inter-study random effect    
       
  and inter-arm random effect    
     
. 
Random effects at study and arm levels are normally distributed with a mean of zero and 
variances to be estimated of        
  and sample-size weighted  
      
 
   
 , respectively, as 
shown in Equation 5.5.  
                             
              
        (5.6) 
  
            (            
 )     
          (  
        
 
   
)  (5.7) 
where         is the maximum response rate with values between 0 and 1. The logit 
model of          in Equation 5.6 consists of the population mean             and 
inter-study random effect   
           and inter-arm random effect    
       . Both of the 
random effects are normally distributed with a mean of zero and variances to be 
estimated of          
  and 
        
 
   
, respectively, as shown in Equation 5.7.  
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      (5.8) 
  
          (          
 )    
        (  
      
 
   
)  (5.9) 
where the log-scaled      is modeled including the population mean         and inter-
study variability   
       
  and inter-arm variability    
     
 in Equation 5.8. Both of 
random effects are normally distributed with a mean of zero and variances to be 
estimated of        
  and 
      
 
   
, respectively in Equation 5.9. 
Figure 5.1 presents the observed response rate according to PR therapy and PI-based 
therapy. It also reveals the triple therapy led to a significantly quicker response onset than 
did the PR therapy alone. Thus, treatment effect was evaluated on speed of response 
onset (k). Furthermore, exploratory analysis of the data found the treatment arms with 
HCV non-genotype 1 infection tended to higher response rate than those with genotype 1 
infection (as shown in Figure 5.1). HCV genotype is also of interest for its effect on the 
magnitude of maximal response rate.  
5.2.3 SAEM Estimation 
The nonlinear-mixed effect model was developed in NONMEM 7 using stochastic 
approximation expectation maximization (SAEM) estimation method.
29,30
 SAEM is one 
of the maximum likelihood estimation methods using expectation-maximization 
algorithms. The expectation of the log-likelihood can be achieved by stochastic 
approximation through Markov Chain Monte Carlo (MCMC).
30,31
 Estimates of 
parameters are updated in the maximization step until a stable and improved objective 
function is achieved. The process is iterative until convergence is reached. Since SAEM 
involves a highly stochastic process, the objective function monitored and computed from 
SAEM cannot be used for model comparison and hypothesis testing. An importance 
sampling is usually performed on the final run of SAEM and provides an appropriate 
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objective function and standard error for model selection and evaluating the parameter 
precision.
29
 
The execution of SAEM estimation in NONMEM 7 allows the user to define the 
convergence criteria. In this study, the convergence was examined according to the fixed 
parameters, random parameters and objective functions as CTYPE=3. This study uses 
10,000 iterations in the burn-in period and 1,000 as the number of iterations to run after 
burn-in. Default settings were applied to the rest options regarding the implementation of 
SAEM. 
5.3 RESULTS 
5.3.1 Systematic Review Result and Analytic Dataset 
The procedure of systematic review of literature of HCV antiviral treatment was 
described in Chapter 4. The model-based meta-analysis was conducted on longitudinal 
response data, arising from 18 studies and 47 arms in total. Twenty-seven arms received 
the dual therapy of peginterferon alpha and ribavirin, and twenty arms received the triple 
therapy of a protease inhibitor combined with PR (12 with telaprevir and 8 with 
boceprevir). The median (range) number of patients in each study is 407 (32-2054), and 
the median (range) number of patients per treatment arm is 114 (16-1035).  Only arms 
with approved dosage of medication were enrolled. Studies or arms within the included 
study were excluded if they received response-guided therapy. The course of treatment 
and time points of response assessment had been determined in the study protocol. 
Information regarding baseline population characteristics and treatment strategies were 
also collected in the dataset. Among studies enrolled in the dataset, twelve studies were 
conducted in patients with HCV genotype 1 infection only, two studies in patients with 
HCV genotype 2 or 3 and four studies in patients with HCV various genotypes. PI-based 
triple therapy was administered only in patients with HCV genotype 1 infection, while 
PR therapy was given to those with genotype 1 or non-genotype 1infection. Further 
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information regarding the final dataset for meta-analysis was described and summarized 
in Chapter 4. 
5.3.2 Longitudinal HCV Response Meta-Analysis 
According to the exploratory graph (Figure 5.1), an asymptotic model was selected to 
describe the time course of HCV virologic response. Different models were attempted to 
explore the inter-arm and inter-study variability. Unfortunately, the covariance step 
always failed in the importance sampling step, although convergence was achieved 
during SAEM process. When both inter-study variability and inter-arm variability were 
added to all model parameters of interest (e.g., Pmax, k and RR), the inter-study variability 
was significantly smaller in parameter RR than its inter-arm variability. The estimates of 
variance of inter-study and inter-arm variability in RR were 1.47E-17 and 3.7, 
respectively. However, the inter-study variability in Pmax and k were comparable to their 
corresponding inter-arm variability. Thus, inter-study variability was retained for Pmax 
and k, and inter-arm variability adjusted by sample size was estimated for each of these 
three model parameters. The resulting OFV in the reduced model was smaller than the 
previous model. The exploratory graph also revealed the significant difference in 
response-time profile between PI-based therapy and PR therapy and variation among 
treatment arms with different HCV genotypes. These covariates were explored for their 
potential effects on model parameters.  
The proportion of patients with HCV genotype1 infection in a treatment arm was 
incorporated in the data set. The analysis found a negative effect of HCV genotype1 on 
the maximum response rate (Pmax). Arms with more genotype 1 infected patients tend to 
reach lower Pmax during treatment. After accounting for the effect of HCV genotype, 
inter-study variability in Pmax decreased dramatically and was estimated to be much 
smaller than the inter-arm variability. The variances of inter-study and inter-arm 
variability on Pmax were 6.25E-17 and 43.3, respectively. The insignificant inter-study 
variability on Pmax was then dropped from the model. The fixed effect of genotype 1 and 
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random effect at arm level on Pmax were still included in the model. The analysis also 
found the effect of treatment on Pmax. After adjusting the genotype, PI therapy has higher 
Pmax than PR therapy. For the treatment arm with HCV genotype 1 patients only, the 
maximum response rate is estimated to be 0.594 in PR therapy and 0.758 in PI-based 
therapy. For the treatment arm only including patients with non-genotype 1 infection, the 
maximum response rate is estimated to be 0.873 in PR therapy.  
The analysis showed that PI-based therapy had more rapid response increase than for PR 
therapy. The rate constant of response onset was estimated to be 0.401week 
-1
 and 0.242 
week
-1 
for PI therapy and PR therapy, respectively. The time needed to achieve the half of 
maximum response rate was derived from the rate constant of response onset. PI therapy 
needs 1.7 weeks to reach half the maximal effect, while the PR therapy needs almost 3 
weeks. The SVR rate during the follow-up period was compared to the response rate at 
the end of treatment. Their ratio was estimated to be 0.76.  Incorporating the treatment 
effect on Pmax and k resulted in decreased inter-arm variability in these two parameters. 
For some treatment arms, the protease inhibitor was initiated after 4-week PR therapy. 
Such delayed administration resulted in a longer lag time estimated at 3.87 week. Arms 
without the lead-in period had a lag time of 1.67 week. The objective function value was 
43595 in the final model, compared to 43634 in the base model. The NONMEM 
estimates of parameters in final model were summarized in Table 5.1. The NONMEM 
code for final model was included in the Appendix. 
The individual predictions from the final model showed good agreement with 
observations in each treatment arm (Figure 5.2). Prediction was performed from the final 
model for treatment arms with genotype 1 patients only and treated for 48 weeks. The 
plot (Figure 5.3) presents the median and 90% prediction intervals of model prediction 
compared to the observation. The model appeared to predict the central tendency of 
response rate over time. The 90% prediction interval included most of observations. But 
the prediction interval was wide, which was mainly due to inter-study and inter-arm 
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variability in model parameters. The median predicted SVR rate (90% prediction 
interval) was 0.56 (0.36, 0.79) in PI therapy and 0.43 (0.24, 0.65) in PR therapy for 
treatment arms with genotype1 patients and 48-week therapy. 
5.4 DISCUSSION 
Our study proposed a mathematical model to describe the time course of virologic 
response across different HCV antiviral treatment regimens. Several meta-analyses and 
systematic reviews have been published to compare the effectiveness among current 
approved treatments including PR therapy and PI combination therapy with telaprevir or 
boceprevir. These analyses are only focused on one single endpoint, the SVR rate 
evaluated during the follow-up period. However, virologic response can vary as the 
treatment proceeds. By incorporating longitudinal information, the current model-based 
meta-analysis enables the response data measured at different time points from various 
studies to be combined and as a result to characterize the time course of virologic 
response. The analysis increases our knowledge in how response evolves along the 
treatment by capturing the speed of response onset and maximum response rate. In 
addition, indirect comparisons were made among treatments for their differing impacts on 
the response-time profile.  
The present study showed that triple therapy with a protease inhibitor combined with PR 
therapy led to a quicker response onset than PR. Previous Phase 3 studies also illustrated 
that telaprevir and boceprevir-based treatment are associated with higher virologic 
response during the early stage of treatment compared to the PR therapy.
17–20
 Studies on 
HCV viral dynamics indicated telaprevir exhibited a more rapid second phase of HCV 
viral decline than PR therapy, which might be due to treatment effectiveness on infected 
cell death.
32–34
 The proportion of patients with HCV genotype 1 infection was found to 
have a negative effect on the maximum response rate during treatment. Arms with more 
genotype 1 patients tend to reach a lower magnitude of maximum response rate. This 
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finding agrees with previous clinical studies that response to treatment depends on HCV 
genotype. Patients with genotype 2 or 3 have better response to PR treatment than those 
with genotype 1 and are eligible to receive a lower dose of ribavirin for a shorter term 
without sacrificing the treatment efficacy. Since PI-based treatment was approved only 
for treating HCV genotype 1 infection, our current study did not include PI studies in 
patients with HCV non-genotype 1 infection. Compared to HCV genotype 1 infection, 
protease inhibitors appeared to be less effective for genotype 2, 3 and 4. 
35,36
 After the 
treatment is completed, the rate of virologic response decreases slightly. The SVR rates 
predicted from the final model were compared to those observed in clinical trials which 
demonstrated greater SVR rate in PI therapy with telaprevir or boceprevir than PR 
therapy.
17–20
 The model prediction plot shows that response rate observed in the 
beginning of the treatment (at week 4) are not described well by the current model, 
especially for PR therapy (Figure 5.3). It suggests the lag time might be different between 
PR therapy and PI therapy and should be estimated separately for each treatment. In 
addition, large variation was observed in the prediction plot which rises from inter-arm 
and inter-study variability in model parameters. The potential variability could be 
explained by incorporating covariate effect. The current study did not perform a 
comprehensive covariate exploration. Without achieving the precision of the parameter 
estimates, it’s hard to evaluate the accuracy of the estimation. 
Several limitations were presented in our current study. We encountered computational 
issues with NONMEM when we were trying to account for both inter-study and inter-arm 
variability on model parameters (e.g., Pmax, k and RR). Despite the estimation of model 
parameters and variance of random effects were obtained, the covariance step during the 
importance sampling always failed and as a result we were unable to access the precision 
of the estimates. It might be due to the complexity of the model that the current data set 
does not provide sufficient information to estimate the parameters. It might also relate to 
the computation challenges in handling with nonlinear mixed effects model when using 
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maximum likelihood algorithm in NONMEM. Model misspecification could also 
contribute to the problem. The current asymptotic model assumed the response rate was 
maintained after it reached the maximum level. However, some treatment arms showed a 
reduction in observed response rate at later time points during treatment. It can be 
attributed to inadequate virologic response, treatment discontinuation or patient non-
compliance to the treatment, where the patient may not be eligible to be considered as a 
responder. The current model did not account for the effect of potential response reverse 
events, which could raise the risk of inaccuracy and bias in the model estimation and 
prediction.  
During the model development, we found inter-study variability was insignificant 
compared to the inter-arm variability in RR. After accounting for the effect of HCV 
genotype, inter-study variability in Pmax also became very small. To avoid the potential of 
over-parameterization and simply the model, the inter-study variability was dropped from 
these two parameters in the final model. However, it should be acknowledged that 
ignoring the inter-study variability can inflate the inter-arm variability and may cause the 
bias. Given the nature of meta-analysis, it’s important to investigate potential sources of 
heterogeneity.  
The current study was conducted as an initial analysis to characterize and compare the 
response-time profile between PI-based therapy and PR therapy. However, the analysis 
did not compare the response-time profile between telaprevir and boceprevir which have 
not been compared head-to-head.  In addition, the present work only evaluated the effects 
of treatment and HCV genotypes. It’s necessary to conduct further studies to have an 
indirect comparison between telaprevir and boceprevir, and a comprehensive exploration 
of potential covariate effects on the time-course of response rate. Considering these 
limitations in the current NONMEM analysis, we continued our model-based meta-
analysis work and proposed a more rational model in the Bayesian framework.  
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Table 5.1 Population estimates of model parameters 
Parameter Description 
Population 
Estimate 
kPR Speed of response onset  in PR therapy 0.242 
kPI Speed of response onset  in PR therapy 0.401 
Pmax, GT1, PR 
Maximum response rate in arms with genotype-1 patients only in 
PR therapy 
0.594 
Pmax, GT1,PI  
Maximum response rate in arms with -genotype-1 patients only in 
PI therapy 
0.758 
Pmax, non-GT1, 
PR 
Maximum response rate in arms with all non-genotype-1 patients 
in PR therapy 
0.873 
tlag Lag time in response onset without lead-in period 1.67 
tlaglead-in Lag time in response onset with lead-in period 3.90 
RR Ratio of SVR rate to ETR rate  0.739 
ω
2
study,Pmax
 
Between-study variability (BSTV) on logit-scale Pmax 4.53e-16 
ω
2
arm,k Between-arm variability (BAV) on log-scale k 1.62 
ω
2
arm,Pmax BAV on logit-scale Pmax 0.25 
ω
2
arm,RR BAV on log-scale RR 0.0158 
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Figure 5.1 Observed response rate over time in a treatment arm during treatment  
 
Note: The graph only showed the virologic response during treatment. There is no SVR rate included. PR: 
peginterferon plus ribavirin; PI: therapy of a protease inhibitor (telaprevir or boceprevir) combined with 
PR; GT1: arms with HCV genotype 1 patients only; Non-GT1: patients in the arm are all non-genotype 1 
HCV infection; Mixed GT1: arms including patients with various HCV genotype infection. 
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Figure 5.2 Individual Prediction versus Observation in each arm
 
Note: EOT: end of treatment. 
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Figure 5.3 Model-based prediction and observation versus time 
 
Note: prediction was performed for 48-week treatment in HCV genotype-1 patients. PI: prediction interval; 
PR: peginterferon plus ribavirin; PI: therapy of a protease inhibitor (telaprevir or boceprevir) plus PR. 
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CHAPTER 6  
Model-Based Meta-Analysis of Hepatitis C Virologic Response Using a 
Bayesian Approach 
6.1 INTRODUCTION 
In Chapter 5, the model-based meta-analysis was conducted to describe aggregate 
longitudinal HCV response data using nonlinear-mixed effect modeling in NONMEM 7. 
A simple asymptotic model was developed to characterize the time course of response 
rate during treatment in terms of speed of response onset and maximum response rate. 
However, there were several limitations in this model. First, the asymptotic model 
assumed the response rate was maintained after it achieved the highest magnitude. This 
ideal situation does not truly reflect the real HCV clinical management. In fact, HCV 
antiviral treatment could be discontinued due to a severe adverse effect or inadequate 
response. Treatment futility rules are usually specified for HCV treatment to avoid the 
unnecessary prolonged therapy in patients who are unlikely to response in order to reduce 
the risk of potential side effects and viral resistance.
1–3
 Given the complexity of treatment 
regimen and increased adverse effects, it becomes challenging to keep patients adherent 
to therapy, which is associated with virologic response both during and after the 
treatment.
4,5
 Non-adherence to the treatment regimen could lead to virologic failure and 
subsequent discontinuation in treatment. The plot of observed response rate over time 
showed that some treatment arms had a reduced response rate in later phase of treatment 
(Figure 6.1). The asymptotic model does not account for this decline. In this chapter, we 
propose an alternative model which allows capturing the response reverse during 
treatment.  
Another concern is the heterogeneous variability in the meta-analysis. During the model 
development process, multiple random effects were explored at the study and arm levels. 
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However, we developed computational challenges when incorporating both inter-study 
and inter-arm variability in NONMEM. The model containing inter-arm variability alone 
seemed to run well. However, disregarding the inter-study variability ignores the data 
structure and within-study randomization, which can lead to bias in parameter estimates.
6
 
In this chapter, we explore new modeling techniques to estimate and evaluate the 
nonlinear mixed effects model that includes both study- and arm-level effects. 
Both telaprevir and boceprevir are required to be administered in conjunction with 
peginterferon alpha and ribavirin (PR). However, treatment can be different in the 
schedule of administration, such as, when to commence the triple therapy and how long it 
lasts. In some treatment arms, triple therapy was not initiated at the start of treatment. 
Instead, PR was given alone for 4 weeks before the protease inhibitor was added. The 
effect of this 4-week lead-in period was accounted for as a lag time of response onset in 
the Chapter 5 model, assuming that the response probability is 0 from the start of 
treatment until the lag time. The results showed the 4-week lead-in period was associated 
with a longer delay in response. As a matter of fact, arms had developed the response to 
PR treatment even before protease inhibitor was initiated, although the magnitude is 
relatively small. Besides, boceprevir clinical trials showed that responsiveness of lead-in 
PR therapy was associated with the outcome of the subsequent triple therapy.
7,8
 The 
model developed in this chapter accommodates the virologic response developed during 
the lead-in period. 
In this chapter, a Bayesian approach was applied to the model-based meta-analysis using 
the same longitudinal response data. A new model was proposed that takes into account 
the potential response reverse during treatment. The hierarchical nonlinear mixed-effect 
model was developed considering covariate effects and multiple levels of random effects, 
such as inter-study variability and inter-arm variability. The software JAGS was used to 
implement the analysis in the Bayesian framework using Marko chain Monte Carlo 
(MCMC) methodology.  
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6.2 METHODS 
6.2.1 Systematic Review and Dataset Construction 
The systematic review of published literature and clinical trials of HCV antiviral 
treatment has been described in the Chapter 4.  Information and data related to the current 
research was abstracted from the selected literatures and synthesized to the data set ready 
for the model-based meta-analysis. Chapter 4 provided the detailed description regarding 
data set construction and the final analytic dataset.  
6.2.2 Bayesian Analysis  
Bayesian analysis was adopted in the current model-based meta-analysis. A full nonlinear 
Bayesian hierarchical model was developed in the software JAGS. 
9
  Like other Bayesian 
software, such as OpenBUGS and WinBUGS, JAGS generates Bayesian inference by 
means of Monte Carlo Markov Chain algorithm (MCMC).
9
 The statistical software, R 
(version 3.0.0)
10
, was used as a working platform where JAGS was directly implemented 
and managed through R packages “rjags” and “r2jags”. The MCMC simulation output 
from JAGS was processed by R package “coda”. RStudio (version 0.97.449, RStudio.Inc., 
Boston, Massachusetts, United States) was used as a user interface to R.  
In the current project, multiple Markov chains were run with different settings of initial 
values. The convergence of MCMC chains were visually inspected based on trace plots 
of multiple chains for every monitored parameter, where a well-mixed “fuzzy caterpillar” 
pattern suggests a stationary distribution has been reached. The Gelman-Rubin statistic 
was also used to assess the convergence of MCMC chains.
11
 The statistics was calculated 
by examining within-chain variance and between-chain variance. When MCMC chains 
converge, the estimated Gelman-Rubin statistics should be nearly 1 (generally less than 
1.2) for every parameter.
12
 If the statistic is greater than 1.2, it means MCMC chains need 
to run longer to reach the stationary distribution .
13
 Pooled samples from the converged 
chains were used to generate the posterior distribution of each model parameter. The 
 121 
 
median of the posterior distribution is considered as the Bayes estimates of the parameter. 
95% Bayesian credible intervals also are presented using the 2.5
th
 and 97.5
th
 percentiles 
of the posterior distribution. Deviance information criteria (DIC) was used to direct the 
model selection, which takes into consideration both model fit and model complexity.
14
  
6.2.3 Model Development 
Base model 
The number of responders (    )  at time t in arm j in study i is considered to follow a 
binomial distribution that depends on the sample size in arm j in study i and the response 
rate at time s in the arm j in study i (         ) as described in Equation 6.1. 
                              (6.1) 
A response reverse model was introduced to address the potential of decline in response 
rate. It should be noted that “response reverse” is used here to indicate any circumstance 
where patients may not be eligible to be considered as a responder. It could be due to 
treatment discontinuation, patient non-adherence to the medication and inadequate 
response. These events increased the number of patients who were not classified as 
responders and therefore decreased the response rate. The response rate during treatment 
can be described as Equation 6.2. 
            |                                |                   (6.2) 
where        |            refers to the probability of a patient having a response 
without a reverse event, whereas       |         means the probability of a patient 
responding to the treatment given a reverse event.               is the probability of 
not having a response reverse event, and            is the probability of having a 
response reverse event. Since the patient cannot be considered as a responder in any 
situation where a reverse event happens,        |         becomes zero. The second 
additive part in the equation was removed.  
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Therefore, the response rate during treatment phase can be explained by a product of two 
components as shown in Equation 6.3, one is the probability of having a response given 
the absence of a reverse event (      |           ), and the other is probability of not 
having reverse event (             ). These two factors are both essential to determine 
the pattern of longitudinal response rate. Each of them was specified as a function of time 
and model parameters. 
            |                          (6.3) 
Without any occasion hampering the response to the treatment, the time-course of the 
response rate is assumed to gradually reach a maximum response during treatment as an 
asymptotic model describe in Equation 6.4. 
     |                   [   
(     (           ))] (6.4) 
where      |           is the response rate given no reverse at time s in arm j in study i, 
        is the maximal response that arm j in study i can achieve,     is the first-order rate 
constant of response increase and represents the speed of response onset after treatment 
commences, and        is the lag-time for delayed initiation of response. The assumption 
for this model was the probability of response was 0 until       . 
The probability that no reverse event (           ) happened at time s in treatment arm j in 
study i can be expressed as 1 minus the probability of treatment reverse (         ) as 
shown in Equation 6.5. Since the value of a probability falls only between 0 and 1, logit 
transformation was applied to constrain the probability of response reverse event within 
the range. Furthermore, the logit regression was conducted to evaluate the time effect. 
                       (6.5) 
     (        )     (
        
          
)                       (6.6) 
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Where           denotes the probability describing a response reverse event at time s in 
arm j in study i,       and       are arm-level regression coefficients of time (     ). Among 
the studies included, the response was evaluated at as early as week 2 of therapy. Time 
was centered on week 2 at the earliest evaluation. Therefore, the formula of on-treatment 
response rate is updated to Equation 6.7.  
               |                                                                                              
                        [   
(     (           ))]  [  
 
   
                       
] (6.7)           
In some arms, the therapy was initiated with PR alone for 4 weeks followed by addition 
of a protease inhibitor, such as, boceprevir. The analysis of the response to the 
subsequent triple therapy should be adjusted for the response gained by the prior lead-in 
PR treatment. The response rate during the lead-in period was assumed to have the same 
response-time course in PR treatment. It can be modeled using Equation 6.7. The 
response after adding the protease inhibitor was associated with the response yielded at 
the end of lead-in period. The response rate at week 4 of PR could be derived as shown in 
Equation 6.8. Then, the response rate during the triple therapy was modeled as Equation 
6.9. 
             
        |              
                   
                                                                    
                           
   [   
(    
   (        ))]  [  
 
   
       
        
         
] (6.8) 
         
                  
   (       
                  
  )  [   
(    
    (      ))]             
     
 (6.9) 
Where              
   represents the response rate at week 4 of lead-in PR therapy,          
      
represents the response rate during the triple therapy period,         
  and        
     denotes 
the maximal response rates to lead-in therapy (PR) and triple therapy, respectively. 
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  and    
    are the speed of response onset given lead-in therapy (PR) and triple therapy, 
respectively.      
   and      
   are coefficients in logistic regression of  probability of 
response reverse event on time in PR therapy.  
 
The SVR rate in arm j in study i was modeled relative to response rate predicted at the 
end of treatment (EOT) as shown in Equation 6.10. 
                             (6.10) 
where         represents the SVR rate in arm j in study i,               is the predicted 
response rate at EOT (ETR) and      denotes relative response, which is the ratio of 
SVR rate to predicted ETR rate.  
To account for inter-study and inter-arm variability, multiple levels of random effects 
were evaluated on model parameters, especially on speed of response onset (k) and 
maximum response rate (Pmax) given no reverse event as well as relative response rate 
(RR) of SVR to ETR. The variance-covariance matrix was modeled separately for inter-
study variability and inter-arm variability and inter-arm random effects were assumed to 
be independent of the inter-study random effects.  
Covariate model 
Heterogeneous variability was primarily attributed to differences in study population and 
in treatment regimens across arms and studies. Potential association of covariates with 
parameters was explored based on initial exploratory analysis, prior knowledge from 
HCV clinical trials, and physiological and pharmacological plausibility. Covariates of 
interest included race/ethnicity, baseline viral load, HCV genotype, advanced fibrosis 
(bridging fibrosis or cirrhosis) and prior treatment experience. The treatment regimen was 
also evaluated in terms of medication composition and duration of therapy. Model 
parameters were assumed log-normally distributed, except the maximum response rate. 
The potential effect of a covariate was investigated on the log-scale of the parameters in a 
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linear way as Equation 6.11. Since the value of maximum response rate should fall 
between 0 and 1, logistic regression was used to explore the covariate effect as shown in 
Equation 6.12. 
                     (6.11) 
                      (6.12) 
where           represents the log scale of parameter,             is the logit-
transformed maximal response rate,               are regression coefficients of covariate 
(COV).The selection of covariate into the final model was guided by exploratory data 
analysis,  prior knowledge from clinical studies, change of DIC and whether the 95% 
posterior credible intervals of covariate coefficients covers zero or not. In addition, 
convergence of the model with the selected covariates was evaluated to ensure the 
reliable and stable parameter estimation. 
Prior distribution 
Uninformative or poor informative prior distributions were assigned to most model 
parameters and random effects. Normal prior distributions were specified to parameters 
with large variance which led to low precision (inverse of variance). Inter-study and 
Inter-arm variance-covariance matrices were given with a Wishart prior distribution. 
6.2.4 Model Evaluation 
The goodness of model fit was evaluated by comparing the observed data and model 
prediction for each treatment arm. A posterior predictive check was conducted to assess 
the predictive performance of the final model. The model parameters (including fixed and 
random effects) were sampled from their resulting posterior distributions. The response 
rate was simulated at each time point from the final model structure and model 
parameters.  The median and 90% prediction intervals of simulated response rates were 
calculated and plotted overlaid with observed data to assess whether observations were 
 126 
 
consistent with the range of model predictions. The predictability of the final model was 
assessed with respect to various treatment strategies and patient characteristics.  
6.3 RESULTS 
6.3.1 Systematic Review Result and Analytic Dataset 
The model-based meta-analysis was conducted on longitudinal response data, arising 
from 18 studies and 47 arms in total. Twenty-seven arms received the dual therapy of 
peginterferon alpha and ribavirin, and twenty arms received the triple therapy of a 
protease inhibitor combined with PR (12 with telaprevir and 8 with boceprevir). The 
median (range) number of patients in each study is 407 (32-2054), and the median 
(range) number of patients per treatment arm is 114 (16-1035).  Only arms with approved 
dosage of medication were enrolled. Studies or arms within the included study were 
excluded if they received response-guided therapy. The course of treatment and time 
points of response assessment had been determined in the study protocol. Information 
regarding baseline population characteristics and treatment strategies were also collected 
in the dataset. Most studies (n=12) only enrolled patients with chronic HCV genotype 1 
infection. Two studies were focused on HCV genotype 2 or 3 infection and four studies 
enrolled patients infected with various HCV genotypes. Treatment-naïve patients were 
given HCV antiviral therapy in 12 studies and patients who had been previously treated 
but failed PR therapy were retreated in the remaining 6 studies.  Further information 
regarding the final dataset for meta-analysis were described and summarized in Chapter 4. 
6.3.2 Longitudinal Model-Based Meta-Analysis 
A Bayesian nonlinear mixed effects model was developed to describe the response data 
over time during treatment and follow-up periods.  Both inter-study and inter-arm 
variability were incorporated into the model. Several covariates were found to be 
significant for response parameters. For the final model, uninformative priors (with wide 
variance) were assigned to most model parameters as presented in Table 6.1. Due to 
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model identifiability, an informative prior was assigned to the maximum response rate 
(Pmax). Each of three MCMC chains started to run at different sets of initial values for 
400,000 iterations with 5,000 samples discarded during the burn-in period in each chain. 
The thinning factor was set as 10 so that only one in every ten samples was saved. The 
posterior distribution for each model parameter was obtained from a total of 105,000 
samples saved from post-burn-in MCMC chains. The posterior median and 95% credible 
intervals of model parameters and relevant convergence statistics were summarized in 
Table 6.2. Trace plots were constructed for each model parameter to assess the 
convergence of MCMC chains. JAGS code for the final model and trace plots of model 
parameters are included in Appendix. 
Structural model 
The potential decrease in response rate during the later phase of treatment was taken into 
consideration in the current analysis by incorporating a component which described the 
response reverse event, such as, patient non-adherence (i.e., drop out) and treatment 
discontinuation due to severe side effects or inadequate response (i.e., virologic 
breakthrough). Accordingly, the model for response rate during treatment period 
consisted of two parts, one of which was used to demonstrate the response rate-time 
profile given the absence of reverse event and the other part was associated with 
probability of having a response reverse event. The first part was well described with an 
asymptotic model characterized with speed of response onset (k) and the maximum 
response rate (Pmax) if no reverse event occurred. In the second part, a logistic regression 
was used to describe the probability of having a response reverse event as a function of 
time. The intercept (β0,ij) in the logistic model was fixed to -5, since there was lack of 
sufficient data at treatment week 2 to support estimation of the parameter. In this way, the 
model assumed response reverse was not likely to occur at treatment week 2. The 
probability of having response reverse at week 2 was 0.0067. After completion of the 
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treatment, the SVR rate was modeled relative to the predicted response rate at the end of 
treatment (ETR). The ratio was defined as relative response (RR) here.  
The heterogeneity that arises from meta-analysis was quantitatively analyzed by 
incorporating covariate effects, and inter-study and inter-arm variability on response 
model parameters. Meanwhile, inter-arm variability was weighted by sample size in the 
corresponding arm. The structural of final model was shown in Figure 6.2. 
Effects of treatment strategies  
Three approved HCV antiviral therapies were evaluated in the current meta-analysis, 
including PR therapy, telaprevir plus PR therapy and boceprevir plus PR therapy. Plots 
revealed these therapies led to different time courses of response rate during treatment in 
Figure 6.1. The PI-based therapy is associated with a more rapid response onset than PR 
therapy alone. The posterior median of speed of response onset (k) was 3.9 week
-1
 with a 
95% credible interval (95% C.I.) of 1.92 to 8.71for telaprevir, 0.617 week
-1 
(95% C.I.: 
0.312, 1.322) for boceprevir, and 0.0748 week
-1
 (95% C.I.: 0.0389, 0.156) for PR therapy. 
The half-time of response increase (T1/2) which represents the time needed to achieve 50% 
of the maximal response rate was then calculated from the estimates of k. T1/2  was 0.18 
weeks in telaprevir and 1.12 weeks in boceprevir, compared to 9.27 weeks in PR therapy. 
There was no statistically significant difference found in the maximum response rate 
(Pmax) among the three treatments. 
For the logistic response reverse model, the coefficient of probability of reverse event on 
time (β1) was estimated to be 0.07 week
-1
 (95% C.I.: 0.056, 0.081) in PR therapy and was 
much smaller (0.000111 week
-1
) in triple therapy, suggesting the probability of having a 
reverse event changed only slightly along PI-based therapy. For the PR therapy, the 
estimated probability of response reverse (95% C.I.) were 0.013 (0.012, 0.015) at 
treatment week 12, 0.031 (0.022, 0.039) at week 24 and 0.15 (0.081, 0.22) at week 48. 
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For PI therapy, the estimated probability of response reverse (95% C.I.) was 0.0067 
(0.00669, 0.0163) at week 24 and 0.0067(0.00669, 0.043) at week 48. 
After treatment completion, the SVR rate during the follow-up period was comparable to 
ETR rate at the end of treatment in PI-based therapy. The relative response (95% C.I.) of 
SVR rate to ETR rate was estimated to be 0.89 (0.78, 1.00), 0.93(0.81, 1.07) and 0.73 
(0.66, 0.79) for telaprevr, boceprevir and PR therapies with the standard term, 
respectively. Treatment duration was found to have a significant effect on the RR. Given 
the same medication composition, RR was decreased by 17% (10%, 25%) if the 
treatment was administered for a shorter term. 
Effects of baseline patient characteristics  
Although the maximum response rate did not show a significant difference across 
treatments, baseline characteristics were explored for their potential effects in this model 
parameter. Arms with a greater proportion of patients with the HCV genotype 1infection, 
black patients and null responders tend to have a lower maximum response rate. Table 
6.3 shows the estimated maximum response rate for the patient populations containing 
combinations of these characteristics.  
Inter-study and inter-arm variability 
After adjusting the inter-arm variability by the median value of sample size in a treatment 
arm (n=114), the standard deviations of inter-arm variability was estimated to be 0.0479, 
0.322, 0.0486 for speed of response onset, maximum response rate and relative response. 
The standard deviation of inter-study variability for these parameters was estimated to be 
1.277, 0.404 and 0.133, respectively.  
Model evaluation and prediction 
Figure 6.3 shows individual predictions of response rate compared with observations. 
The observed data in each treatment arm fall mostly within 90% Bayesian predictive 
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intervals. No systematic overprediction or underprediction was found. For the posterior 
predictive check, the simulations were performed based on model structure and posterior 
distributions of model parameters given different treatments and different patient 
populations. The plots show that the 90% prediction intervals include most of 
observations (Figure 6.4 to Figure 6.6). These plots were constructed for patients with 
genotype 1 infection and used to compare the time course of the response rate among PR, 
telaprevir and boceprevir therapy. For standard-term PR therapy (48 weeks), the median 
of predicted SVR rate (90% prediction interval) was 38.8% (12.5%, 55.9%) in the 
treatment arm with HCV genotype 1 patients only, no prior null responders and 5.05% 
black patients.  For 48-week telaprevir therapy, the median predicted SVR rate (90% 
prediction interval) was 64.1% (46.2%, 83.2%) in the treatment arm with HCV genotype 
1 patients only, no prior null responders and 14.6% black patients. For 48-week 
boceprevir therapy with a 4-week lead-in PR period, the median of predicted SVR rate 
(90% prediction interval) was 65.9% (48.9%, 84.25) in treatment arms with HCV 
genotype 1 patients only, no prior null responders and 14.6% black patients. Predictions 
of response rate at other time points (e.g., treatment week 4, 12 and the end of treatment) 
were compared among treatments and are summarized in Table 6.4.   
6.4 DISCUSSION 
In the current work, a model-based meta-analysis was performed to quantitatively 
describe the aggregate longitudinal response data by means of Bayesian methodology. 
The proposed model presents an approach to accomplish indirect treatment comparisons 
in the time course of clinical responses. To date, several meta-analyses have been 
published to compare the effectiveness across approved HCV antiviral treatments 
including PR therapy, telaprevir and boceprevir.
15–20
  However, one major limitation of 
these analyses is that only the primary clinical outcome, SVR, was evaluated and 
compared as an efficacy endpoint across treatments. These SVR-based analyses did not 
find a significant difference between telaprevir and boceprevir therapy. In addition, such 
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one-endpoint analyses did not capture the variation in treatment effect/response over the 
time, especially during treatment. In fact, monitoring patient response along the treatment 
course is important for HCV management. Furthermore, it may not be appropriate to 
generalize the covariate effect found on one endpoint to other responses assessed at 
different time points.  To address these limits, the current study integrated the 
longitudinal information of response data, allowing us to enroll more studies with 
different treatment regimens and different response assessment schedules. The current 
analysis enables the indirect treatment comparison based on the time course of response 
featured with the speed of response onset and maximum response. Baseline patient 
population characteristics were also acknowledged for their potential effects on the 
response-time profile, which provided additional information to better understand the 
variability in treatment outcomes.  
A simple asymptotic model was presented in Chapter 5 to describe the time course of 
response rate during treatment. The major drawback of this model was not accounting for 
the potential reverse in response rate during the later phase of treatment. Such a decrease 
in response rate could be attributable to treatment discontinuation due to inadequate 
response or adverse effects and patient non-adherence to the treatment. In these events, a 
patient might not be eligible to be considered as a responder, which usually occurs in a 
HCV antiviral therapy. A model ignoring these factors might not be practical for clinical 
management and may lead to a biased estimate and prediction. Appropriately considering 
these events is important during the model development. The current study adopted a 
latent logistic model to describe the probability of having a response reverse event as a 
function of time. Accordingly, the response rate was driven together by two components, 
which are the probability of response without any reverse event and the probability of no 
reverse event. In the response reverse model, the chance of having a reverse event 
increased as treatment proceeded. It was estimated that PI-based therapy had much 
slower increase in probability of reverse event over time. Several clinical trials showed 
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PI-based therapies were associated with more adverse events than PR therapy. Virologic 
breakthrough was also observed with the presence of resistant variants to the PI. The 
occurrence of these events is generally summarized at the end of study. However, the 
detailed information is missing regarding when and how many patients have experienced 
what kind of response-reverse events. Lack of such information makes it challenging to 
differentiate the independent effects of these events and affect the interpretation of the 
current response reverse model. Further analysis is needed with more data regarding the 
response reverse events available.  
The response rate without any reverse event was well described using an asymptotic 
model, where treatment effect increased and reached a maximum over time. Response 
rates grew more rapidly in arms with PI-based therapy than did those in PR therapy. 
Phase 3 studies illustrated addition of telaprevir or boceprevir was associated with a 
higher rate of early responses at treatment week 4 or 12. 
7,8,21,22
 Furthermore, the current 
meta-analysis found that the response increased more rapidly with telaprevir therapy than 
boceprevir therapy. In addition, the response developed during the 4-week PR lead-in 
period was also accounted in the model. The subsequent response after boceprevir 
initiated from week 4 was developed based on the lead-in PR response. However, the 
previous model in Chapter 5 only estimated the different lag times for treatments with 
and without a lead-in period, which also assumed the response rate was 0 until the lag 
time. That model led to under-prediction in the response during the lead-in period and 
also affected prediction of the response after boceprevir was added.  
For the maximum treatment response/ efficacy, HCV genotype, race and previous 
response to PR therapy were illustrated as significant factors. Maximum treatment effect 
was lower in arms including more patients with HCV genotype 1 infection, black race 
and prior null response. However, the current analysis did not find a significant 
difference in the maximum response rates between PI-based therapy and PR therapy. It 
should be noted that the maximum response rate represents the magnitude of treatment 
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efficacy while on treatment, which is unlike the SVR rate which is assessed after 
completion of treatment.  
The SVR was the only response evaluation performed after completion of treatment; the 
relative response was introduced in our analysis as a ratio to describe how SVR rate 
during the follow-up period differed from response rate at the end of treatment (ETR). 
The estimates of the ratio were closer to 1 in PI-based therapy, suggesting the SVR rate is 
more comparable to the ETR rate than PR therapy. It may be related to less frequent 
virologic relapse in patients given triple treatment. In addition, the current study showed 
boceprevir had a slightly higher RR than telaprevir. Higher SVR rates and lower relapse 
rates have been observed in several clinical trials of telaprevir or boceprevir therapy 
combined with PR therapy, which confirms the superiority of triple therapy to PR 
therapy.
7,8,21,22
 Extending the course of therapy could enhance the suppression of HCV 
and prevent virologic relapse. PR therapy is generally given for the standard 48 weeks to 
treat HCV genotype 1 infection. The combination of telaprevir or boceprevir with PR 
therapy is usually followed by PR therapy alone for several weeks. The whole PI-based 
treatment could vary from 24 weeks to 48 weeks. According to approved prescribing 
information, the treatment duration of telaprevir or boceprevir-based therapy can be 
determined based on patient early response.
2,3
  In the current analysis, we only focused on 
treatment regimens with a fixed course which have been defined in the protocol. Because 
treatment is generally given for 48 weeks in patients with genotype 1 infection, any 
therapy with less than 48 weeks were considered as short term treatment, whereas for 
patients with non-genotype 1(e.g., 2 or 3),  24 weeks are standard duration for the 
treatment and any therapies less than 24 weeks were defined as short term. Our analysis 
found treatments with truncated periods were associated with a smaller RR, suggesting 
that the response rate at week 24 of follow-up period (SVR rate) dropped markedly from 
the response rate assessed at the end of treatment (ETR). It suggested the longer 
treatment could improve the SVR rate. However, it should also be kept in mind that the 
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longer treatment may raise the risk of adverse effects and patient non-compliance. An 
appropriate design in treatment regimen should take into consideration both benefit and 
risk. Other covariates (e.g., baseline HCV RNA, relapse, advanced fibrosis) were also 
explored for their impact on model parameters. However, they were not found to be 
significant. It might be due to a confounding effect among some covariates. Studies in PI-
based therapy had more patients with high baseline HCV RNA. The cut-off value to 
define high or low baseline HCV RNA level was not consistent among studies. Small 
numbers of patients with bridging fibrosis or cirrhosis in studies also affected the analysis 
results. Given these limitations in the available data, the current analysis cannot estimate 
the effects of all these covariates. However, some clinical studies demonstrated these 
covariates were associated with primary clinical outcome, SVR. These covariates are still 
important for further study due to their potential clinical significance.  
In the meta-analysis framework, heterogeneity arises when combining information from 
different trials with various treatment, patient population and study design. In the current 
study, it is addressed by incorporating covariate effects, and inter-study and inter-arm 
variability. After accounting for the impact of the covariate on model parameters, high 
variability was still observed in the model. For example, inter-study variability was 
relatively high in model parameter k which represents the speed of response onset. It was 
primarily attributable to inconsistencies in study design and difference in patient 
population among enrolled trials. Not all studies assessed/reported the response early in 
the treatment. Underlying inconsistencies among patient populations also raise the 
between-study variability. Further work is needed to further explore the inter-study 
variability in this parameter.  
The current model-based meta-analysis presents a quantitative evaluation and indirect 
comparison in the time profile of HCV response across PR and novel triple therapy with 
direct acting agents. Protease inhibitors were found to have a favorable efficacy with 
more rapid response and a higher SVR rate. The impact of patient population 
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characteristics was also taken into consideration. The analysis could be useful to predict 
the response at certain time points and in particular patient populations that have not been 
studied.  It might also be helpful to apply the current model to compare a new PI drug 
with approved treatments. 
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Table 6.1 Prior distribution 
Fixed effect 
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Inter-study variability for parameters k, Pmax, RR, β1 
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Table 6.2 Summary of Bayes estimate and 95% credible interval of model parameters and 
convergence statistics  
Parameter Description 
Posterior 
Median 
Posterior 95% 
credible interval 
Rhat 
Effective 
size  
μk 
Log-scaled speed of response onset (log 
(k )) in PR therapy  
-2.593 (-3.280, -1.955) 1.005 470 
θ1,k Telaprevir therapy effect on log (k) 3.954 (3.599, 4.324) 1.001 10000 
θ2,k Boceprevir therapy effect on log (k) 2.108 (1.864, 2.370) 1.001 30000 
μPmax 
Logit-transfromed maximum response 
rate (logit (Pmax)) in non-genotype 1, 
non-black and non-null response 
patients 
3.022 (2.834, 3.215) 1.001 6300 
θ1,Pmax HCV genotype 1 effect on logit(Pmax) -1.838 (-2.232, -1.478) 1.002 1700 
θ2,Pmax Black race effect on logit(Pmax) -1.309 (-1.988, -0.649) 1.001 12000 
θ3,Pmax 
Prior null responder effect on logit 
(Pmax ) 
-1.366 (-2.065, -0.667) 1.001 59000 
μRR 
Log-scaled relative resposne (log(RR)) 
of SVR to ETR in standard-term PR 
therapy 
-0.290 (-0.414, -0.232) 1.003 920 
θ1,RR Telaprevir therapy effect on log (RR) 0.200 (-0.060, 0.338) 1.001 19000 
θ2,RR Boceprevir therapy effect on log(RR) 0.250 (0.109, 0.391) 1.001 15000 
θ3,RR Short-term treatment effect on log (RR) -0.191 (-0.278, -0.106) 1.001 35000 
μβ1 
Log-scaled slope of response reverse 
(log(β1)) in PR therapy 
-2.654 (-2.886, -2.505) 1.002 2600 
θβ1 
Triple therapy with protease inhibitor 
effect on log(β1) 
-6.444 (-22.262, -0.536) 1.001 54000 
tlag 
Lag time (tlag) in response onset in PR 
therapy 
1.358 (1.186, 1.497) 1.001 7400 
θtlag 
Lag time in triple therapy with protease 
inhibitor 
1.546 (1.302, 1.711) 1.001 59000 
ωstudy,k 
Between-study variability (BSTV) on 
log(k) 
1.230 (0.854, 1.899) 1.002 3800 
ωstudy,Pmax BSTV on logit(Pmax) 0.401 (0.206, 0.727) 1.001 11000 
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ωstudy,RR BSTV on log (RR) 0.132 (0.091, 0.207) 1.001 24000 
ωstudy,β1 BSTV on log (β1) 0.197 (0.022, 0.456) 1.003 3100 
ωarm,k 
Between-arm variability (BAV) on log 
(k) 
0.511 (0.166, 1.284) 1.001 16000 
ωarm,Pmax BAV on logit (Pmax)  3.435 (2.326, 4.979) 1.001 24000 
ωarm,RR BAV on log (RR) 0.519 (0.219, 0.953) 1.002 3100 
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Table 6.3 Posterior estimation of maximum response rate (Pmax) in arms with certain population 
characteristics 
Population characteristics  Posterior median  
(95% Bayesian credible interval)  
 
Genotype 1 Black 
Prior null 
responder 
+ + + 0.184 (0.076, 0.372) 
+ + - 0.468 (0.313, 0.626) 
+ - + 0.456 (0.280, 0.628) 
+ - - 0.766 (0.698, 0.816) 
- - - 0.954 (0.944, 0.961) 
- + - 0.846 (0.733, 0.916) 
Note: + means all patients in the arm have the corresponding characteristics (covariate value is 100%); - 
means none of patients in the arm has the corresponding characteristics (covariate value is 0). 
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Table 6.4 Model-based prediction of response rate in arms with certain population characteristics (90% 
prediction interval) 
TRT 
 
 
Population 
characteristics 
 Response rate 
GT 
1 
Black
a
 
(%) 
Null-
RESP 
TW 4 TW12 ETR SVR 
PR  + 5.06 - 
0.132 
(0.0185, 0.490) 
0.392  
(0.0717, 0.685) 
0.536 
(0.189, 0.704) 
0.388 
(0.125, 0.559) 
TELA + 8.08 - 
0.709 
(0.456, 0.834) 
0.738 
(0.521, 0.864) 
0.738 
(0.524, 0.870) 
0.641 
(0.462, 0.832) 
BOCE + 14.6 - 
0.127 
(0.0182, 0.469) 
0.658 
(0.341, 0.800) 
0.718 
(0.495, 0.846) 
0.659 
(0.471, 0.839) 
Note: TRT: treatment; PR: dual therapy of peginterferon alpha and ribavirin; TELA: telaprevir plus PR 
therapy; BOCE: boceprevir plus PR therapy; GT1: HCV genotype 1 infection; Null-RESP: null-responders; 
TW: treatment week; ETR: response rate at the end of treatment; SVR: sustained virologic response; Black
a
: 
the median value according to each therapy in original dataset; + means all patients in the arm have the 
corresponding characteristics (covariate value is 100%); - means none of patients in the arm has the 
corresponding characteristics (covariate value is 0). 
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Figure 6.1 Observed response rate over time during treatment period according to therapies 
  
Note: PR, therapy of peginterferon alpha and ribavirin; BOC:therapy of boceprevir plus PR; TELA: therapy 
of telaprevir  plus PR; non-GT1: none-genotype 1; GT1: HCV genotype 1; mixed GTs: mixed HCV 
genotypes. 
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Figure 6.2 Mathematical structure of model 
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Covariate and Random Effect Model 
                                     
      
    
      
  
       
   (         
 )         
       (  
     
 
   
) 
                                                                 
                                   
               
          
  
            (            
 )     
          (  
        
 
   
) 
                                                   
                         
       
    
       
  
       
   (          
 )    
        (  
      
 
   
) 
                           
          
  
          (          
 ) 
                                   
 
 
 
Note: PR: peginterferon alpha and ribavirin; TELA: telaprevir-based therapy; BOCE: boceprevir-based 
therapy; STERM: short-term therapy; TRI: triple therapy with a protease inhibitor (telparevir or boceprevir) 
plus PR; GTONE: proportion of patients with genotype 1 HCV infection in a treatment arm; BLK: 
proportion of African American patients in a treatment arm; NRESP: proportion of prior null responders in 
a treatment arm. TELA, BOCE, STERM and TRI are categorical covariates with two levels (yes:1 and 
no:0). GTONE, BLK and NRESP are continuous covariates. 
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Figure 6.3 Comparison of observations and individual prediction in each treatment arm. 
 
Note: EOT: end of treatment. 
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Figure 6.4 Model-based prediction for 48-week PR therapy in arms with certain population 
characteristics 
 
Note: The prediction was performed for treatment arms with genotype 1 patients only, no null-responders 
and 5.06% black patients; ETR: response rate at the end of treatment (week48); SVR: sustained virologic 
response (week 72); Black dot represents the observations, blue solid line represents the median of 
prediction and grey area represents the 90% prediction interval. 
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Figure 6.5 Model-based prediction for 48-week telaprevir therapy in arms with certain population 
characteristics 
 
Note: The prediction was performed for treatment arms with genotype 1 patients only, no null-responders 
and 8.08% black patients; ETR: response rate at the end of treatment (week48); SVR: sustained virologic 
response (week 72); Black dot represents the observations, blue solid line represents the median of 
prediction and grey area represents the 90% prediction interval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 147 
 
Figure 6.6 Model-based prediction for 48-week boceprevir therapy (with 4-week lead-in period) in 
treatment arms with certain population characteristics. 
Note: The prediction was performed for treatment arms with genotype 1 patients only, no null-responders 
and 14.6% black patients; ETR: response rate at the end of treatment (week48); SVR: sustained virologic 
response (week 72); Black dot represents the observations, blue solid line represents the median of 
prediction and grey area resprensents the 90% prediction interval. 
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CHAPTER 7  
Conclusions  
The current thesis work consists of two projects presenting the pharmacometric analyses 
of drug exposure and response data. The first project applied a population 
pharmacokinetic modeling approach to estimate the in vivo inhibition constant (Ki) 
across different CYP2C9 genotypes. In the second project, model-based meta-analysis 
was performed to describe the time-course of virologic response in hepatitis C clinical 
trials across current approved treatments.  
7.1 IN VIVO INHIBITION CONSTANT 
The inhibition constant (Ki) reflects the inhibitor potency of interacting with the enzyme. 
It is usually determined from in vitro experiments. The in vitro Ki has been used to 
predict the potential of drug interactions in vivo. According to the guidance of the United 
States Food and Drug Administration (USFDA), the need of in vivo drug interaction 
studies for a new molecular entity (NME) is guided by comparing the in vitro Ki of the 
NME to its relevant concentration in vivo. Extrapolation from in vitro data provides a 
time and cost saving approach to predict in vivo drug interactions. It serves as a good 
qualitative evaluation method.
1
 However, the predictive utility of in vitro approaches can 
be confounded by uncertainty and variability during in vitro experiments and 
complexities in clinical practice.
2–6
 It is challenging to quantitatively assess the in vivo 
drug interaction. 
Given the differences between in vivo and in vitro environments and potential variability 
in experimental conditions, an in vitro Ki may not accurately describe inhibitor potency 
in vivo. To better evaluate clinical drug interactions, some studies have proposed to 
determine the in vivo Ki which is considered a more rational and practical indictor of the 
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inhibitor-enzyme interaction in vivo.
7–10
  In these studies, the in vivo Ki was calculated 
from the formation clearances of the metabolite in the absence and presence of the 
inhibitor along with inhibitor plasma concentration in each study subject. The average of 
the in vivo Ki from all subjects was reported as the final estimate of the in vivo Ki. The 
major limitation of this approach is that the estimation of the in vivo Ki is affected by the 
inter-individual variability in formation clearance of the metabolite.  
Evaluation of an in vivo drug interaction needs to consider multiple clinical factors, such 
as, pharmacokinetics of inhibitor and substrate and genetic polymorphisms. CYP2C9*3 is 
one of the mutant alleles that were found to have reduced catalytic activity from both in 
vitro and in vivo studies.
11,12
 The presence of *3 allele leads to a lower oral clearance of 
the CYP2C9 substrate and also diminishes the interaction between a CYP2C9 inhibitor 
and the enzyme.
13
 A previous study showed that the in vitro Ki varied across three 
CYP2C9 genotypes, suggesting the inhibitor-enzyme interaction in vivo also depends on 
CYP2C9 genotype.
14
  
In the current work, we implemented a population pharmacokinetic modeling approach to 
determine the in vivo Ki of fluconazole (CYP2C9 inhibitor) for each of three CYP2C9 
genotype groups (*1*1, *1*3, and *3*3). The proposed model was developed 
incorporating parallel elimination pathways of the CYP2C9 substrate (flurbiprofen) 
including CYP2C9 mediated metabolic pathway, renal clearance and residual elimination 
pathway. The study showed the estimates of in vivo Ki were different across the CYP2C9 
genotypes. In addition, the magnitude of in vivo Ki was greater in groups with the 
presence of CYP2C9*3 than that in CYP2C9*1*1, suggesting the inhibition potency of 
fluconazole in vivo was diminished with the reduced activity in the CYP2C9*3. The in 
vivo estimates of Ki are comparable to those estimates from in vitro experiments. The 
analysis also found that the contribution of CYP2C9-mediated metabolism to the total 
flurbiprofen clearance was less in groups with CYP2C9*3 compared to CYP2C9*1*1. 
The overall magnitude of drug interaction was less significant in the CYP2C9*3 group 
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than the CYP2C9*1*1 group. The current population pharmacokinetic analysis allows us 
to estimate in vivo Ki and also provides a quantitative assessment of in vivo drug 
interaction. Based on the current findings, the potential of a drug interaction highly 
depends on the individual CYP2C9 genotypes. It suggests that CYP2C9 genotype needs 
to be checked when making decisions on dosage modification based on the drug 
interaction. The major limitation of the current study is that only few subjects with 
CYP2C9*3*3 were enrolled. By using a population pharmacokinetic approach, it is 
possible to determine the in vivo Ki and drug interaction in a large number of subjects 
with fewer samples of substrate and fewer levels of inhibitor. The relevant simulation is 
needed to optimize the study design with better sampling technique without introducing 
the bias and precision of the parameter estimates.  
7.2 MODEL-BASED META-ANALYSIS OF HEPATITIS C RESPONSE RATE  
Hepatitis C is a liver disease caused by infection with the hepatitis C virus (HCV). It can 
be cured by using antiviral treatment. Peginterferon alpha combined with ribavirin (PR) 
has been used for decades as standard care of chronic hepatitis C. With the increasing 
knowledge on molecular pathways of the viral life cycle, more research efforts are 
focused on the agents that can directly interfere the viral replication process.
15
 Two 
protease inhibitors (PIs), telaprevir and boceprevir, were approved by the USFDA in 
2011 for treating chronic HCV genotype 1 infection in adult patients. Both telaprevir and 
boceprevir are required to be administered along with peginterferon and ribavirin.  The 
efficacy of HCV treatment is primarily determined based on sustained virologic response 
(SVR), defined as undetectable HCV RNA at week 24 after completion of the treatment. 
Studies showed SVR rates in PR therapy were 40-50% in patients with HCV genotype 1 
infection and 70-80% in patients with genotype 2 or 3 infection.
16–20
 With the addition of 
PI, SVR rate is improved up to 68%-75% in treatment naïve patients and to 41%-52% in 
patients who failed to achieve SVR in previous PR treatment.
21–24
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To better understand the therapeutic effect of antiviral treatment and minimize the 
potential risk, it is recommended that patient HCV RNA level be monitored along the 
treatment, typically at treatment weeks 4, 12 and 24, as well as at the end of treatment. 
Virologic responses are determined based on measurements of patient HCV RNA levels.  
Most clinical trials usually report these responses in form of the number of responders 
whose HCV RNA levels are undetectable at a given time. Several published meta-
analyses or systematic reviews have conducted the comparison of treatment effectiveness. 
However, they were only based on the primary endpoint, the SVR data, while virologic 
responses at other time points were not included.
25–30
 
In the current thesis work, a model-based meta-analysis was conducted to provide a 
mathematical model describing the time course of longitudinal virologic response during 
treatment and follow-up periods across approved HCV antiviral treatments including PR 
therapy, telaprevir combined with PR therapy and boceprevir plus PR therapy. The 
analysis was firstly conducted in NONMEM 7 by using a maximum likelihood algorithm. 
However, the initial model had several limitations and computational difficulties when 
trying to incorporate random effects at multiple levels. An asymptotic model was used to 
describe the response rate over time during treatment period. However, response rates in 
some arms were observed to decrease at later time points. The asymptotic model did not 
account for such potential response reverse.  This analysis only compared the response-
time profile between PI-based therapy and PR therapy. The treatment effect was not 
differentiated between telaprevir and boceprevir. In addition, the inter-study variability 
was not analyzed for all model parameters, which may inflate the corresponding inter-
arm variability. This work was our first attempt and it did not include the comprehensive 
exploration of potential covariate effects. However, the analysis showed that treatment 
arms with greater proportion of genotype-1 patients tend to have the lower maximum 
response rate during treatment. The PI-based therapy was associated with quicker 
response onset than PR therapy.  
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To overcome these limitations, we continued our model-based meta-analysis work in a 
Bayesian framework using Markov Chain Monte Carlo algorithm. The potential of 
response reverse was incorporated into the new model of longitudinal response rate. The 
reduction in response reverse could be due to treatment discontinuation, inadequate 
virologic response and patient non-compliance to the treatment. Due to lack of the 
detailed information regarding these response reverse events, a latent logistic model was 
used to describe the probability of event occurrence as a function of time. An asymptotic 
model was used to describe the time course of response rate given no response reverse. 
Inter-study variability and inter-arm variability weighted by sample size were 
quantitatively analyzed for model parameters.  
The analysis found the telaprevir had the fastest response onset, followed by boceprevir 
and PR therapy alone. The maximum response rates were lower in treatment arms with 
greater proportion of genotype 1 patients, black patients and prior null-responders. In the 
model, the SVR rate was compared to the response rate at the end of treatment. Their 
ratio was associated with the type and duration of the treatment. Other covariates (e.g., 
baseline HCV RNA level and advanced fibrosis) were also explored for their effects on 
model parameters but not found to be significant. It might be due to their confounding 
with other covariates. In addition, the cut-off value for defining high baseline HCV RNA 
level varies across studies. Such inconsistence also affects the analysis. The IL28B 
polymorphism has been demonstrated as a prognostic factor for SVR in some analyses. 
31,32
 This potential covariate was not included in our current work since the information 
regarding IL28B was generally not reported in published studies. Further analysis needs 
to be done to explore potential covariates with more information. 
For the response reverse model, the analysis showed that probability of response reverse 
increased quite slow over time in PI-based therapy and was lower compared to PR 
therapy. However, more adverse events were observed in clinical trials of PI therapy than 
PR therapy. Due to the lack of detailed information of response reverse events, the model 
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cannot differentiate the probability from each kind of possible event. But still, including 
the latent response reverse model allows evaluation of the potential reduction in response 
rate in the later phase of treatment. Further study with more data is needed to better 
characterize the response reverse.  
Previous one-endpoint meta-analyses
25–30
 did not find the significant differences between 
telaprevir and boceprevir. By incorporating the longitudinal information of virologic 
response, the current study evaluated different effects of these two protease inhibitors on 
the time course of the response rate. The proposed model may be helpful to predict the 
virologic response for a new candidate drug with the same mechanism of action and 
compare it with the approved treatments.  It can provide more information to support the 
decision making during the drug development.  
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APPENDIX  
Chapter 2: NONMEM Code for Population Pharmacokinetic Model 
;Model Desc: FLUPLASMA+URINE+ META   
;Project Name: flurbiprofen 
  
$PROB RUN# 055 
$INPUT C ID PID FLUCD IFLUC GT TIME NTIM EVID UVOL DV CMT AMT 
$DATA FLUBCOMEAN.CSV IGNORE=C 
$SUBROUTINES ADVAN6 TOL=9  
$MODEL 
COMP=(DEPOT) 
COMP=(PLASMA) 
COMP=(URINE) 
COMP=(URIMETA) 
 
$PK 
;KI UMOLAR 
IF(GT.EQ.1)THEN 
KI=THETA(1) 
ELSEIF(GT.EQ.2) THEN 
KI=THETA(2) 
ELSE 
KI=THETA(3) 
ENDIF 
 
;INHIBITION FACTOR OF FLUCO ON 2C9META 
INH=1/(1+IFLUC/KI) 
 
;BIOFORM OH VIA CYP2C9 BY GENOTYPE  
IF(GT.EQ.1) THEN 
TVCLFM=THETA(4)*INH 
ELSEIF(GT.EQ.2) THEN 
TVCLFM=THETA(5)*INH 
ELSE 
TVCLFM=THETA(6)*INH 
ENDIF 
 
   CLFM=TVCLFM*EXP(ETA(1)) 
   CLR=THETA(7)*EXP(ETA(2))  
   CLRES=THETA(8)*EXP(ETA(6)) 
   CL=CLFM+CLR+CLRES 
   TVV=THETA(9) 
   V=TVV*EXP(ETA(3)) 
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   TVK12=THETA(10) 
   K12=TVK12*EXP(ETA(4)) 
   ALAG1=THETA(11)*EXP(ETA(5)) 
   K23=CLR/V 
   K24=CLFM/V 
   K20=CLRES/V 
   S2=V 
   S3=UVOL/1000 
   S4=UVOL/1000 
 
SID=ID 
TAD=NTIM 
 
$DES 
DADT(1)=-K12*A(1) 
DADT(2)=K12*A(1)-K23*A(2)-K24*A(2)-K20*A(2) 
DADT(3)=K23*A(2) 
DADT(4)=K24*A(2) 
 
$ERROR 
ASY1=0 
IF (CMT.EQ.2)ASY1=1 ; FLUPLASMA 
ASY2=0 
IF (CMT.EQ.3)ASY2=1; FLURINE 
 
Y=F+F*ASY1*ERR(1)+F*ASY2*ERR(2)+F*(1-ASY1)*(1-ASY2)*ERR(3) 
 
IPRE=F 
IRES=DV-IPRE 
IWRED=IPRE 
IWRE=IRES; W=1 
 
 
$THETA 
(0, 10) ;[KI*1*1] 
(0, 15) ;[KI*1*3] 
(0, 30) ;[KI*3*3] 
(0,0.7) ;[CLFM*1*1] 
(0,0.5) ;[CLFM*1*3] 
(0,0.3) ;[CLFM*3*3] 
(0,0.1) ;[CLR] 
(0,0.1) ;[CLRES] 
(0,9)   ;[V]        
(0,1.5) ;[KA]        
(0,0.1) ;[TLAG]       
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$OMEGA 
  0.1 ;[P] omega(1,1) CLM 
  0.1 ;[P] omega(1,1) CLR 
  0.1 ;[P] omega(2,2) V 
  0.1 ;[P] omega(3,3) KA 
  0.1 ;[P] omega(4,4) CLRES 
  0.1 ;[P] omega(4,4) CLRES 
 
 
$SIGMA 
 0.1 ;[P] sigma(1,1) 
 0.1 ;[P] sigma(2,2) 
 0.1 ;[P] sigma(2,2) 
 
 
$EST METHOD=1 INTERACTION PRINT=5 MAX=9999 NSIG=3 SIGL=9    
MSFO=055.MSF  
  
$COV PRINT=E 
$TABLE ID TIME NTIM IPRE CMT FLUCD IFLUC GT KI CLFM CLR V K12 CWRES 
CPRED ONEHEADER NOPRINT FILE=055.tab 
$TABLE ID CLR CLRES V K12  FIRSTONLY NOAPPEND NOPRINT FILE=055.par 
$TABLE ID ETA1 ETA2 ETA3  FIRSTONLY NOAPPEND NOPRINT FILE=055.eta 
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Chapter 5: NONMEM Code for model-based meta-analysis of longitudinal hepatitis 
C virologic response 
 
 
$PROBLEM    RUN# 29 ;COV MODEL 
$INPUT C ID STUDY UNIT=DROP ARM TIME RESP=DV POPN EOT BOD EOD STERM 
TRI TELA TrtNaiv GTONE Nullresp Relap BriCir Black HRNA 
$DATA ../hcvstudycovgtcon.csv IGNORE=C 
$PRED 
ARM1=0 
ARM2=0 
ARM3=0 
ARM4=0 
ARM5=0 
ARM6=0 
IF(ARM.EQ.1)ARM1=1 
IF(ARM.EQ.2)ARM2=1 
IF(ARM.EQ.3)ARM3=1 
IF(ARM.EQ.4)ARM4=1 
IF(ARM.EQ.5)ARM5=1 
IF(ARM.EQ.6)ARM6=1 
LEAD=0 
IF(BOD.EQ.4)LEAD=1 
W=1/SQRT(POPN) 
 
TVLOGITPSS=THETA(1)+GTONE*THETA(6)+TRI*THETA(7) 
LOGITPSS=TVLOGITPSS+ETA(1)+(ARM1*ETA(4)+ARM2*ETA(5)+ARM3*ETA(6)+ARM
4*ETA(7)+ARM5*ETA(8)+ARM6*ETA(9))*W 
PSS=EXP(LOGITPSS)/(1+EXP(LOGITPSS)) 
TVLOGK=THETA(2)+TRI*THETA(8) 
LOGK=TVLOGK+ETA(2)+(ARM1*ETA(10)+ARM2*ETA(11)+ARM3*ETA(12)+ARM4*ET
A(13)+ARM5*ETA(14)+ARM6*ETA(15))*W 
K=EXP(LOGK) 
TVLOGRR=THETA(3) 
LOGRR=TVLOGRR+ETA(3)+(ARM1*ETA(16)+ARM2*ETA(17)+ARM3*ETA(18)+ARM4*
ETA(19)+ARM5*ETA(20)+ARM6*ETA(21))*W 
RR=EXP(LOGRR) 
TLAG=THETA(4) 
IF(LEAD.EQ.1)TLAG=THETA(5) 
DELPSS=PSS-EXP(TVLOGITPSS)/(1+EXP(TVLOGITPSS)) 
DELK=K-EXP(TVLOGK) 
DELRR=RR-EXP(TVLOGRR) 
 
MU_1=TVLOGITPSS 
MU_2=TVLOGK 
MU_3=TVLOGRR 
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IF(TIME.LT.TLAG) THEN 
P=0 
ENDIF 
IF(TIME.LE.EOT.AND.TIME.GE.TLAG) THEN 
P=PSS*(1-EXP(-K*(TIME-TLAG))) 
ENDIF 
IF (TIME.GT.EOT) THEN 
P=PSS*(1-EXP(-K*(EOT-TLAG)))*RR 
ENDIF 
Y=-2*(RESP*LOG(P)+(POPN-RESP)*LOG(1-P)) 
 
$THETA 
3;[LOGITPSS] 
-2;[LOGK] 
-1;[LOGRR] 
(0,1);[TLAG] 
(0,1);[TLAG] 
-1;[GTONEPSS] 
1;[TRIPSS] 
1;[TRIK] 
 
 
$OMEGA 
0 FIX; [A] omega2,2 
1; [A] omega2,2 
0 FIX; [A] omega2,2 
 
 
 
$OMEGA BLOCK(1) 9 ;ETA4-ETA9 BAV LOGITPSS 
$OMEGA BLOCK(1) SAME 
$OMEGA BLOCK(1) SAME 
$OMEGA BLOCK(1) SAME 
$OMEGA BLOCK(1) SAME 
$OMEGA BLOCK(1) SAME 
 
$OMEGA BLOCK(1) 9 ;ETA410-ETA15 BAV LOGK 
$OMEGA BLOCK(1) SAME 
$OMEGA BLOCK(1) SAME 
$OMEGA BLOCK(1) SAME 
$OMEGA BLOCK(1) SAME 
$OMEGA BLOCK(1) SAME 
 
 178 
 
$OMEGA BLOCK(1) 9 ;ETA416-ETA21 BAV LOGITRR 
$OMEGA BLOCK(1) SAME 
$OMEGA BLOCK(1) SAME 
$OMEGA BLOCK(1) SAME 
$OMEGA BLOCK(1) SAME 
$OMEGA BLOCK(1) SAME 
 
$ESTIMATION MET=SAEM LAPLACE -2LL NBURN=10000 NITER=1000 CTYPE=3 
PRINT=200 MSFO=./29.MSF 
$ESTIMATION MET=IMP EONLY=1 ISAMPLE=3000 NITER=5 
$COV PRINT=E 
$TABLE NOPRINT FILE=./29.tab ID TIME POPN P K PSS RR DELPSS DELK DELRR TRI 
GTONE BriCir TrtNaiv Nullresp Relap Black HRNA 
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Chapter 6 JAGS Code for model-based meta-analysis of longitudinal hepatitis C 
virologic response  
 
model 
{ 
for (i in 1:nobs) {  
nvr[i] ~dbin(pvr[i], n[i]) 
slop0[i]<-exp(alpha.slop+etaslopstudy[obsstudy[i]]) 
slop[i]<-slop0[i]*exp(beta1*tri1[i]) 
pbk[i]<-1/(1+exp(-(-5+slop[i]*(time[i]-2)))) 
pbk0[i]<-1/(1+exp(-(-5+slop0[i]*(time[i]-2)))) 
 
 
st1[i]<-max(0, pss[arm[i]]*(1-exp(-k[arm[i]]*(time[i]-tlag[arm[i]])))*(1-pbk[i])) 
st2[i]<-pss[arm[i]]*(1-exp(-k[arm[i]]*(eot[i]-tlag[arm[i]])))*(1-1/(1+exp(-(-5+slop[i]*(eot[i]-
2)))))*rr[arm[i]] 
 
st0[i]<-max(0, pss0[arm[i]]*(1-exp(-k0[arm[i]]*(time[i]-tlag0[arm[i]])))*(1-pbk0[i])) 
pbase[i]<-max(0,pss0[arm[i]]*(1-exp(-k0[arm[i]]*(bod1[i]-tlag0[arm[i]])))*(1-1/(1+exp(-(-
5+slop0[i]*(bod1[i]-2)))))) 
st1bod[i]<-max(0, pbase[i]+(pss[arm[i]]-pbase[i])*(1-exp(-k[arm[i]]*(time[i]-bod1[i])))*(1-
pbk[i])) 
st2bod[i]<-(pbase[i]+(pss[arm[i]]-pbase[i])*(1-exp(-k[arm[i]]*(eot[i]-bod1[i])))*(1-1/(1+exp(-(-
5+slop[i]*(eot[i]-2))))))*rr[arm[i]] 
 
pvr[i]<-step(4-bod1[i]-0.1)*(step(time[i]-bod1[i]-0.1)*step(eot[i]-time[i])*st1[i]+step(time[i]-
eot[i]-0.1)*st2[i]) 
+step(bod1[i]-4)*(step(bod1[i]-time[i])*st0[i]+step(time[i]-bod1[i]-0.1)*step(eot[i]-
time[i])*st1bod[i]+step(time[i]-eot[i]-0.1)*st2bod[i]) 
 
 
nvrCond[i]~dbin(pvr[i], n[i])## posterior prediction for the same trtarm same study 
pvrCond[i]<-nvrCond[i]/n[i] 
} 
 
 
for(i in 1:nstudy){ 
etaslopstudy[i]~dnorm(0, tau.etaslopstudy) 
etastudy[i,1:3]~dmnorm(mu.eta,tau.etastudy[1:3,1:3]) 
etapsstudy[i]<-etastudy[i,1] 
etakstudy[i]<-etastudy[i,2] 
etarrstudy[i]<-etastudy[i,3] 
} 
 
 
for (i in 1:narm) { 
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k0[i]<-exp(logk0[i]) 
logk0[i]<-mu.logk0[i]+etakarm[i]/sqrt(n[i]) 
mu.logk0[i]<-alpha.k+etakstudy[study[i]] 
 
k[i]<-exp(logk[i]) 
logk[i]<-mu.logk[i]+etakarm[i]/sqrt(n[i]) 
mu.logk[i]<-mu.logk0[i]+beta3*TEL[i]+beta4*BOC[i] 
 
pss0[i]<-1/(1+exp(-logitpss0[i])) 
logitpss0[i]<-mu.logitpss0[i]+etapssarm[i]/sqrt(n[i]) 
mu.logitpss0[i]<-
alpha.pss+etapsstudy[study[i]]+beta2*GTONE[i]+beta7*BLACK[i]+beta9*NULLRESP[i] 
 
pss[i]<-1/(1+exp(-logitpss[i])) 
logitpss[i]<-mu.logitpss[i]+etapssarm[i]/sqrt(n[i]) 
mu.logitpss[i]<-mu.logitpss0[i] 
 
rr[i]<-exp(logrr[i]) 
logrr[i]<-mu.logrr[i]+etarrarm[i]/sqrt(n[i]) 
mu.logrr[i]<-alpha.rr+etarrstudy[study[i]]+beta5*TEL[i]+beta6*STERM[i]+beta10*BOC[i] 
tlag0[i]<-lagt 
tlag[i]<-lagt*(1-TRI[i])+beta8*TRI[i] 
 
etaarm[i,1:3]~dmnorm(mu.eta,tau.etaarm[1:3,1:3]) 
etapssarm[i]<-etaarm[i,1] 
etakarm[i]<-etaarm[i,2] 
etarrarm[i]<-etaarm[i,3] 
 
} 
 
### prior dist 
alpha.slop~dnorm(-2, 1.0E-6) 
alpha.pss~dnorm(3, 100) 
alpha.k~dnorm(-2,1.0E-6) 
alpha.rr~dnorm(-0.2, 1.0E-6) 
lagt~dunif(0,2) 
beta1~dnorm(0, 1.0E-2) 
beta2~dnorm(0, 1.0E-6) 
beta3~dnorm(0, 1.0E-6) 
beta4~dnorm(0, 1.0E-6) 
beta5~dnorm(0, 1.0E-6) 
beta6~dnorm(0, 1.0E-6) 
beta7~dnorm(0, 1.0E-6) 
beta8~dunif(0,2) 
beta9~dnorm(0, 1.0E-6) 
beta10~dnorm(0, 1.0E-6) 
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tau.etaarm[1:3,1:3]~dwish(R[1:3,1:3],3) 
sigma.etaarm2[1:3,1:3]<-inverse(tau.etaarm[1:3,1:3]) 
omega.pss<-sqrt(sigma.etaarm2[1,1]) 
omega.k<-sqrt(sigma.etaarm2[2,2]) 
omega.rr<-sqrt(sigma.etaarm2[3,3]) 
 
tau.etastudy[1:3,1:3]~dwish(R[1:3,1:3],3) 
sigma.etastudy2[1:3,1:3]<-inverse(tau.etastudy[1:3,1:3]) 
omega.psstudy<-sqrt(sigma.etastudy2[1,1]) 
omega.kstudy<-sqrt(sigma.etastudy2[2,2]) 
omega.rrstudy<-sqrt(sigma.etastudy2[3,3]) 
 
omega.slopstudy~dunif(0, 10) 
tau.etaslopstudy<-1/(omega.slopstudy*omega.slopstudy) 
} 
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